Novel lipid compound, composition and nucleic acid lipid nanoparticle preparation

Abstract

The invention provides a cationic lipid compound, a composition containing the same and application. In order to provide more choices for delivery of preparations such as gene drugs, nucleic acid vaccines, small molecule drugs and the like, the invention provides a cationic lipid compound shown as a general formula # imgabs0 #, or a salt, a prodrug or a stereoisomer of the cationic lipid compound which can be used by the drug. The cationic lipid compound provided by the invention can be used for delivering nucleic acid drugs or small molecule drugs, enriches the types of cationic lipid compounds, and has important significance on development and application of nucleic acid preventive and therapeutic agents.

Description

Technical Field

[0001] This application belongs to the field of biomedical technology, and specifically relates to a lipid compound, a lipid carrier containing the same,

[0002] a nucleic acid-lipid nanoparticle composition, and a pharmaceutical preparation. Background Art

[0003] Gene therapy technology is a research hotspot in the field of modern biomedical technology. Nucleic acid drugs can be used to prevent cancer, bacterial and viral infections, and treat diseases with genetic causes. Due to the characteristics of nucleic acid drugs such as easy degradation and difficulty in entering cells, it is necessary to encapsulate them with a carrier and deliver them to target cells. Therefore, the development of a safe and efficient delivery carrier has become a prerequisite for the clinical application of gene therapy.

[0004] Lipid nanoparticles (LNP) are currently a research hotspot in the field of non-viral gene carriers. As a class of safe and efficient nucleic acid drug delivery carriers, they have been proven to be able to deliver RNA efficiently to the liver. In 2018, the US FDA approved the world's first LNP-based liver-targeted siRNA drug for the treatment of hereditary transthyretin-mediated amyloidosis. However, the LNP nucleic acid delivery system still faces several challenges, including the main limitation of the target tissue of LNP to the liver and the possible immunogenicity.

[0005] LNP usually consists of four lipid compounds, namely cationic lipids, neutral lipids, steroids, and PEG-lipids. Among them, the selection of cationic lipids has the greatest impact on LNP, such as affecting the encapsulation rate of nucleic acid drugs, the delivery site and efficiency of nucleic acid drugs in the body, and cytotoxicity.

[0006] In view of this, the development of a new compound that can be used as a cationic lipid will be of great significance. Summary of the Invention

[0007] Problems to be Solved by the Invention

[0008] The first object of this application is to provide a series of compounds that can be used together with other lipid compounds to prepare a lipid carrier, improve the delivery efficiency of nucleic acid drugs in the body, and a lipid compound with a specific structure can be selected as the lipid carrier according to the organ where the nucleic acid drug needs to be enriched.

[0009] The second object of this application is to provide a lipid carrier containing the above compound.

[0010] The third object of this application is to provide a nucleic acid-lipid nanoparticle composition containing the above compound or the above lipid carrier.

[0011] The fourth object of the present application is to provide a pharmaceutical preparation comprising the above-mentioned compound, or the above-mentioned lipid carrier, or the above-mentioned nucleic acid-lipid nanoparticle composition.

[0012] Specific Technical Solution of the Invention

[0013] In one embodiment, the present application provides a cationic lipid compound represented by the general formula (I), or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof, wherein X, Y, Z, G1, G2, G3, G4, G5, G6, L1, L2, L3, L4 are as defined in the present application or elsewhere.

[0014]

[0015] In one embodiment, the present application provides a nanoparticle composition comprising the compound provided by the present application and a therapeutic or prophylactic agent. In one embodiment, the therapeutic or prophylactic agent comprises at least one mRNA encoding an antigen or a fragment or epitope thereof.

[0016] Those skilled in the art will appreciate additional features of the present disclosure after considering the following detailed description of specific embodiments.

[0017] Advantages of the Invention

[0018] The cationic lipid compound and its composition of the present application can be used for delivering nucleic acid drugs or small molecule drugs, enriching the types of cationic lipid compounds, and having important significance for the development and application of nucleic acid prophylactic and therapeutic agents. Detailed Embodiments

[0019] Terms

[0020] Unless otherwise described, all technical and scientific terms used in the present application have the same meaning as commonly understood by those skilled in the art. For the purpose of interpreting this specification, the following terms will be applied, and where appropriate, terms used in the singular will also include the plural, and vice versa. All patents, applications, published applications and other publications are incorporated by reference in their entirety. If any description of a term conflicts with any document incorporated by reference into the present application, the description of the term set forth below shall prevail.

[0021] Unless the context otherwise requires, in this specification and the claims, the word "comprise" and its variations, such as "comprises" and "comprising", are to be interpreted in an open and inclusive sense, i.e., "including, but not limited to".

[0022] As used in this application and unless otherwise specified, the term "lipid" refers to a group of organic compounds, including but not limited to fatty acid esters, and is generally characterized by being poorly soluble in water but soluble in many non-polar organic solvents. Although lipids generally have weak water solubility, certain classes of lipids (such as lipids modified with polar groups, e.g., DMG-PEG2000) have limited water solubility and are soluble in water under certain conditions. Known lipid types include biomolecules such as fatty acids, waxes, sterols, fat-soluble vitamins, monoglycerides, diglycerides, triglycerides, and phospholipids. Lipids can be classified into at least three categories: (1) "simple lipids", including fats and oils, and waxes; (2) "compound lipids", including phospholipids and glycolipids (e.g., DMPE-PEG2000); and (3) "derived lipids", such as steroids. In addition, as used in this application, lipids also include lipid-like compounds. The term "lipid-like compound" is also abbreviated as "lipoid", and refers to lipid-like compounds (e.g., amphiphilic compounds with lipid-like physical properties).

[0023] As used in this application and unless otherwise specified, the term "lipid nanoparticle" or "LNP" refers to a particle having at least one nanometer (nm)-scale dimension (e.g., 1 to 1,000 nm) that contains one or more types of lipid molecules. The LNPs provided in this application may further contain at least one non-lipid payload molecule (e.g., one or more nucleic acid molecules) or small molecule drugs. In some embodiments, the LNP contains a non-lipid payload molecule that is partially or completely encapsulated within a lipid shell. Where the payload is a negatively charged molecule (e.g., mRNA encoding a viral protein), and the lipid component of the LNP contains at least one cationic lipid. Without being bound by theory, it is expected that the cationic lipid can interact with the negatively charged payload molecule and facilitate the incorporation and / or encapsulation of the payload into the LNP during LNP formation. Other lipids that can form part of the LNPs provided in this application include but are not limited to neutral lipids and charged lipids, such as steroids or their analogs, polymer-conjugated lipids, and various zwitterionic lipids.

[0024] As used in this application and unless otherwise specified, the term: "cationic lipid" refers to a lipid capable of being positively charged. Exemplary cationic lipids include one or more amine groups bearing a positive charge. Preferred cationic lipids are ionizable so that they can exist in a positively charged form or a neutral form depending on the pH value. The ionization of the cationic lipid affects the surface charge of the lipid nanoparticle under different pH conditions. This charge state can affect plasma protein uptake, blood clearance, and tissue distribution (Semple, S.C. et al., Adv Drug Deliv Rev 32:3-17 (1998)) and the ability to form endosomolytic non-bilayer structures (Hafez, I.M. et al., Gene Ther 8:1188-1196 (2001)), which is crucial for intracellular delivery of nucleic acids.

[0025] As used in this application and unless otherwise specified, the term "steroid" refers to a compound having the following carbon skeleton:

[0026]

[0027] Non-limiting examples of steroids include cholesterol and the like.

[0028] As used in this application and unless otherwise specified, the term "neutral lipid" encompasses any lipid molecule that exists in an uncharged form or in a neutral zwitterionic form at a selected pH value or within a selected pH range. In some embodiments, the selected useful pH value or range corresponds to the pH conditions in the environment of a predetermined lipid use, such as physiological pH. As non-limiting examples, neutral lipids that can be used in conjunction with the present disclosure include, but are not limited to, phosphatidylcholines such as 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC); phosphatidylethanolamines such as 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 2-((2,3-bis(oleyloxy)propyl))dimethylammonio)ethyl hydrogen phosphate (DOCP); sphingomyelin (SM); ceramides; steroids such as sterols, phytosterols, and their derivatives. The neutral lipids provided in this application can be synthetic or derived from natural sources or compounds (from which they are isolated or modified).

[0029] As used in this application and unless otherwise specified, the term "alkyl" refers to a saturated straight-chain or branched-chain hydrocarbon chain group consisting only of carbon and hydrogen atoms. In one embodiment, the alkyl has, for example, from one to twenty-four carbon atoms (C1-C24 alkyl), from four to twenty carbon atoms (C4-C20 alkyl), from six to sixteen carbon atoms (C6-C16 alkyl), from six to nine carbon atoms (C6-C9 alkyl), from one to fifteen carbon atoms (C1-C15 alkyl), from one to twelve carbon atoms (C1-C12 alkyl), from one to eight carbon atoms (C1-C8 alkyl), or from one to six carbon atoms (C1-C6 alkyl) and is attached to the remainder of the molecule by a single bond. Examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, 1-methylethyl (isopropyl), n-butyl, n-pentyl, 1,1-dimethylethyl (tert-butyl), 3-methylhexyl, 2-methylhexyl, and the like. Unless otherwise specified, the alkyl is optionally substituted.

[0030] As used in this application and unless otherwise specified, the term "alkenyl" refers to a straight-chain or branched-chain hydrocarbon chain group consisting only of carbon and hydrogen atoms and containing one or more carbon-carbon double bonds. Those skilled in the art will understand that the term "alkenyl" also encompasses groups having "cis" and "trans" configurations, or having "E" and "Z" configurations. In one embodiment, the alkenyl has, for example, from two to twenty-four carbon atoms (C2-C24 alkenyl), from four to twenty carbon atoms (C4-C20 alkenyl), from six to sixteen carbon atoms (C6-C16 alkenyl), from six to nine carbon atoms (C6-C9 alkenyl), from two to fifteen carbon atoms (C2-C15 alkenyl), from two to twelve carbon atoms (C2-C12 alkenyl), from two to eight carbon atoms (C2-C8 alkenyl), or from two to six carbon atoms (C2-C6 alkenyl) and is attached to the remainder of the molecule by a single bond. Examples of alkenyl include, but are not limited to, vinyl, prop-1-enyl, but-1-enyl, pent-1-enyl, pent-1,4-dienyl, and the like. Unless otherwise specified, the alkenyl is optionally substituted.

[0031] As used in this application and unless otherwise specified, the term "alkynyl" refers to a straight-chain or branched-chain hydrocarbon chain group consisting only of carbon and hydrogen atoms and containing one or more carbon-carbon triple bonds. In one embodiment, the alkynyl has, for example, from two to twenty-four carbon atoms (C2-C24 alkynyl), from four to twenty carbon atoms (C4-C20 alkynyl), from six to sixteen carbon atoms (C6-C16 alkynyl), from six to nine carbon atoms (C6-C9 alkynyl), from two to fifteen carbon atoms (C2-C15 alkynyl), from two to twelve carbon atoms (C2-C12 alkynyl), from two to eight carbon atoms (C2-C8 alkynyl), or from two to six carbon atoms (C2-C6 alkynyl) and is attached to the remainder of the molecule by a single bond. Examples of alkynyl include, but are not limited to, ethynyl, propynyl, butynyl, pentynyl, and the like. Unless otherwise specified, the alkynyl is optionally substituted.

[0032] As used in this application and unless otherwise specified, the term "cyclization" refers to the partial or complete connection within or between the molecules to form a cyclic molecular structure, and the connection points can be made by including but not limited to one C or N or several Cs or Ns, and the cyclized molecular structure can be saturated or unsaturated. Unless otherwise specified, the cyclized molecular moiety is optionally substituted.

[0033] When the groups described in this application are referred to as "substituted", they can be substituted by one or more any suitable substituents. Illustrative examples of substituents include but are not limited to the substituents found in the exemplary compounds and embodiments provided in this application, and: halogen atoms, such as F, Cl, Br or I; cyano; oxo (=O); hydroxy (-OH); alkyl; alkenyl; alkynyl; cycloalkyl; aryl; -(C=O)OR'; -O(C=O)R'; -C(=O)R'; -OR'; -S(O) x R'; -S-SR'; -C(=O)SR'; -SC(=O)R'; -NR'R'; -NR'C(=O)R'; -C(=O)NR'R'; -NR'C(=O)NR'R'; -OC(=O)NR'R'; -NR'C(=O)OR'; -NR'S(O) x NR'R'; -NR'S(O) x R'; and -S(O) x NR'R', where: R' is independently H, C1-C15 alkyl or cycloalkyl each time it appears, and x is 0, 1 or 2.

[0034] As used in this application and unless otherwise specified, the term "optionally selected" or "optionally" (e.g., optionally substituted) means that the subsequent described event or situation may or may not occur, and this description includes both the situation where the event or situation occurs and the situation where it does not occur. For example, "optionally substituted alkyl" means that the alkyl may be substituted or may not be substituted, and this description includes both the substituted alkyl and the alkyl without substitution.

[0035] The term "prodrug" refers to a derivative of a compound or nucleic acid drug of the present application that can directly or indirectly provide the compound or nucleic acid drug of the present application after being administered to a patient. The prodrug of a composition can be prepared by modifying the functional groups present in the compound or nucleic acid (DNA, ASO, siRNA, mRNA, tRNA) in such a way that the modification can be cleaved in a conventional operation or in vivo to give the parent compound or nucleic acid. Particularly preferred prodrugs are compounds and nucleic acid drugs that can improve the bioavailability of the composition of the present application (e.g., more readily absorbed into the blood) when administered to a patient, or compounds and nucleic acid drugs that facilitate the delivery of the parent compound to the site of action (e.g., the lymphatic system). Unless otherwise indicated, all prodrug forms of the compounds of the present application are within the scope of the present application, and various prodrug forms are well known in the art.

[0036] As used in the present application and unless otherwise specified, the term "pharmaceutically acceptable salt" includes both acid addition salts and base addition salts.

[0037] Examples of pharmaceutically acceptable acid addition salts include, but are not limited to, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, etc.; and organic acids, such as, but not limited to, acetic acid, 2,2-dichloroacetic acid, adipic acid, alginic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, 4-acetamidobenzoic acid, camphoric acid, camphor-10-sulfonic acid, capric acid, caproic acid, caprylic acid, carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid, glucuronic acid, glutamic acid, glutaric acid, 2-oxoglutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, mucic acid, naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, 1-hydroxy-2-naphthoic acid, nicotinic acid, oleic acid, orotic acid, oxalic acid, palmitic acid, pamoic acid, propionic acid, pyroglutamic acid, pyruvic acid, salicylic acid, 4-aminosalicylic acid, sebacic acid, stearic acid, succinic acid, tartaric acid, thiocyanic acid, p-toluenesulfonic acid, trifluoroacetic acid, undecylenic acid, etc.

[0038] Examples of pharmaceutically acceptable base addition salts include, but are not limited to, salts prepared by adding an inorganic base or an organic base to a free acid compound. Salts derived from inorganic bases include, but are not limited to, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts, etc. In one embodiment, the inorganic salts are ammonium salts, sodium salts, potassium salts, calcium salts, and magnesium salts. Salts derived from organic bases include, but are not limited to, salts of primary amines, secondary amines, and tertiary amines; substituted amines, including naturally occurring substituted amines; cyclic amines, and basic ion exchange resins, such as ammonia, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, diethanolamine, ethanolamine, deanol, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, benethamine, benzathine, ethylenediamine, glucosamine, methylglucosamine, theobromine, triethanolamine, tromethamine, purines, piperazine, piperidine, N-ethylpiperidine, polyamine resins, etc.

[0039] The compounds provided in this application may contain one or more asymmetric centers and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms, which may be defined as (R)- or (S)- according to absolute stereochemistry or as (D)- or (L)- for amino acids. Unless otherwise specified, the compounds provided in this application are intended to include all such possible isomers, as well as their racemic and optically pure forms. When the compounds described in this application contain an olefinic double bond or other geometrically asymmetric centers, unless otherwise specified, the compounds are intended to include E and Z geometric isomers. Similarly, all tautomeric forms are also intended to be included.

[0040] As used in this application and unless otherwise specified, the term "isomer" refers to different compounds having the same molecular formula. "Stereoisomers" are isomers that differ only in the arrangement of atoms in space. "Atropisomers" are stereoisomers obtained by restricted rotation about a single bond. "Enantiomers" are a pair of stereoisomers that are non-superimposable mirror images of each other. A mixture of any ratio of a pair of enantiomers may be called a "racemic" mixture. "Diastereomers" are stereoisomers that have at least two asymmetric atoms but are not mirror images of each other.

[0041] "Stereoisomers" may also include E and Z isomers or mixtures thereof, as well as cis and trans isomers or mixtures thereof. In certain embodiments, the compounds described in this application are separated into E or Z isomers. In other embodiments, the compounds described in this application are a mixture of E and Z isomers.

[0042] The term "nucleic acid" refers to a polymer of nucleotides of any length and includes, for example, DNA and RNA. The nucleotides can be deoxyribonucleotides, ribonucleotides, modified nucleotides or bases and / or their analogs, or any substrate that can be incorporated into the polymer by DNA or RNA polymerase or by a synthetic reaction. The nucleic acid can be in single-stranded or double-stranded form. As used in this application and unless otherwise specified, "nucleic acid" also includes nucleic acid mimics such as locked nucleic acid (LNA), peptide nucleic acid (PNA), and morpholino nucleic acid. As used in this application, "oligonucleotide" refers to a short synthetic polynucleotide, which generally but not necessarily has a length of less than about 200 nucleotides. The terms "oligonucleotide" and "polynucleotide" are not mutually exclusive. The above description of polynucleotides applies equally and fully to oligonucleotides. Unless otherwise specified, the left end of any single-stranded polynucleotide sequence disclosed in this application is the 5′ end; the leftward direction of a double-stranded polynucleotide sequence is called the 5′ direction. The 5′ to 3′ addition direction of nascent RNA transcripts is called the transcription direction; the sequence region on a DNA strand that has the same sequence as the RNA transcript and is located at the 5′ end relative to the 5′ end of the RNA transcript is called the "upstream sequence"; the sequence region on a DNA strand that has the same sequence as the RNA transcript and is located at the 3′ end relative to the 3′ end of the RNA transcript is called the "downstream sequence".

[0043] "Isolated nucleic acid" refers to a nucleic acid that is substantially separated from other genomic DNA sequences and proteins or complexes (such as ribosomes and polymerases) that are naturally associated with the native sequence, such as RNA, DNA, or hybrid nucleic acids. An "isolated" nucleic acid molecule is a nucleic acid molecule that is separated from other nucleic acid molecules present in the natural source of the nucleic acid molecule. In addition, when produced by recombinant techniques, an "isolated" nucleic acid molecule, such as an mRNA molecule, can be substantially free of other cellular materials or media, or when chemically synthesized, it can be substantially free of chemical precursors or other chemicals. In certain embodiments, one or more nucleic acid molecules encoding an antigen described in this application are isolated or purified. The term includes nucleic acid sequences that have been removed from their natural environment, and includes recombinant or cloned DNA or RNA isolates, as well as chemically synthesized analogs or analogs biosynthesized by heterologous systems. Substantially pure molecules can include isolated forms of the molecule.

[0044] The term "coding nucleic acid" or its grammatical equivalent when used to refer to a nucleic acid molecule includes: (a) a nucleic acid molecule that, when in its native state or when manipulated by methods well known to those of skill in the art, can be transcribed to produce mRNA and then translated into a peptide and / or polypeptide; and (b) the mRNA molecule itself. The antisense strand is the complementary sequence of such a nucleic acid molecule, and the coding sequence can be deduced therefrom. The term "coding region" refers to the portion of a coding nucleic acid sequence that is translated into a peptide or polypeptide. The term "untranslated region" or "UTR" refers to the portion of a coding nucleic acid that is not translated into a peptide or polypeptide. Depending on the orientation of the UTR relative to the coding region of the nucleic acid molecule, if the UTR is located at the 5' end of the coding region, it is called the 5'-UTR, and if the UTR is located at the 3' end of the coding region, it is called the 3'-UTR.

[0045] As used herein, the term "mRNA" refers to a messenger RNA molecule that contains one or more open reading frames (ORFs) that can be translated by a cell or organism having the mRNA to produce one or more peptide or protein products. The region containing one or more ORFs is called the coding region of the mRNA molecule. In certain embodiments, the mRNA molecule further contains one or more untranslated regions (UTRs).

[0046] In certain embodiments, the mRNA is a monocistronic mRNA that contains only one ORF. In certain embodiments, the monocistronic mRNA encodes a peptide or protein that contains at least one epitope of a selected antigen (such as a pathogenic antigen or a tumor-associated antigen). In other embodiments, the mRNA is a polycistronic mRNA that contains two or more ORFs. In certain embodiments, the polycistronic mRNA encodes two or more peptides or proteins that can be the same or different from each other. In certain embodiments, each peptide or protein encoded by the polycistronic mRNA contains at least one epitope of a selected antigen. In certain embodiments, the different peptides or proteins encoded by the polycistronic mRNA each contain at least one epitope of a different antigen. In any of the embodiments described herein, the at least one epitope can be at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10 epitopes of an antigen.

[0047] The term "nucleobase" encompasses purines and pyrimidines, including the natural compounds adenine, thymine, guanine, cytosine, uracil, inosine, and their natural or synthetic analogs or derivatives.

[0048] As used herein, the term "functional nucleotide analogue" refers to a modified form of a classical nucleotide A, G, C, U or T, which form (a) retains the base pairing properties of the corresponding classical nucleotide, and (b) contains at least one chemical modification of the corresponding natural nucleotide to (i) the nucleobase, (ii) the glycosyl group, (iii) the phosphate group or (iv) any combination of (i) to (iii). As used herein, base pairing not only encompasses the classical Watson-Crick adenine-thymine, adenine-uracil or guanine-cytosine base pairs, but also base pairs formed between a classical nucleotide and a functional nucleotide analogue or between a pair of functional nucleotide analogues, wherein the arrangement of hydrogen bond donors and hydrogen bond acceptors permits the formation of hydrogen bonds between the modified nucleobase and the classical nucleobase or between two complementary modified nucleobase structures. For example, a functional analogue of guanosine (G) retains the ability to base pair with cytosine (C) or a functional analogue of cytosine. An example of such non-classical base pairing is the base pairing between the modified nucleotide inosine and adenine, cytosine or uracil. As described herein, functional nucleotide analogues can be naturally occurring or non-naturally occurring. Thus, a nucleic acid molecule containing a functional nucleotide analogue can have at least one modified nucleobase, glycosyl group and / or internucleoside linkage. Exemplary chemical modifications of the nucleobase, glycosyl group or internucleoside linkage of a nucleic acid molecule are provided herein.

[0049] As used herein, the terms "translation enhancer element", "TEE" and "translation enhancer" refer to a region in a nucleic acid molecule that promotes the translation of a coding sequence of a nucleic acid into a protein or peptide product, such as by cap-dependent or cap-independent translation. into a protein or peptide product. TEEs are typically located in the UTR region of a nucleic acid molecule (e.g., mRNA) and enhance the translation level of a coding sequence located upstream or downstream. For example, a TEE in the 5'-UTR of a nucleic acid molecule can be located between the promoter and the start codon of the nucleic acid molecule. Various TEE sequences are known in the art (Wellensiek et al., Genome-wide profiling of human cap-independent translation-enhancing elements, Nature Methods, August 2013; 10(8):747-750; Chappell et al., PNAS, June 29, 2004, 101(26)9590-9594). Some TEEs are known to be conserved in multiple species (Pánek et al., Nucleic Acids Research, Vol. 41, No. 16, September 1, 2013, pp. 7625-7634).

[0050] As used herein, the term "peptide" refers to a polymer containing from two to fifty (2-50) amino acid residues linked by one or more covalent peptide bonds. The term applies to naturally occurring amino acid polymers as well as amino acid polymers in which one or more amino acid residues are non-naturally occurring amino acids (e.g., amino acid analogs or non-natural amino acids).

[0051] The terms "polypeptide" and "protein" are used interchangeably herein to refer to a polymer having more than fifty (50) amino acid residues linked by covalent peptide bonds. That is, a description of a polypeptide equally applies to a description of a protein, and vice versa. The terms apply to naturally occurring amino acid polymers as well as amino acid polymers in which one or more amino acid residues is a non-naturally occurring amino acid (e.g., an amino acid analog). As used herein, the terms encompass amino acid chains of any length, including full-length proteins (e.g., antigens).

[0052] The term "antigen" refers to a substance that can be recognized by a subject's immune system (including the adaptive immune system) and can trigger an immune response (including an antigen-specific immune response) after the subject contacts the antigen. In certain embodiments, the antigen is a protein associated with a diseased cell, such as a cell infected with a pathogen or a neoplastic cell (e.g., a tumor-associated antigen (TAA)).

[0053] An "epitope" is a site on the surface of an antigen molecule that binds to a single antibody molecule, such as a localized area on an antigen surface that is capable of binding to one or more antigen-binding regions of an antibody and that has antigenic or immunogenic activity in an animal, such as a mammal (e.g., a human), and is capable of eliciting an immune response. An epitope with immunogenic activity is a portion of a polypeptide that elicits an antibody response in an animal. An epitope with antigenic activity is a portion of a polypeptide that is bound by an antibody as determined by any method known in the art, including, for example, immunoassays. An antigenic epitope is not necessarily immunogenic. An epitope is typically composed of chemically active surface groups of a molecule, such as amino acids or sugar side chains, and has specific three-dimensional structural characteristics and specific charge characteristics. Antibody epitopes can be linear or conformational. Linear epitopes are formed by continuous amino acid sequences in proteins. Conformational epitopes are formed by amino acids that are discontinuous in the protein sequence but bind together when the protein folds into its three-dimensional structure. Inducible epitopes are formed when the three-dimensional structure of a protein assumes an altered conformation, such as after activation or binding by another protein or ligand. In certain embodiments, an epitope is a three-dimensional surface feature of a polypeptide. In other embodiments, an epitope is a linear feature of a polypeptide. Generally, an antigen has several or many different epitopes and can react with many different antibodies.

[0054] Lipid composition

[0055] In one embodiment, the present application provides a compound of formula (I):

[0056]

[0057] or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof, wherein:

[0058] G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group;

[0059] L1 and L2 are each independently -OC(=O)-, -C(=O)O-, -OC(=O)O-, -C(=O)-, -O-, -S(O) x -, -SS-, -C(=O)S-, -SC(=O)-, -NR a C(=O)-, -C(=O)NR b -, -NR a C(=O)NR b -, -OC(=O)NR b -, -NR a C(=O)O-, -SC(=S)-, -C(=S)S-, -C(=S)-, -CH(OH)-, -P(=O)(OR b )O-, -(C6-C10 arylene)- or -(6- to 10-membered heteroarylene)-;

[0060] R a and R b are each independently H, an optionally substituted C1-C12 alkyl group or an optionally substituted C1-C12 alkenyl group;

[0061] x is 0, 1 or 2;

[0062] G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene group;

[0063] L3 and L4 are each independently -OC(=O)-, -C(=O)O-, -OC(=O)O-, -C(=O)-, -O-, -S(O) i -, -SS-, -C(=O)S-, -SC(=O)-, -NR c C(=O)-, -C(=O)NR c -, -NR c C(=O)NR d -, -OC(=O)NR c -, -NR c C(=O)O-, -SC(=S)-, -C(=S)S-, -C(=S)-, -CH(OH)-, -P(=O)(ORc ) O-, -(C6-C10 arylene)-, or -(6- to 10-membered heteroarylene)-;

[0064] R c and R d are each independently H, optionally substituted C1-C12 alkyl, or optionally substituted C1-C12 alkenyl;

[0065] i is 0, 1, or 2;

[0066] Said G5 and G6 are each independently optionally substituted C2-C24 straight-chain alkyl, optionally substituted C2-C24 straight-chain alkenyl;

[0067] Said Z is optionally substituted C1-C12 alkylene, optionally substituted -R e G7R f -;

[0068] wherein, R e and R f are optionally substituted C1-C12 alkylene;

[0069] G7 is -NR g -, (3-7-membered saturated cycloalkylene), -(3-7-membered heterocycloalkylene)-, -(3-7-membered cyclic arylene)-, or -(3-7-membered cyclic heteroarylene)-;

[0070] R g is optionally substituted C1-C12 alkylene;

[0071] Said X and Y are each independently optionally substituted C1-C12 straight-chain alkyl, -G1L1G3L3G5 or X, Z together with the nitrogen to which they are attached form a ring;

[0072] Preferably, Z is optionally substituted C1-C12 alkylene, and the compound has the structure of formula (I-A):

[0073]

[0074] wherein, G1, G2, G3, G4, G5, G6, L1, L2, L3, L4, X and Y are as defined in formula (I), and G8 is optionally substituted C1-C12 alkylene.

[0075] Or preferably, optionally substituted -R e G7R f -, and the compound has the structure shown in formula (I-B):

[0076]

[0077] Wherein, G1, G2, G3, G4, G5, G6, G7, L1, L2, L3, L4, R e , R f , X and Y are as defined in formula (I);

[0078] Preferably, G1 and G2 are unsubstituted C2-C4 alkylene groups, and each of L1 and L2 is independently -OC(=O)-, -C(=O)O-, -OC(=O)O-, -C(=O)-, -O-, -S(O) x -, -SS-, -C(=O)S-, -SC(=O)-, -NR a C(=O)-, -C(=O)NR b -, -NR a C(=O)NR b -, -OC(=O)NR b -, -NR a C(=O)O-, -SC(=S)-, -C(=S)S-, -C(=S)-, -CH(OH)-, -P(=O)(OR b )O-, -(C6-C10 arylene)- or -(6 to 10-membered heteroarylene)-; R a and R b are each independently H, optionally substituted C1-C12 alkyl or optionally substituted C1-C12 alkenyl; x is 0, 1 or 2; each of G3 and G4 is independently a bond, optionally substituted C2-C24 straight-chain alkylene; each of L3 and L4 is independently a bond, -OC(=O)-, -C(=O)O-, -OC(=O)O-, -C(=O)-, -O-, -S(O) i -, -SS-, -C(=O)S-, -SC(=O)-, -NR c C(=O)-, -C(=O)NR c -, -NR c C(=O)NR d -, -OC(=O)NR c -, -NR c C(=O)O-, -SC(=S)-, -C(=S)S-, -C(=S)-, -CH(OH)-, -P(=O)(OR c )O-, -(C6-C10 arylene)- or -(6 to 10-membered heteroarylene)-; R c and R dEach is independently H, optionally substituted C1-C12 alkyl or optionally substituted C1-C12 alkenyl; i is 0, 1 or 2; G5 and G6 are each independently optionally substituted C2-C24 straight-chain alkyl, optionally substituted C2-C24 straight-chain alkenyl; Z is optionally substituted C1-C12 alkylene, optionally substituted -R e G7R f -; wherein, R e and R f are optionally substituted C1-C12 alkylene; G7 is -NR g -, (3-7 member saturated cycloalkylene), -(3-7 member heterocycloalkylene)-, -(3-7 member cyclic arylene)- or -(3-7 member cyclic heteroarylene)-; R g is optionally substituted C1-C12 alkylene; X and Y are each independently optionally substituted C1-C12 straight-chain alkyl, -G1L1G3L3G5 or X, Z together with the nitrogen to which they are attached form a ring.

[0079] Preferably, L1 and L2 are -C(=O)O-, G1 and G2 are each independently optionally substituted C2-C24 straight-chain alkylene; G3 and G4 are each independently a bond, optionally substituted C2-C24 straight-chain alkylene; L3 and L4 are each independently a bond, -OC(=O)-, -C(=O)O-, -OC(=O)O-, -C(=O)-, -O-, -S(O) i -, -SS-, -C(=O)S-, -SC(=O)-, -NR c C(=O)-, -C(=O)NR c -, -NR c C(=O)NR d -, -OC(=O)NR c -, -NR c C(=O)O-, -SC(=S)-, -C(=S)S-, -C(=S)-, -CH(OH)-, -P(=O)(OR c )O-, -(C6-C10 arylene)- or -(6 to 10 member heteroarylene)-; R c and R d are each independently H, optionally substituted C1-C12 alkyl or optionally substituted C1-C12 alkenyl; i is 0, 1 or 2; G5 and G6 are each independently optionally substituted C2-C24 straight-chain alkyl, optionally substituted C2-C24 straight-chain alkenyl; Z is optionally substituted C1-C12 alkylene, optionally substituted -R e G7R f -; wherein, R e and R fis an optionally substituted C1-C12 alkylene; G7 is -NR g -, (3-7 member saturated cycloalkylene), -(3-7 member heterocycloalkylene)-, -(3-7 member cyclic arylene)- or -(3-7 member cyclic heteroarylene)-; R g is an optionally substituted C1-C12 alkylene; X and Y are each independently an optionally substituted C1-C12 straight-chain alkyl, -G1L1G3L3G5 or X, Z together with the nitrogen to which they are attached form a ring.

[0080] Preferably, G3 and G4 are a bond or an unsubstituted C2-C4 alkylene, and G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene; L1 and L2 are each independently -OC(=O)-, -C(=O)O-, -OC(=O)O-, -C(=O)-, -O-, -S(O) x -, -SS-, -C(=O)S-, -SC(=O)-, -NR a C(=O)-, -C(=O)NR b -, -NR a C(=O)NR b -, -OC(=O)NR b -, -NR a C(=O)O-, -SC(=S)-, -C(=S)S-, -C(=S)-, -CH(OH)-, -P(=O)(OR b )O-, -(C6-C10 arylene)- or -(6 to 10 member heteroarylene)-; R a and R b are each independently H, an optionally substituted C1-C12 alkyl or an optionally substituted C1-C12 alkenyl; x is 0, 1 or 2; L3 and L4 are each independently a bond, -OC(=O)-, -C(=O)O-, -OC(=O)O-, -C(=O)-, -O-, -S(O) i -, -SS-, -C(=O)S-, -SC(=O)-, -NR c C(=O)-, -C(=O)NR c -, -NR c C(=O)NR d -, -OC(=O)NR c -, -NR c C(=O)O-, -SC(=S)-, -C(=S)S-, -C(=S)-, -CH(OH)-, -P(=O)(OR c )O-, -(C6-C10 arylene)- or -(6 to 10 member heteroarylene)-; R c and R dEach is independently H, optionally substituted C1-C12 alkyl or optionally substituted C1-C12 alkenyl; i is 0, 1 or 2; G5 and G6 are each independently optionally substituted C2-C24 straight-chain alkyl, optionally substituted C2-C24 straight-chain alkenyl; Z is optionally substituted C1-C12 alkylene, optionally substituted -R e G7R f -; wherein, R e and R f is optionally substituted C1-C12 alkylene; G7 is -NR g -, (3-7 membered saturated cycloalkylene), -(3-7 membered heterocycloalkylene)-, -(3-7 membered cyclic arylene)- or -(3-7 membered cyclic heteroarylene)-; R g is optionally substituted C1-C12 alkylene; X and Y are each independently optionally substituted C1-C12 straight-chain alkyl, -G1L1G3L3G5 or X, Z together with the nitrogen to which they are attached form a ring.

[0081] Preferably, L3 and L4 are a bond or -OC(=O)O-, G1 and G2 are each independently optionally substituted C2-C24 straight-chain alkylene; L1 and L2 are each independently -OC(=O)-, -C(=O)O-, -OC(=O)O-, -C(=O)-, -O-, -S(O) x -, -SS-, -C(=O)S-, -SC(=O)-, -NR a C(=O)-, -C(=O)NR b -, -NR a C(=O)NR b -, -OC(=O)NR b -, -NR a C(=O)O-, -SC(=S)-, -C(=S)S-, -C(=S)-, -CH(OH)-, -P(=O)(OR b )O-, -(C6-C10 arylene)- or -(6 to 10 membered heteroarylene)-; R a and R b are each independently H, optionally substituted C1-C12 alkyl or optionally substituted C1-C12 alkenyl; x is 0, 1 or 2; G3 and G4 are each independently a bond, optionally substituted C2-C24 straight-chain alkylene; G5 and G6 are each independently optionally substituted C2-C24 straight-chain alkyl, optionally substituted C2-C24 straight-chain alkenyl; Z is optionally substituted C1-C12 alkylene, optionally substituted -R e G7R f -; wherein, R e and Rf is an optionally substituted C1-C12 alkylene; G7 is -NR g -, (3-7 member saturated cycloalkylene), -(3-7 member heterocycloalkylene)-, -(3-7 member cyclic arylene)- or -(3-7 member cyclic heteroarylene)-; R g is an optionally substituted C1-C12 alkylene; X and Y are each independently an optionally substituted C1-C12 straight-chain alkyl, -G1L1G3L3G5 or X, Z together with the nitrogen to which they are attached form a ring.

[0082] Preferably, L3 and L4 are bonds, G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene; L1 and L2 are each independently -OC(=O)-, -C(=O)O-, -OC(=O)O-, -C(=O)-, -O-, -S(O) x -, -SS-, -C(=O)S-, -SC(=O)-, -NR a C(=O)-, -C(=O)NR b -, -NR a C(=O)NR b -, -OC(=O)NR b -, -NR a C(=O)O-, -SC(=S)-, -C(=S)S-, -C(=S)-, -CH(OH)-, -P(=O)(OR b )O-, -(C6-C10 arylene)- or -(6 to 10 member heteroarylene)-; R a and R b are each independently H, an optionally substituted C1-C12 alkyl or an optionally substituted C1-C12 alkenyl; x is 0, 1 or 2; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene; G5 and G6 are each independently an optionally substituted C2-C24 straight-chain alkyl, an optionally substituted C2-C24 straight-chain alkenyl; Z is an optionally substituted C1-C12 alkylene, an optionally substituted -R e G7R f -; wherein, R e and R f are an optionally substituted C1-C12 alkylene; G7 is -NR g -, (3-7 member saturated cycloalkylene), -(3-7 member heterocycloalkylene)-, -(3-7 member cyclic arylene)- or -(3-7 member cyclic heteroarylene)-; R g is an optionally substituted C1-C12 alkylene; X and Y are each independently an optionally substituted C1-C12 straight-chain alkyl, -G1L1G3L3G5 or X, Z together with the nitrogen to which they are attached form a ring.

[0083] Preferably, G5 and G6 are optionally substituted C4-C16 linear alkenyl groups, and each of G1 and G2 is independently an optionally substituted C2-C24 linear alkylene group; each of L1 and L2 is independently -OC(=O)-, -C(=O)O-, -OC(=O)O-, -C(=O)-, -O-, -S(O) x -, -SS-, -C(=O)S-, -SC(=O)-, -NR a C(=O)-, -C(=O)NR b -, -NR a C(=O)NR b -, -OC(=O)NR b -, -NR a C(=O)O-, -SC(=S)-, -C(=S)S-, -C(=S)-, -CH(OH)-, -P(=O)(OR b )O-, -(C6-C10 arylene)- or -(6- to 10-membered heteroarylene)-; R a and R b are each independently H, an optionally substituted C1-C12 alkyl group or an optionally substituted C1-C12 alkenyl group; x is 0, 1 or 2; each of G3 and G4 is independently a bond, an optionally substituted C2-C24 linear alkylene group; each of L3 and L4 is independently a bond, -OC(=O)-, -C(=O)O-, -OC(=O)O-, -C(=O)-, -O-, -S(O) i -, -SS-, -C(=O)S-, -SC(=O)-, -NR c C(=O)-, -C(=O)NR c -, -NR c C(=O)NR d -, -OC(=O)NR c -, -NR c C(=O)O-, -SC(=S)-, -C(=S)S-, -C(=S)-, -CH(OH)-, -P(=O)(OR c )O-, -(C6-C10 arylene)- or -(6- to 10-membered heteroarylene)-; R c and R d are each independently H, an optionally substituted C1-C12 alkyl group or an optionally substituted C1-C12 alkenyl group; i is 0, 1 or 2; Z is an optionally substituted C1-C12 alkylene group, an optionally substituted -R e G7R f -; wherein, R e and R fis an optionally substituted C1-C12 alkylene; G7 is -NR g -, (3-7 member saturated cycloalkylene), -(3-7 member heterocycloalkylene)-, -(3-7 member cyclic arylene)- or -(3-7 member cyclic heteroarylene)-; R g is an optionally substituted C1-C12 alkylene; X and Y are each independently an optionally substituted C1-C12 straight-chain alkyl, -G1L1G3L3G5 or X, Z together with the nitrogen to which they are attached form a ring.

[0084] In one specific embodiment, X and Y are each independently an optionally substituted C1-C3 straight-chain alkyl; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene; L1 and L2 are each independently -OC(=O)-, -C(=O)O-, -OC(=O)O-, -C(=O)-, -O-, -S(O) x -, -SS-, -C(=O)S-, -SC(=O)-, -NR a C(=O)-, -C(=O)NR b -, -NR a C(=O)NR b -, -OC(=O)NR b -, -NR a C(=O)O-, -SC(=S)-, -C(=S)S-, -C(=S)-, -CH(OH)-, -P(=O)(OR b )O-, -(C6-C10 arylene)- or -(6 to 10 member heteroarylene)-; R a and R b are each independently H, an optionally substituted C1-C12 alkyl or an optionally substituted C1-C12 alkenyl; x is 0, 1 or 2; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene; L3 and L4 are each independently a bond, -OC(=O)-, -C(=O)O-, -OC(=O)O-, -C(=O)-, -O-, -S(O) i -, -SS-, -C(=O)S-, -SC(=O)-, -NR c C(=O)-, -C(=O)NR c -, -NR c C(=O)NR d -, -OC(=O)NR c -, -NR c C(=O)O-, -SC(=S)-, -C(=S)S-, -C(=S)-, -CH(OH)-, -P(=O)(OR c) O-, -(C6-C10 arylene)-, or -(6- to 10-membered heteroarylene)-; R c and R d are each independently H, optionally substituted C1-C12 alkyl, or optionally substituted C1-C12 alkenyl; i is 0, 1, or 2; said G5 and G6 are each independently optionally substituted C2-C24 straight-chain alkyl, optionally substituted C2-C24 straight-chain alkenyl; said Z is optionally substituted C1-C12 alkylene, optionally substituted -R e G7R f -; wherein, R e and R f is optionally substituted C1-C12 alkylene; G7 is -NR g -, (3-7-membered saturated cycloalkylene), -(3-7-membered heterocycloalkylene)-, -(3-7-membered cyclic arylene)-, or -(3-7-membered cyclic heteroarylene)-; R g is optionally substituted C1-C12 alkylene.

[0085] In a specific embodiment, X and Y are each independently -G1L1G3L3G5; said G1 and G2 are each independently optionally substituted C2-C24 straight-chain alkylene; said L1 and L2 are each independently -OC(=O)-, -C(=O)O-, -OC(=O)O-, -C(=O)-, -O-, -S(O) x -, -SS-, -C(=O)S-, -SC(=O)-, -NR a C(=O)-, -C(=O)NR b -, -NR a C(=O)NR b -, -OC(=O)NR b -, -NR a C(=O)O-, -SC(=S)-, -C(=S)S-, -C(=S)-, -CH(OH)-, -P(=O)(OR b )O-, -(C6-C10 arylene)-, or -(6- to 10-membered heteroarylene)-; R a and R b are each independently H, optionally substituted C1-C12 alkyl, or optionally substituted C1-C12 alkenyl; x is 0, 1, or 2; said G3 and G4 are each independently a bond, optionally substituted C2-C24 straight-chain alkylene; said L3 and L4 are each independently a bond, -OC(=O)-, -C(=O)O-, -OC(=O)O-, -C(=O)-, -O-, -S(O) i -, -SS-, -C(=O)S-, -SC(=O)-, -NR cC(=O)-, -C(=O)NR c -, -NR c C(=O)NR d -, -OC(=O)NR c -, -NR c C(=O)O-, -SC(=S)-, -C(=S)S-, -C(=S)-, -CH(OH)-, -P(=O)(OR c )O-, -(C6-C10 arylene)- or -(6- to 10-membered heteroarylene)-; R c and R d are each independently H, optionally substituted C1-C12 alkyl or optionally substituted C1-C12 alkenyl; i is 0, 1 or 2; said G5 and G6 are each independently optionally substituted C2-C24 straight-chain alkyl, optionally substituted C2-C24 straight-chain alkenyl; said Z is optionally substituted C1-C12 alkylene, optionally substituted -R e G7R f -; wherein, R e and R f are optionally substituted C1-C12 alkylene; G7 is -NR g -, (3-7 membered saturated cycloalkylene), -(3-7 membered heterocycloalkylene)-, -(3-7 membered cyclic arylene)- or -(3-7 membered cyclic heteroarylene)-; R g is optionally substituted C1-C12 alkylene.

[0086] In a specific embodiment, X is optionally substituted C1-C3 straight-chain alkyl, Y is -G1L1G3L3G5; said G1 and G2 are each independently optionally substituted C2-C24 straight-chain alkylene; said L1 and L2 are each independently -OC(=O)-, -C(=O)O-, -OC(=O)O-, -C(=O)-, -O-, -S(O) x -, -SS-, -C(=O)S-, -SC(=O)-, -NR a C(=O)-, -C(=O)NR b -, -NR a C(=O)NR b -, -OC(=O)NR b -, -NR a C(=O)O-, -SC(=S)-, -C(=S)S-, -C(=S)-, -CH(OH)-, -P(=O)(OR b )O-, -(C6-C10 arylene)- or -(6- to 10-membered heteroarylene)-; R a and R bEach is independently H, optionally substituted C1-C12 alkyl or optionally substituted C1-C12 alkenyl; x is 0, 1 or 2; said G3 and G4 are each independently a bond, optionally substituted C2-C24 straight-chain alkylene; said L3 and L4 are each independently a bond, -OC(=O)-, -C(=O)O-, -OC(=O)O-, -C(=O)-, -O-, -S(O) i -, -SS-, -C(=O)S-, -SC(=O)-, -NR c C(=O)-, -C(=O)NR c -, -NR c C(=O)NR d -, -OC(=O)NR c -, -NR c C(=O)O-, -SC(=S)-, -C(=S)S-, -C(=S)-, -CH(OH)-, -P(=O)(OR c )O-, -(C6-C10 arylene)- or -(6 to 10-membered heteroarylene)-; R c and R d are each independently H, optionally substituted C1-C12 alkyl or optionally substituted C1-C12 alkenyl; i is 0, 1 or 2; said G5 and G6 are each independently optionally substituted C2-C24 straight-chain alkyl, optionally substituted C2-C24 straight-chain alkenyl; said Z is optionally substituted C1-C12 alkylene, optionally substituted -R e G7R f -; wherein, R e and R f are optionally substituted C1-C12 alkylene; G7 is -NR g -, (3-7-membered saturated cycloalkane), -(3-7-membered heterocycloalkane)-, -(3-7-membered cyclic arylene)- or -(3-7-membered cyclic heteroarylene)-; R g is optionally substituted C1-C12 alkylene.

[0087] In a specific embodiment, X is -G1L1G3L3G5, Y is optionally substituted C1-C3 straight-chain alkyl; said G1 and G2 are each independently optionally substituted C2-C24 straight-chain alkylene; said L1 and L2 are each independently -OC(=O)-, -C(=O)O-, -OC(=O)O-, -C(=O)-, -O-, -S(O) x -, -SS-, -C(=O)S-, -SC(=O)-, -NR a C(=O)-, -C(=O)NR b -, -NR a C(=O)NRb -, -OC(=O)NR b -, -NR a C(=O)O-, -SC(=S)-, -C(=S)S-, -C(=S)-, -CH(OH)-, -P(=O)(OR b )O-, -(C6-C10 arylene)- or -(6 to 10-membered heteroarylene)-; R a and R b are each independently H, optionally substituted C1-C12 alkyl or optionally substituted C1-C12 alkenyl; x is 0, 1 or 2; said G3 and G4 are each independently a bond, optionally substituted C2-C24 straight-chain alkylene; said L3 and L4 are each independently a bond, -OC(=O)-, -C(=O)O-, -OC(=O)O-, -C(=O)-, -O-, -S(O) i -, -SS-, -C(=O)S-, -SC(=O)-, -NR c C(=O)-, -C(=O)NR c -, -NR c C(=O)NR d -, -OC(=O)NR c -, -NR c C(=O)O-, -SC(=S)-, -C(=S)S-, -C(=S)-, -CH(OH)-, -P(=O)(OR c )O-, -(C6-C10 arylene)- or -(6 to 10-membered heteroarylene)-; R c and R d are each independently H, optionally substituted C1-C12 alkyl or optionally substituted C1-C12 alkenyl; i is 0, 1 or 2; said G5 and G6 are each independently optionally substituted C2-C24 straight-chain alkyl, optionally substituted C2-C24 straight-chain alkenyl; said Z is optionally substituted C1-C12 alkylene, optionally substituted -R e G7R f -; wherein, R e and R f are optionally substituted C1-C12 alkylene; G7 is -NR g -, (3-7-membered saturated cycloalkylene), -(3-7-membered heterocycloalkylene)-, -(3-7-membered cyclic arylene)- or -(3-7-membered cyclic heteroarylene)-; R g is optionally substituted C1-C12 alkylene.

[0088] In a specific embodiment, Z is a C2-C4 alkylene group, and G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -OC(=O)-, -C(=O)O-, -OC(=O)O-, -C(=O)-, -O-, -S(O) x -, -SS-, -C(=O)S-, -SC(=O)-, -NR a C(=O)-, -C(=O)NR b -, -NR a C(=O)NR b -, -OC(=O)NR b -, -NR a C(=O)O-, -SC(=S)-, -C(=S)S-, -C(=S)-, -CH(OH)-, -P(=O)(OR b )O-, -(C6-C10 arylene)- or -(6- to 10-membered heteroarylene)-; R a and R b are each independently H, an optionally substituted C1-C12 alkyl group or an optionally substituted C1-C12 alkenyl group; x is 0, 1 or 2; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene group; L3 and L4 are each independently a bond, -OC(=O)-, -C(=O)O-, -OC(=O)O-, -C(=O)-, -O-, -S(O) i -, -SS-, -C(=O)S-, -SC(=O)-, -NR c C(=O)-, -C(=O)NR c -, -NR c C(=O)NR d -, -OC(=O)NR c -, -NR c C(=O)O-, -SC(=S)-, -C(=S)S-, -C(=S)-, -CH(OH)-, -P(=O)(OR c )O-, -(C6-C10 arylene)- or -(6- to 10-membered heteroarylene)-; R c and R d are each independently H, an optionally substituted C1-C12 alkyl group or an optionally substituted C1-C12 alkenyl group; i is 0, 1 or 2; G5 and G6 are each independently an optionally substituted C2-C24 straight-chain alkyl group, an optionally substituted C2-C24 straight-chain alkenyl group; X and Y are each independently an optionally substituted C1-C12 straight-chain alkyl group, -G1L1G3L3G5 or X, Z together with the nitrogen to which it is attached forms a ring.

[0089] In a specific embodiment, Z is optionally substituted -R e G7R f -, R e and R f are each independently optionally substituted C2-C4 alkylene, G7 is -(3-7 membered heteroalkylene)-; G1 and G2 are each independently optionally substituted C2-C24 straight-chain alkylene; L1 and L2 are each independently -OC(=O)-, -C(=O)O-, -OC(=O)O-, -C(=O)-, -O-, -S(O) x -, -SS-, -C(=O)S-, -SC(=O)-, -NR a C(=O)-, -C(=O)NR b -, -NR a C(=O)NR b -, -OC(=O)NR b -, -NR a C(=O)O-, -SC(=S)-, -C(=S)S-, -C(=S)-, -CH(OH)-, -P(=O)(OR b )O-, -(C6-C10 arylene)- or -(6 to 10 membered heteroarylene)-; R a and R b are each independently H, optionally substituted C1-C12 alkyl or optionally substituted C1-C12 alkenyl; x is 0, 1 or 2; G3 and G4 are each independently a bond, optionally substituted C2-C24 straight-chain alkylene; L3 and L4 are each independently a bond, -OC(=O)-, -C(=O)O-, -OC(=O)O-, -C(=O)-, -O-, -S(O) i -, -SS-, -C(=O)S-, -SC(=O)-, -NR c C(=O)-, -C(=O)NR c -, -NR c C(=O)NR d -, -OC(=O)NR c -, -NR c C(=O)O-, -SC(=S)-, -C(=S)S-, -C(=S)-, -CH(OH)-, -P(=O)(OR c )O-, -(C6-C10 arylene)- or -(6 to 10 membered heteroarylene)-; R c and R dEach is independently H, an optionally substituted C1-C12 alkyl group, or an optionally substituted C1-C12 alkenyl group; i is 0, 1, or 2; G5 and G6 are each independently an optionally substituted C2-C24 straight-chain alkyl group or an optionally substituted C2-C24 straight-chain alkenyl group; X and Y are each independently an optionally substituted C1-C12 straight-chain alkyl group, -G1L1G3L3G5, or X, Z together with the nitrogen to which they are attached form a ring.

[0090] In a specific embodiment, X and Y are each independently an optionally substituted C1-C3 straight-chain alkyl group, and Z is a C2-C4 alkylene group; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -OC(=O)-, -C(=O)O-, -OC(=O)O-, -C(=O)-, -O-, -S(O) x -, -SS-, -C(=O)S-, -SC(=O)-, -NR a C(=O)-, -C(=O)NR b -, -NR a C(=O)NR b -, -OC(=O)NR b -, -NR a C(=O)O-, -SC(=S)-, -C(=S)S-, -C(=S)-, -CH(OH)-, -P(=O)(OR b )O-, -(C6-C10 arylene)-, or -(6- to 10-membered heteroarylene)-; R a and R b are each independently H, an optionally substituted C1-C12 alkyl group, or an optionally substituted C1-C12 alkenyl group; x is 0, 1, or 2; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene group; L3 and L4 are each independently a bond, -OC(=O)-, -C(=O)O-, -OC(=O)O-, -C(=O)-, -O-, -S(O) i -, -SS-, -C(=O)S-, -SC(=O)-, -NR c C(=O)-, -C(=O)NR c -, -NR c C(=O)NR d -, -OC(=O)NR c -, -NR c C(=O)O-, -SC(=S)-, -C(=S)S-, -C(=S)-, -CH(OH)-, -P(=O)(OR c )O-, -(C6-C10 arylene)-, or -(6- to 10-membered heteroarylene)-; Rc and R d each independently is H, optionally substituted C1-C12 alkyl or optionally substituted C1-C12 alkenyl; i is 0, 1 or 2; said G5 and G6 each independently is optionally substituted C2-C24 straight-chain alkyl, optionally substituted C2-C24 straight-chain alkenyl.

[0091] In a specific embodiment, X and Y each independently is -G1L1G3L3G5, Z is C2-C4 alkylene; said G1 and G2 each independently is optionally substituted C2-C24 straight-chain alkylene; said L1 and L2 each independently is -OC(=O)-, -C(=O)O-, -OC(=O)O-, -C(=O)-, -O-, -S(O) x -, -SS-, -C(=O)S-, -SC(=O)-, -NR a C(=O)-, -C(=O)NR b -, -NR a C(=O)NR b -, -OC(=O)NR b -, -NR a C(=O)O-, -SC(=S)-, -C(=S)S-, -C(=S)-, -CH(OH)-, -P(=O)(OR b )O-, -(C6-C10 arylene)- or -(6 to 10-membered heteroarylene)-; R a and R b each independently is H, optionally substituted C1-C12 alkyl or optionally substituted C1-C12 alkenyl; x is 0, 1 or 2; said G3 and G4 each independently is a bond, optionally substituted C2-C24 straight-chain alkylene; said L3 and L4 each independently is a bond, -OC(=O)-, -C(=O)O-, -OC(=O)O-, -C(=O)-, -O-, -S(O) i -, -SS-, -C(=O)S-, -SC(=O)-, -NR c C(=O)-, -C(=O)NR c -, -NR c C(=O)NR d -, -OC(=O)NR c -, -NR c C(=O)O-, -SC(=S)-, -C(=S)S-, -C(=S)-, -CH(OH)-, -P(=O)(OR c )O-, -(C6-C10 arylene)- or -(6 to 10-membered heteroarylene)-; R c and R dEach is independently H, an optionally substituted C1-C12 alkyl group, or an optionally substituted C1-C12 alkenyl group; i is 0, 1, or 2; G5 and G6 are each independently an optionally substituted C2-C24 straight-chain alkyl group or an optionally substituted C2-C24 straight-chain alkenyl group.

[0092] In a specific embodiment, X is an optionally substituted C1-C3 straight-chain alkyl group, Y is -G1L1G3L3G5, Z is a C2-C4 alkylene group; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -OC(=O)-, -C(=O)O-, -OC(=O)O-, -C(=O)-, -O-, -S(O) x -, -SS-, -C(=O)S-, -SC(=O)-, -NR a C(=O)-, -C(=O)NR b -, -NR a C(=O)NR b -, -OC(=O)NR b -, -NR a C(=O)O-, -SC(=S)-, -C(=S)S-, -C(=S)-, -CH(OH)-, -P(=O)(OR b )O-, -(C6-C10 arylene)- or -(6- to 10-membered heteroarylene)-; R a and R b are each independently H, an optionally substituted C1-C12 alkyl group, or an optionally substituted C1-C12 alkenyl group; x is 0, 1, or 2; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene group; L3 and L4 are each independently a bond, -OC(=O)-, -C(=O)O-, -OC(=O)O-, -C(=O)-, -O-, -S(O) i -, -SS-, -C(=O)S-, -SC(=O)-, -NR c C(=O)-, -C(=O)NR c -, -NR c C(=O)NR d -, -OC(=O)NR c -, -NR c C(=O)O-, -SC(=S)-, -C(=S)S-, -C(=S)-, -CH(OH)-, -P(=O)(OR c )O-, -(C6-C10 arylene)- or -(6- to 10-membered heteroarylene)-; R c and R dEach is independently H, optionally substituted C1-C12 alkyl or optionally substituted C1-C12 alkenyl; i is 0, 1 or 2; G5 and G6 are each independently optionally substituted C2-C24 straight-chain alkyl or optionally substituted C2-C24 straight-chain alkenyl.

[0093] In a specific embodiment, X is -G1L1G3L3G5, Y is optionally substituted C1-C3 straight-chain alkyl, and Z is C2-C4 alkylene; G1 and G2 are each independently optionally substituted C2-C24 straight-chain alkylene; L1 and L2 are each independently -OC(=O)-, -C(=O)O-, -OC(=O)O-, -C(=O)-, -O-, -S(O) x -, -SS-, -C(=O)S-, -SC(=O)-, -NR a C(=O)-, -C(=O)NR b -, -NR a C(=O)NR b -, -OC(=O)NR b -, -NR a C(=O)O-, -SC(=S)-, -C(=S)S-, -C(=S)-, -CH(OH)-, -P(=O)(OR b )O-, -(C6-C10 arylene)- or -(6 to 10-membered heteroarylene)-; R a and R b Each is independently H, optionally substituted C1-C12 alkyl or optionally substituted C1-C12 alkenyl; x is 0, 1 or 2; G3 and G4 are each independently a bond, optionally substituted C2-C24 straight-chain alkylene; L3 and L4 are each independently a bond, -OC(=O)-, -C(=O)O-, -OC(=O)O-, -C(=O)-, -O-, -S(O) i -, -SS-, -C(=O)S-, -SC(=O)-, -NR c C(=O)-, -C(=O)NR c -, -NR c C(=O)NR d -, -OC(=O)NR c -, -NR c C(=O)O-, -SC(=S)-, -C(=S)S-, -C(=S)-, -CH(OH)-, -P(=O)(OR c )O-, -(C6-C10 arylene)- or -(6 to 10-membered heteroarylene)-; R c and R dEach is independently H, optionally substituted C1-C12 alkyl or optionally substituted C1-C12 alkenyl; i is 0, 1 or 2; G5 and G6 are each independently optionally substituted C2-C24 straight-chain alkyl or optionally substituted C2-C24 straight-chain alkenyl.

[0094] In a specific embodiment, X and Y are each independently optionally substituted C1-C3 straight-chain alkyl, and Z is optionally substituted -R e G7R f -, R e and R f are optionally substituted C2-C4 alkylene, G7 is -(3-7 membered heterocyclic alkylene)-; G1 and G2 are each independently optionally substituted C2-C24 straight-chain alkylene; L1 and L2 are each independently -OC(=O)-, -C(=O)O-, -OC(=O)O-, -C(=O)-, -O-, -S(O) x -, -SS-, -C(=O)S-, -SC(=O)-, -NR a C(=O)-, -C(=O)NR b -, -NR a C(=O)NR b -, -OC(=O)NR b -, -NR a C(=O)O-, -SC(=S)-, -C(=S)S-, -C(=S)-, -CH(OH)-, -P(=O)(OR b )O-, -(C6-C10 arylene)- or -(6 to 10 membered heteroarylene)-; R a and R b are each independently H, optionally substituted C1-C12 alkyl or optionally substituted C1-C12 alkenyl; x is 0, 1 or 2; G3 and G4 are each independently a bond, optionally substituted C2-C24 straight-chain alkylene; L3 and L4 are each independently a bond, -OC(=O)-, -C(=O)O-, -OC(=O)O-, -C(=O)-, -O-, -S(O) i -, -SS-, -C(=O)S-, -SC(=O)-, -NR c C(=O)-, -C(=O)NR c -, -NR c C(=O)NR d -, -OC(=O)NR [[ID= / / ID=42]] c -, -NR c C(=O)O-, -SC(=S)-, -C(=S)S-, -C(=S)-, -CH(OH)-, -P(=O)(OR c)O-, -(C6-C10 arylene)-, or -(6- to 10-membered heteroarylene)-; R c and R d are each independently H, optionally substituted C1-C12 alkyl, or optionally substituted C1-C12 alkenyl; i is 0, 1, or 2; G5 and G6 are each independently optionally substituted C2-C24 straight-chain alkyl, optionally substituted C2-C24 straight-chain alkenyl.

[0095] In a specific embodiment, X and Y are each independently -G1L1G3L3G5, Z is optionally substituted -R e G7R f -, R e and R f is optionally substituted C2-C4 alkylene, G7 is -(3- to 7-membered heterocycloalkylene)-; G1 and G2 are each independently optionally substituted C2-C24 straight-chain alkylene; L1 and L2 are each independently -OC(=O)-, -C(=O)O-, -OC(=O)O-, -C(=O)-, -O-, -S(O) x -, -SS-, -C(=O)S-, -SC(=O)-, -NR a C(=O)-, -C(=O)NR b -, -NR a C(=O)NR b -, -OC(=O)NR b -, -NR a C(=O)O-, -SC(=S)-, -C(=S)S-, -C(=S)-, -CH(OH)-, -P(=O)(OR b )O-, -(C6-C10 arylene)-, or -(6- to 10-membered heteroarylene)-; R a and R b are each independently H, optionally substituted C1-C12 alkyl, or optionally substituted C1-C12 alkenyl; x is 0, 1, or 2; G3 and G4 are each independently a bond, optionally substituted C2-C24 straight-chain alkylene; L3 and L4 are each independently a bond, -OC(=O)-, -C(=O)O-, -OC(=O)O-, -C(=O)-, -O-, -S(O) i -, -SS-, -C(=O)S-, -SC(=O)-, -NR c C(=O)-, -C(=O)NR c -, -NR c C(=O)NR d -, -OC(=O)NR c -, -NR cC(=O)O-, -SC(=S)-, -C(=S)S-, -C(=S)-, -CH(OH)-, -P(=O)(OR c )O-, -(C6-C10 arylene)- or -(6 to 10-member heteroarylene)-; R c and R d are each independently H, optionally substituted C1-C12 alkyl or optionally substituted C1-C12 alkenyl; i is 0, 1 or 2; said G5 and G6 are each independently optionally substituted C2-C24 straight-chain alkyl, optionally substituted C2-C24 straight-chain alkenyl.

[0096] In a specific embodiment, X is optionally substituted C1-C3 straight-chain alkyl, Y is -G1L1G3L3G5, Z is optionally substituted -R e G7R f -, R e and R f is optionally substituted C2-C4 alkylene, G7 is -(3-7-member heterocycloalkylene)-; said G1 and G2 are each independently optionally substituted C2-C24 straight-chain alkylene; said L1 and L2 are each independently -OC(=O)-, -C(=O)O-, -OC(=O)O-, -C(=O)-, -O-, -S(O) x -, -SS-, -C(=O)S-, -SC(=O)-, -NR a C(=O)-, -C(=O)NR b -, -NR a C(=O)NR b -, -OC(=O)NR b -, -NR a C(=O)O-, -SC(=S)-, -C(=S)S-, -C(=S)-, -CH(OH)-, -P(=O)(OR b )O-, -(C6-C10 arylene)- or -(6 to 10-member heteroarylene)-; R a and R b are each independently H, optionally substituted C1-C12 alkyl or optionally substituted C1-C12 alkenyl; x is 0, 1 or 2; said G3 and G4 are each independently a bond, optionally substituted C2-C24 straight-chain alkylene; said L3 and L4 are each independently a bond, -OC(=O)-, -C(=O)O-, -OC(=O)O-, -C(=O)-, -O-, -S(O) i -, -SS-, -C(=O)S-, -SC(=O)-, -NR c C(=O)-, -C(=O)NR c -, -NRc C(=O)NR d -, -OC(=O)NR c -, -NR c C(=O)O-, -SC(=S)-, -C(=S)S-, -C(=S)-, -CH(OH)-, -P(=O)(OR c )O-, -(C6-C10 arylene)- or -(6 to 10-membered heteroarylene)-; R c and R d are each independently H, optionally substituted C1-C12 alkyl or optionally substituted C1-C12 alkenyl; i is 0, 1 or 2; said G5 and G6 are each independently optionally substituted C2-C24 straight-chain alkyl, optionally substituted C2-C24 straight-chain alkenyl.

[0097] In a specific embodiment, X is -G1L1G3L3G5, Y is optionally substituted C1-C3 straight-chain alkyl, Z is optionally substituted -R e G7R f -, R e and R f is optionally substituted C2-C4 alkylene, G7 is -(3-7-membered heterocycloalkylene)-; said G1 and G2 are each independently optionally substituted C2-C24 straight-chain alkylene; said L1 and L2 are each independently -OC(=O)-, -C(=O)O-, -OC(=O)O-, -C(=O)-, -O-, -S(O) x -, -SS-, -C(=O)S-, -SC(=O)-, -NR a C(=O)-, -C(=O)NR b -, -NR a C(=O)NR b -, -OC(=O)NR b -, -NR a C(=O)O-, -SC(=S)-, -C(=S)S-, -C(=S)-, -CH(OH)-, -P(=O)(OR b )O-, -(C6-C10 arylene)- or -(6 to 10-membered heteroarylene)-; R a and R b are each independently H, optionally substituted C1-C12 alkyl or optionally substituted C1-C12 alkenyl; x is 0, 1 or 2; said G3 and G4 are each independently a bond, optionally substituted C2-C24 straight-chain alkylene; said L3 and L4 are each independently a bond, -OC(=O)-, -C(=O)O-, -OC(=O)O-, -C(=O)-, -O-, -S(O) i-, -SS-, -C(=O)S-, -SC(=O)-, -NR c C(=O)-, -C(=O)NR c -, -NR c C(=O)NR d -, -OC(=O)NR c -, -NR c C(=O)O-, -SC(=S)-, -C(=S)S-, -C(=S)-, -CH(OH)-, -P(=O)(OR c )O-, -(C6-C10 arylene)- or -(6 to 10-member heteroarylene)-; R c and R d each independently is H, optionally substituted C1-C12 alkyl or optionally substituted C1-C12 alkenyl; i is 0, 1 or 2; said G5 and G6 each independently is optionally substituted C2-C24 straight-chain alkyl, optionally substituted C2-C24 straight-chain alkenyl.

[0098] In a specific embodiment, X and Y each independently is C1-C3 straight-chain alkyl, Z is C2-C4 alkylene, and X, Z together with the nitrogen to which they are attached form a ring; said G1 and G2 each independently is optionally substituted C2-C24 straight-chain alkylene; said L1 and L2 each independently is -OC(=O)-, -C(=O)O-, -OC(=O)O-, -C(=O)-, -O-, -S(O) x -, -SS-, -C(=O)S-, -SC(=O)-, -NR a C(=O)-, -C(=O)NR b -, -NR a C(=O)NR b -, -OC(=O)NR b -, -NR a C(=O)O-, -SC(=S)-, -C(=S)S-, -C(=S)-, -CH(OH)-, -P(=O)(OR b )O-, -(C6-C10 arylene)- or -(6 to 10-member heteroarylene)-; R a and R b each independently is H, optionally substituted C1-C12 alkyl or optionally substituted C1-C12 alkenyl; x is 0, 1 or 2; said G3 and G4 each independently is a bond, optionally substituted C2-C24 straight-chain alkylene; said L3 and L4 each independently is a bond, -OC(=O)-, -C(=O)O-, -OC(=O)O-, -C(=O)-, -O-, -S(O) i-, -SS-, -C(=O)S-, -SC(=O)-, -NR c C(=O)-, -C(=O)NR c -, -NR c C(=O)NR d -, -OC(=O)NR c -, -NR c C(=O)O-, -SC(=S)-, -C(=S)S-, -C(=S)-, -CH(OH)-, -P(=O)(OR c )O-, -(C6-C10 arylene)- or -(6- to 10-membered heteroarylene)-; R c and R d each independently is H, optionally substituted C1-C12 alkyl or optionally substituted C1-C12 alkenyl; i is 0, 1 or 2; said G5 and G6 each independently is optionally substituted C2-C24 straight-chain alkyl, optionally substituted C2-C24 straight-chain alkenyl.

[0099] In a specific embodiment, X and Y each independently is optionally substituted C1-C3 straight-chain alkyl, Z is C2-C4 alkylene; said G1 and G2 each independently is optionally substituted C2-C24 straight-chain alkylene; said L1 and L2 each independently is -C(=O)O-; said G3 and G4 each independently is a bond, optionally substituted C2-C24 straight-chain alkylene; said L3 and L4 each independently is a bond, -OC(=O)-, -C(=O)O-, -OC(=O)O-, -C(=O)-, -O-, -S(O) i -, -SS-, -C(=O)S-, -SC(=O)-, -NR c C(=O)-, -C(=O)NR c -, -NR c C(=O)NR d -, -OC(=O)NR c -, -NR c C(=O)O-, -SC(=S)-, -C(=S)S-, -C(=S)-, -CH(OH)-, -P(=O)(OR c )O-, -(C6-C10 arylene)- or -(6- to 10-membered heteroarylene)-; R c and R d each independently is H, optionally substituted C1-C12 alkyl or optionally substituted C1-C12 alkenyl; i is 0, 1 or 2; said G5 and G6 each independently is optionally substituted C2-C24 straight-chain alkyl, optionally substituted C2-C24 straight-chain alkenyl.

[0100] In a specific embodiment, X and Y are each independently -G1L1G3L3G5, Z is a C2-C4 alkylene group; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene group; L3 and L4 are each independently a bond, -OC(=O)-, -C(=O)O-, -OC(=O)O-, -C(=O)-, -O-, -S(O) i -, -SS-, -C(=O)S-, -SC(=O)-, -NR c C(=O)-, -C(=O)NR c -, -NR c C(=O)NR d -, -OC(=O)NR c -, -NR c C(=O)O-, -SC(=S)-, -C(=S)S-, -C(=S)-, -CH(OH)-, -P(=O)(OR c )O-, -(C6-C10 arylene)- or -(6- to 10-membered heteroarylene)-; R c and R d are each independently H, an optionally substituted C1-C12 alkyl group or an optionally substituted C1-C12 alkenyl group; i is 0, 1 or 2; G5 and G6 are each independently an optionally substituted C2-C24 straight-chain alkyl group, an optionally substituted C2-C24 straight-chain alkenyl group.

[0101] In a specific embodiment, X is an optionally substituted C1-C3 straight-chain alkyl group, Y is -G1L1G3L3G5, Z is a C2-C4 alkylene group; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene group; L3 and L4 are each independently a bond, -OC(=O)-, -C(=O)O-, -OC(=O)O-, -C(=O)-, -O-, -S(O) i -, -SS-, -C(=O)S-, -SC(=O)-, -NR c C(=O)-, -C(=O)NR c -, -NR c C(=O)NR d -, -OC(=O)NR c -, -NR cC(=O)O-, -SC(=S)-, -C(=S)S-, -C(=S)-, -CH(OH)-, -P(=O)(OR c )O-, -(C6-C10 arylene)- or -(6- to 10-membered heteroarylene)-; R c and R d are each independently H, optionally substituted C1-C12 alkyl or optionally substituted C1-C12 alkenyl; i is 0, 1 or 2; said G5 and G6 are each independently optionally substituted C2-C24 straight-chain alkyl, optionally substituted C2-C24 straight-chain alkenyl.

[0102] In a specific embodiment, X is -G1L1G3L3G5, Y is optionally substituted C1-C3 straight-chain alkyl, and Z is C2-C4 alkylene; said G1 and G2 are each independently optionally substituted C2-C24 straight-chain alkylene; said L1 and L2 are each independently -C(=O)O-; said G3 and G4 are each independently a bond, optionally substituted C2-C24 straight-chain alkylene; said L3 and L4 are each independently a bond, -OC(=O)-, -C(=O)O-, -OC(=O)O-, -C(=O)-, -O-, -S(O) i -, -SS-, -C(=O)S-, -SC(=O)-, -NR c C(=O)-, -C(=O)NR c -, -NR c C(=O)NR d -, -OC(=O)NR c -, -NR c C(=O)O-, -SC(=S)-, -C(=S)S-, -C(=S)-, -CH(OH)-, -P(=O)(OR c )O-, -(C6-C10 arylene)- or -(6- to 10-membered heteroarylene)-; R c and R d are each independently H, optionally substituted C1-C12 alkyl or optionally substituted C1-C12 alkenyl; i is 0, 1 or 2; said G5 and G6 are each independently optionally substituted C2-C24 straight-chain alkyl, optionally substituted C2-C24 straight-chain alkenyl.

[0103] In a specific embodiment, X and Y are each independently optionally substituted C1-C3 straight-chain alkyl, and Z is optionally substituted -R e G7R f -, R e and R fis an optionally substituted C2-C4 alkylene, G7 is -(3-7-member heterocyclic alkylene)-; said G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene; said L1 and L2 are each independently -C(=O)O-; said G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene; said L3 and L4 are each independently a bond, -OC(=O)-, -C(=O)O-, -OC(=O)O-, -C(=O)-, -O-, -S(O) i -, -SS-, -C(=O)S-, -SC(=O)-, -NR c C(=O)-, -C(=O)NR c -, -NR c C(=O)NR d -, -OC(=O)NR c -, -NR c C(=O)O-, -SC(=S)-, -C(=S)S-, -C(=S)-, -CH(OH)-, -P(=O)(OR c )O-, -(C6-C10 arylene)- or -(6- to 10-member heteroarylene)-; R c and R d are each independently H, an optionally substituted C1-C12 alkyl or an optionally substituted C1-C12 alkenyl; i is 0, 1 or 2; said G5 and G6 are each independently an optionally substituted C2-C24 straight-chain alkyl, an optionally substituted C2-C24 straight-chain alkenyl.

[0104] In a specific embodiment, X and Y are each independently -G1L1G3L3G5, Z is an optionally substituted -R e G7R f (-), R e and R f is an optionally substituted C2-C4 alkylene, G7 is -(3-7-member heterocyclic alkylene)-; said G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene; said L1 and L2 are each independently -C(=O)O-; said G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene; said L3 and L4 are each independently a bond, -OC(=O)-, -C(=O)O-, -OC(=O)O-, -C(=O)-, -O-, -S(O) i -, -SS-, -C(=O)S-, -SC(=O)-, -NR c C(=O)-, -C(=O)NR c -, -NR c C(=O)NR d -, -OC(=O)NRc -, -NR c C(=O)O-, -SC(=S)-, -C(=S)S-, -C(=S)-, -CH(OH)-, -P(=O)(OR c )O-, -(C6-C10 arylene)- or -(6 to 10-membered heteroarylene)-; R c and R d each independently is H, optionally substituted C1-C12 alkyl or optionally substituted C1-C12 alkenyl; i is 0, 1 or 2; said G5 and G6 each independently is optionally substituted C2-C24 straight-chain alkyl, optionally substituted C2-C24 straight-chain alkenyl.

[0105] In a specific embodiment, X is optionally substituted C1-C3 straight-chain alkyl, Y is -G1L1G3L3G5, Z is optionally substituted -R e G7R f -, R e and R f is optionally substituted C2-C4 alkylene, G7 is -(3-7-membered heterocycloalkylene)-; said G1 and G2 each independently is optionally substituted C2-C24 straight-chain alkylene; said L1 and L2 each independently is -C(=O)O-; said G3 and G4 each independently is a bond, optionally substituted C2-C24 straight-chain alkylene; said L3 and L4 each independently is a bond, -OC(=O)-, -C(=O)O-, -OC(=O)O-, -C(=O)-, -O-, -S(O) i -, -SS-, -C(=O)S-, -SC(=O)-, -NR c C(=O)-, -C(=O)NR c -, -NR c C(=O)NR d -, -OC(=O)NR c -, -NR c C(=O)O-, -SC(=S)-, -C(=S)S-, -C(=S)-, -CH(OH)-, -P(=O)(OR c )O-, -(C6-C10 arylene)- or -(6 to 10-membered heteroarylene)-; R c and R d each independently is H, optionally substituted C1-C12 alkyl or optionally substituted C1-C12 alkenyl; i is 0, 1 or 2; said G5 and G6 each independently is optionally substituted C2-C24 straight-chain alkyl, optionally substituted C2-C24 straight-chain alkenyl.

[0106] In a specific embodiment, X is -G1L1G3L3G5, Y is an optionally substituted C1-C3 straight-chain alkyl group, and Z is an optionally substituted -R e G7R f -, R e and R f is an optionally substituted C2-C4 alkylene group, G7 is -(3-7-membered heterocyclic alkylene)-; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene group; L3 and L4 are each independently a bond, -OC(=O)-, -C(=O)O-, -OC(=O)O-, -C(=O)-, -O-, -S(O) i -, -SS-, -C(=O)S-, -SC(=O)-, -NR c C(=O)-, -C(=O)NR c -, -NR c C(=O)NR d -, -OC(=O)NR c -, -NR c C(=O)O-, -SC(=S)-, -C(=S)S-, -C(=S)-, -CH(OH)-, -P(=O)(OR c )O-, -(C6-C10 arylene)- or -(6- to 10-membered heteroarylene)-; R c and R d are each independently H, an optionally substituted C1-C12 alkyl group or an optionally substituted C1-C12 alkenyl group; i is 0, 1 or 2; G5 and G6 are each independently an optionally substituted C2-C24 straight-chain alkyl group, an optionally substituted C2-C24 straight-chain alkenyl group.

[0107] In a specific embodiment, X and Y are each independently a C1-C3 straight-chain alkyl group, Z is a C2-C4 alkylene group, and X, Z together with the nitrogen to which they are attached form a ring; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene group; L3 and L4 are each independently a bond, -OC(=O)-, -C(=O)O-, -OC(=O)O-, -C(=O)-, -O-, -S(O) i -, -SS-, -C(=O)S-, -SC(=O)-, -NR c C(=O)-, -C(=O)NR c -, -NR cC(=O)NR d -, -OC(=O)NR c -, -NR c C(=O)O-, -SC(=S)-, -C(=S)S-, -C(=S)-, -CH(OH)-, -P(=O)(OR c )O-, -(C6-C10 arylene)- or -(6- to 10-membered heteroarylene)-; R c and R d each independently is H, optionally substituted C1-C12 alkyl or optionally substituted C1-C12 alkenyl; i is 0, 1 or 2; G5 and G6 each independently is optionally substituted C2-C24 straight-chain alkyl, optionally substituted C2-C24 straight-chain alkenyl.

[0108] In a specific embodiment, X and Y each independently is optionally substituted C1-C3 straight-chain alkyl, Z is C2-C4 alkylene; G1 and G2 each independently is optionally substituted C2-C24 straight-chain alkylene; L1 and L2 each independently is -C(=O)O-; G3 and G4 each independently is a bond, optionally substituted C2-C24 straight-chain alkylene; L3 and L4 each independently is a bond, -OC(=O)-, -C(=O)O-, -OC(=O)O-, -C(=O)-, -O-, -S(O) i -, -SS-, -C(=O)S-, -SC(=O)-, -NR c C(=O)-, -C(=O)NR c -, -NR c C(=O)NR d -, -OC(=O)NR c -, -NR c C(=O)O-, -SC(=S)-, -C(=S)S-, -C(=S)-, -CH(OH)-, -P(=O)(OR c )O-, -(C6-C10 arylene)- or -(6- to 10-membered heteroarylene)-; R c and R d each independently is H, optionally substituted C1-C12 alkyl or optionally substituted C1-C12 alkenyl; i is 0, 1 or 2; G5 and G6 each independently is optionally substituted C2-C24 straight-chain alkyl, optionally substituted C2-C24 straight-chain alkenyl.

[0109] In a specific embodiment, X and Y are each independently -G1L1G3L3G5, Z is a C2-C4 alkylene group; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene group; L3 and L4 are each independently a bond, -OC(=O)-, -C(=O)O-, -OC(=O)O-, -C(=O)-, -O-, -S(O) i -, -SS-, -C(=O)S-, -SC(=O)-, -NR c C(=O)-, -C(=O)NR c -, -NR c C(=O)NR d -, -OC(=O)NR c -, -NR c C(=O)O-, -SC(=S)-, -C(=S)S-, -C(=S)-, -CH(OH)-, -P(=O)(OR c )O-, -(C6-C10 arylene)- or -(6- to 10-membered heteroarylene)-; R c and R d are each independently H, an optionally substituted C1-C12 alkyl group or an optionally substituted C1-C12 alkenyl group; i is 0, 1 or 2; G5 and G6 are each independently an optionally substituted C2-C24 straight-chain alkyl group, an optionally substituted C2-C24 straight-chain alkenyl group.

[0110] In a specific embodiment, X is an optionally substituted C1-C3 straight-chain alkyl group, Y is -G1L1G3L3G5, Z is a C2-C4 alkylene group; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene group; L3 and L4 are each independently a bond, -OC(=O)-, -C(=O)O-, -OC(=O)O-, -C(=O)-, -O-, -S(O) i -, -SS-, -C(=O)S-, -SC(=O)-, -NR c C(=O)-, -C(=O)NR c -, -NR c C(=O)NR d -, -OC(=O)NR c -, -NR cC(=O)O-, -SC(=S)-, -C(=S)S-, -C(=S)-, -CH(OH)-, -P(=O)(OR c )O-, -(C6-C10 arylene)- or -(6 to 10-member heteroarylene)-; R c and R d are each independently H, optionally substituted C1-C12 alkyl or optionally substituted C1-C12 alkenyl; i is 0, 1 or 2; said G5 and G6 are each independently optionally substituted C2-C24 straight-chain alkyl, optionally substituted C2-C24 straight-chain alkenyl.

[0111] In a specific embodiment, X is -G1L1G3L3G5, Y is optionally substituted C1-C3 straight-chain alkyl, Z is C2-C4 alkylene; said G1 and G2 are each independently optionally substituted C2-C24 straight-chain alkylene; said L1 and L2 are each independently -C(=O)O-; said G3 and G4 are each independently a bond, optionally substituted C2-C24 straight-chain alkylene; said L3 and L4 are each independently a bond, -OC(=O)-, -C(=O)O-, -OC(=O)O-, -C(=O)-, -O-, -S(O) i -, -SS-, -C(=O)S-, -SC(=O)-, -NR c C(=O)-, -C(=O)NR c -, -NR c C(=O)NR d -, -OC(=O)NR c -, -NR c C(=O)O-, -SC(=S)-, -C(=S)S-, -C(=S)-, -CH(OH)-, -P(=O)(OR c )O-, -(C6-C10 arylene)- or -(6 to 10-member heteroarylene)-; R c and R d are each independently H, optionally substituted C1-C12 alkyl or optionally substituted C1-C12 alkenyl; i is 0, 1 or 2; said G5 and G6 are each independently optionally substituted C2-C24 straight-chain alkyl, optionally substituted C2-C24 straight-chain alkenyl.

[0112] In a specific embodiment, X and Y are each independently optionally substituted C1-C3 straight-chain alkyl, Z is optionally substituted -R e G7R f -, R e and R fis an optionally substituted C2-C4 alkylene, G7 is -(3-7 membered heterocyclic alkylene)-; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene; L3 and L4 are each independently a bond, -OC(=O)-, -C(=O)O-, -OC(=O)O-, -C(=O)-, -O-, -S(O) i -, -SS-, -C(=O)S-, -SC(=O)-, -NR c C(=O)-, -C(=O)NR c -, -NR c C(=O)NR d -, -OC(=O)NR c -, -NR c C(=O)O-, -SC(=S)-, -C(=S)S-, -C(=S)-, -CH(OH)-, -P(=O)(OR c )O-, -(C6-C10 arylene)- or -(6 to 10 membered heteroarylene)-; R c and R d are each independently H, an optionally substituted C1-C12 alkyl or an optionally substituted C1-C12 alkenyl; i is 0, 1 or 2; G5 and G6 are each independently an optionally substituted C2-C24 straight-chain alkyl, an optionally substituted C2-C24 straight-chain alkenyl.

[0113] In a specific embodiment, X and Y are each independently -G1L1G3L3G5, Z is an optionally substituted -R e G7R f (-), R e and R f is an optionally substituted C2-C4 alkylene, G7 is -(3-7 membered heterocyclic alkylene)-; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene; L3 and L4 are each independently a bond, -OC(=O)-, -C(=O)O-, -OC(=O)O-, -C(=O)-, -O-, -S(O) i -, -SS-, -C(=O)S-, -SC(=O)-, -NR c C(=O)-, -C(=O)NR c -, -NR c C(=O)NR d -, -OC(=O)NRc -, -NR c C(=O)O-, -SC(=S)-, -C(=S)S-, -C(=S)-, -CH(OH)-, -P(=O)(OR c )O-, -(C6-C10 arylene)- or -(6- to 10-membered heteroarylene)-; R c and R d each independently is H, optionally substituted C1-C12 alkyl or optionally substituted C1-C12 alkenyl; i is 0, 1 or 2; said G5 and G6 each independently is optionally substituted C2-C24 straight-chain alkyl, optionally substituted C2-C24 straight-chain alkenyl.

[0114] In a specific embodiment, X is optionally substituted C1-C3 straight-chain alkyl, Y is -G1L1G3L3G5, Z is optionally substituted -R e G7R f -, R e and R f is optionally substituted C2-C4 alkylene, G7 is -(3- to 7-membered heterocycloalkylene)-; said G1 and G2 each independently is optionally substituted C2-C24 straight-chain alkylene; said L1 and L2 each independently is -C(=O)O-; said G3 and G4 each independently is a bond, optionally substituted C2-C24 straight-chain alkylene; said L3 and L4 each independently is a bond, -OC(=O)-, -C(=O)O-, -OC(=O)O-, -C(=O)-, -O-, -S(O) i -, -SS-, -C(=O)S-, -SC(=O)-, -NR c C(=O)-, -C(=O)NR c -, -NR c C(=O)NR d -, -OC(=O)NR c -, -NR c C(=O)O-, -SC(=S)-, -C(=S)S-, -C(=S)-, -CH(OH)-, -P(=O)(OR c )O-, -(C6-C10 arylene)- or -(6- to 10-membered heteroarylene)-; R c and R d each independently is H, optionally substituted C1-C12 alkyl or optionally substituted C1-C12 alkenyl; i is 0, 1 or 2; said G5 and G6 each independently is optionally substituted C2-C24 straight-chain alkyl, optionally substituted C2-C24 straight-chain alkenyl.

[0115] In a specific embodiment, X is -G1L1G3L3G5, Y is an optionally substituted C1-C3 straight-chain alkyl group, and Z is an optionally substituted -R e G7R f -, R e and R f is an optionally substituted C2-C4 alkylene group, G7 is -(3-7-membered heterocyclic alkylene)-; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene group; L3 and L4 are each independently a bond, -OC(=O)-, -C(=O)O-, -OC(=O)O-, -C(=O)-, -O-, -S(O) i -, -SS-, -C(=O)S-, -SC(=O)-, -NR c C(=O)-, -C(=O)NR c -, -NR c C(=O)NR d -, -OC(=O)NR c -, -NR c C(=O)O-, -SC(=S)-, -C(=S)S-, -C(=S)-, -CH(OH)-, -P(=O)(OR c )O-, -(C6-C10 arylene)- or -(6- to 10-membered heteroarylene)-; R c and R d are each independently H, an optionally substituted C1-C12 alkyl group or an optionally substituted C1-C12 alkenyl group; i is 0, 1 or 2; G5 and G6 are each independently an optionally substituted C2-C24 straight-chain alkyl group, an optionally substituted C2-C24 straight-chain alkenyl group.

[0116] In a specific embodiment, X and Y are each independently a C1-C3 straight-chain alkyl group, Z is a C2-C4 alkylene group, and X, Z together with the nitrogen to which they are attached form a ring; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene group; L3 and L4 are each independently a bond, -OC(=O)-, -C(=O)O-, -OC(=O)O-, -C(=O)-, -O-, -S(O) i -, -SS-, -C(=O)S-, -SC(=O)-, -NR c C(=O)-, -C(=O)NR c -, -NR cC(=O)NR d -, -OC(=O)NR c -, -NR c C(=O)O-, -SC(=S)-, -C(=S)S-, -C(=S)-, -CH(OH)-, -P(=O)(OR c )O-, -(C6-C10 arylene)- or -(6 to 10-member heteroarylene)-; R c and R d are each independently H, optionally substituted C1-C12 alkyl or optionally substituted C1-C12 alkenyl; i is 0, 1 or 2; said G5 and G6 are each independently optionally substituted C2-C24 straight-chain alkyl, optionally substituted C2-C24 straight-chain alkenyl.

[0117] In a specific embodiment, X and Y are each independently optionally substituted C1-C3 straight-chain alkyl, Z is C2-C4 alkylene; said G1 and G2 are each independently optionally substituted C2-C24 straight-chain alkylene; said L1 and L2 are each independently -C(=O)O-; said G3 and G4 are each independently a bond, optionally substituted C2-C24 straight-chain alkylene; said L3 and L4 are each independently a bond; said G5 and G6 are each independently optionally substituted C2-C24 straight-chain alkyl, optionally substituted C2-C24 straight-chain alkenyl.

[0118] In a specific embodiment, X and Y are each independently -G1L1G3L3G5, Z is C2-C4 alkylene; said G1 and G2 are each independently optionally substituted C2-C24 straight-chain alkylene; said L1 and L2 are each independently -C(=O)O-; said G3 and G4 are each independently a bond, optionally substituted C2-C24 straight-chain alkylene; said L3 and L4 are each independently a bond; said G5 and G6 are each independently optionally substituted C2-C24 straight-chain alkyl, optionally substituted C2-C24 straight-chain alkenyl.

[0119] In a specific embodiment, X is optionally substituted C1-C3 straight-chain alkyl, Y is -G1L1G3L3G5, Z is C2-C4 alkylene; said G1 and G2 are each independently optionally substituted C2-C24 straight-chain alkylene; said L1 and L2 are each independently -C(=O)O-; said G3 and G4 are each independently a bond, optionally substituted C2-C24 straight-chain alkylene; said L3 and L4 are each independently a bond; said G5 and G6 are each independently optionally substituted C2-C24 straight-chain alkyl, optionally substituted C2-C24 straight-chain alkenyl.

[0120] In a specific embodiment, X is -G1L1G3L3G5, Y is an optionally substituted C1-C3 straight-chain alkyl group, and Z is a C2-C4 alkylene group; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene group; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C2-C24 straight-chain alkyl group, an optionally substituted C2-C24 straight-chain alkenyl group.

[0121] In a specific embodiment, X and Y are each independently an optionally substituted C1-C3 straight-chain alkyl group, and Z is an optionally substituted -R e G7R f -, R e and R f is an optionally substituted C2-C4 alkylene group, and G7 is -(3-7 membered heterocyclic alkylene)-; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene group; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C2-C24 straight-chain alkyl group, an optionally substituted C2-C24 straight-chain alkenyl group.

[0122] In a specific embodiment, X and Y are each independently -G1L1G3L3G5, and Z is an optionally substituted -R e G7R f -, R e and R f is an optionally substituted C2-C4 alkylene group, and G7 is -(3-7 membered heterocyclic alkylene)-; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene group; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C2-C24 straight-chain alkyl group, an optionally substituted C2-C24 straight-chain alkenyl group.

[0123] In a specific embodiment, X is an optionally substituted C1-C3 straight-chain alkyl group, Y is -G1L1G3L3G5, and Z is an optionally substituted -R e G7R f -, R e and R fis an optionally substituted C2-C4 alkylene, G7 is -(3-7-membered heterocyclic alkylene)-; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C2-C24 straight-chain alkyl, an optionally substituted C2-C24 straight-chain alkenyl.

[0124] In a specific embodiment, X is -G1L1G3L3G5, Y is an optionally substituted C1-C3 straight-chain alkyl, and Z is an optionally substituted -R e G7R f -, R e and R f is an optionally substituted C2-C4 alkylene, G7 is -(3-7-membered heterocyclic alkylene)-; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C2-C24 straight-chain alkyl, an optionally substituted C2-C24 straight-chain alkenyl.

[0125] In a specific embodiment, X and Y are each independently a C1-C3 straight-chain alkyl, Z is a C2-C4 alkylene, and X, Z together with the nitrogen to which they are attached form a ring; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C2-C24 straight-chain alkyl, an optionally substituted C2-C24 straight-chain alkenyl.

[0126] In a specific embodiment, X and Y are each independently an optionally substituted C1-C3 straight-chain alkyl, Z is a C2-C4 alkylene; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene; L3 and L4 are each independently -OC(=O)O-; G5 and G6 are each independently an optionally substituted C2-C24 straight-chain alkyl, an optionally substituted C2-C24 straight-chain alkenyl.

[0127] In a specific embodiment, X and Y are each independently -G1L1G3L3G5, Z is a C2-C4 alkylene group; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene group; L3 and L4 are each independently -OC(=O)O-; G5 and G6 are each independently an optionally substituted C2-C24 straight-chain alkyl group, an optionally substituted C2-C24 straight-chain alkenyl group.

[0128] In a specific embodiment, X is an optionally substituted C1-C3 straight-chain alkyl group, Y is -G1L1G3L3G5, Z is a C2-C4 alkylene group; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene group; L3 and L4 are each independently -OC(=O)O-; G5 and G6 are each independently an optionally substituted C2-C24 straight-chain alkyl group, an optionally substituted C2-C24 straight-chain alkenyl group.

[0129] In a specific embodiment, X is -G1L1G3L3G5, Y is an optionally substituted C1-C3 straight-chain alkyl group, Z is a C2-C4 alkylene group; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene group; L3 and L4 are each independently -OC(=O)O-; G5 and G6 are each independently an optionally substituted C2-C24 straight-chain alkyl group, an optionally substituted C2-C24 straight-chain alkenyl group.

[0130] In a specific embodiment, X and Y are each independently an optionally substituted C1-C3 straight-chain alkyl group, Z is an optionally substituted -R e G7R f -, R e and R f are each independently an optionally substituted C2-C4 alkylene group, G7 is -(3-7 membered heterocyclic alkylene)-; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene group; L3 and L4 are each independently -OC(=O)O-; G5 and G6 are each independently an optionally substituted C2-C24 straight-chain alkyl group, an optionally substituted C2-C24 straight-chain alkenyl group.

[0131] In a specific embodiment, X and Y are each independently -G1L1G3L3G5, and Z is optionally substituted -R e G7R f -, R e and R f are optionally substituted C2-C4 alkylene, G7 is -(3-7 membered heterocyclic alkylene)-; G1 and G2 are each independently optionally substituted C2-C24 straight-chain alkylene; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, optionally substituted C2-C24 straight-chain alkylene; L3 and L4 are each independently -OC(=O)O-; G5 and G6 are each independently optionally substituted C2-C24 straight-chain alkyl, optionally substituted C2-C24 straight-chain alkenyl.

[0132] In a specific embodiment, X is optionally substituted C1-C3 straight-chain alkyl, Y is -G1L1G3L3G5, and Z is optionally substituted -R e G7R f -, R e and R f are optionally substituted C2-C4 alkylene, G7 is -(3-7 membered heterocyclic alkylene)-; G1 and G2 are each independently optionally substituted C2-C24 straight-chain alkylene; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, optionally substituted C2-C24 straight-chain alkylene; L3 and L4 are each independently -OC(=O)O-; G5 and G6 are each independently optionally substituted C2-C24 straight-chain alkyl, optionally substituted C2-C24 straight-chain alkenyl.

[0133] In a specific embodiment, X is -G1L1G3L3G5, Y is optionally substituted C1-C3 straight-chain alkyl, and Z is optionally substituted -R e G7R f -, R e and R f are optionally substituted C2-C4 alkylene, G7 is -(3-7 membered heterocyclic alkylene)-; G1 and G2 are each independently optionally substituted C2-C24 straight-chain alkylene; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, optionally substituted C2-C24 straight-chain alkylene; L3 and L4 are each independently -OC(=O)O-; G5 and G6 are each independently optionally substituted C2-C24 straight-chain alkyl, optionally substituted C2-C24 straight-chain alkenyl.

[0134] In a specific embodiment, X and Y are each independently a C1-C3 straight-chain alkyl group, Z is a C2-C4 alkylene group, and X, Z together with the nitrogen to which they are attached form a ring; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene group; L3 and L4 are each independently -OC(=O)O-; G5 and G6 are each independently an optionally substituted C2-C24 straight-chain alkyl group, an optionally substituted C2-C24 straight-chain alkenyl group.

[0135] In a specific embodiment, X and Y are each independently an optionally substituted C1-C3 straight-chain alkyl group, Z is a C2-C4 alkylene group; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene group; L3 and L4 are each independently -OC(=O)O-; G5 and G6 are each independently an optionally substituted C2-C24 straight-chain alkyl group, an optionally substituted C2-C24 straight-chain alkenyl group.

[0136] In a specific embodiment, X and Y are each independently -G1L1G3L3G5, Z is a C2-C4 alkylene group; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene group; L3 and L4 are each independently -OC(=O)O-; G5 and G6 are each independently an optionally substituted C2-C24 straight-chain alkyl group, an optionally substituted C2-C24 straight-chain alkenyl group.

[0137] In a specific embodiment, X is an optionally substituted C1-C3 straight-chain alkyl group, Y is -G1L1G3L3G5, Z is a C2-C4 alkylene group; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene group; L3 and L4 are each independently -OC(=O)O-; G5 and G6 are each independently an optionally substituted C2-C24 straight-chain alkyl group, an optionally substituted C2-C24 straight-chain alkenyl group.

[0138] In a specific embodiment, X is -G1L1G3L3G5, Y is an optionally substituted C1-C3 straight-chain alkyl group, and Z is a C2-C4 alkylene group; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene group; L3 and L4 are each independently -OC(=O)O-; G5 and G6 are each independently an optionally substituted C2-C24 straight-chain alkyl group, an optionally substituted C2-C24 straight-chain alkenyl group.

[0139] In a specific embodiment, X and Y are each independently an optionally substituted C1-C3 straight-chain alkyl group, and Z is an optionally substituted -R e G7R f -, R e and R f are an optionally substituted C2-C4 alkylene group, G7 is -(3-7 membered heterocyclic alkylene)-; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene group; L3 and L4 are each independently -OC(=O)O-; G5 and G6 are each independently an optionally substituted C2-C24 straight-chain alkyl group, an optionally substituted C2-C24 straight-chain alkenyl group.

[0140] In a specific embodiment, X and Y are each independently -G1L1G3L3G5, and Z is an optionally substituted -R e G7R f -, R e and R f are an optionally substituted C2-C4 alkylene group, G7 is -(3-7 membered heterocyclic alkylene)-; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene group; L3 and L4 are each independently -OC(=O)O-; G5 and G6 are each independently an optionally substituted C2-C24 straight-chain alkyl group, an optionally substituted C2-C24 straight-chain alkenyl group.

[0141] In a specific embodiment, X is an optionally substituted C1-C3 straight-chain alkyl group, Y is -G1L1G3L3G5, and Z is an optionally substituted -R e G7R f -, R e and R fis an optionally substituted C2-C4 alkylene, G7 is -(3-7-membered heterocyclic alkylene)-; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene; L3 and L4 are each independently -OC(=O)O-; G5 and G6 are each independently an optionally substituted C2-C24 straight-chain alkyl, an optionally substituted C2-C24 straight-chain alkenyl.

[0142] In a specific embodiment, X is -G1L1G3L3G5, Y is an optionally substituted C1-C3 straight-chain alkyl, and Z is an optionally substituted -R e G7R f -, R e and R f is an optionally substituted C2-C4 alkylene, G7 is -(3-7-membered heterocyclic alkylene)-; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene; L3 and L4 are each independently -OC(=O)O-; G5 and G6 are each independently an optionally substituted C2-C24 straight-chain alkyl, an optionally substituted C2-C24 straight-chain alkenyl.

[0143] In a specific embodiment, X and Y are each independently a C1-C3 straight-chain alkyl, Z is a C2-C4 alkylene, and X, Z together with the nitrogen to which they are attached form a ring; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene; L3 and L4 are each independently -OC(=O)O-; G5 and G6 are each independently an optionally substituted C2-C24 straight-chain alkyl, an optionally substituted C2-C24 straight-chain alkenyl.

[0144] In a specific embodiment, X and Y are each independently an optionally substituted C1-C3 straight-chain alkyl, Z is a C2-C4 alkylene; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C2-C24 straight-chain alkyl, an optionally substituted C2-C24 straight-chain alkenyl.

[0145] In a specific embodiment, X and Y are each independently -G1L1G3L3G5, Z is a C2-C4 alkylene group; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene group; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C2-C24 straight-chain alkyl group, an optionally substituted C2-C24 straight-chain alkenyl group.

[0146] In a specific embodiment, X is an optionally substituted C1-C3 straight-chain alkyl group, Y is -G1L1G3L3G5, Z is a C2-C4 alkylene group; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene group; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C2-C24 straight-chain alkyl group, an optionally substituted C2-C24 straight-chain alkenyl group.

[0147] In a specific embodiment, X is -G1L1G3L3G5, Y is an optionally substituted C1-C3 straight-chain alkyl group, Z is a C2-C4 alkylene group; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene group; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C2-C24 straight-chain alkyl group, an optionally substituted C2-C24 straight-chain alkenyl group.

[0148] In a specific embodiment, X and Y are each independently an optionally substituted C1-C3 straight-chain alkyl group, Z is an optionally substituted -R e G7R f -, R e and R f are each independently an optionally substituted C2-C4 alkylene group, G7 is -(3-7 membered heterocyclic alkylene)-; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene group; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C2-C24 straight-chain alkyl group, an optionally substituted C2-C24 straight-chain alkenyl group.

[0149] In a specific embodiment, X and Y are each independently -G1L1G3L3G5, and Z is optionally substituted -R e G7R f -, R e and R f are optionally substituted C2-C4 alkylene, G7 is -(3-7 membered heterocyclic alkylene)-; G1 and G2 are each independently optionally substituted C2-C24 straight-chain alkylene; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, optionally substituted C2-C24 straight-chain alkylene; L3 and L4 are each independently a bond; G5 and G6 are each independently optionally substituted C2-C24 straight-chain alkyl, optionally substituted C2-C24 straight-chain alkenyl.

[0150] In a specific embodiment, X is optionally substituted C1-C3 straight-chain alkyl, Y is -G1L1G3L3G5, and Z is optionally substituted -R e G7R f -, R e and R f are optionally substituted C2-C4 alkylene, G7 is -(3-7 membered heterocyclic alkylene)-; G1 and G2 are each independently optionally substituted C2-C24 straight-chain alkylene; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, optionally substituted C2-C24 straight-chain alkylene; L3 and L4 are each independently a bond; G5 and G6 are each independently optionally substituted C2-C24 straight-chain alkyl, optionally substituted C2-C24 straight-chain alkenyl.

[0151] In a specific embodiment, X is -G1L1G3L3G5, Y is optionally substituted C1-C3 straight-chain alkyl, and Z is optionally substituted -R e G7R f -, R e and R f are optionally substituted C2-C4 alkylene, G7 is -(3-7 membered heterocyclic alkylene)-; G1 and G2 are each independently optionally substituted C2-C24 straight-chain alkylene; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, optionally substituted C2-C24 straight-chain alkylene; L3 and L4 are each independently a bond; G5 and G6 are each independently optionally substituted C2-C24 straight-chain alkyl, optionally substituted C2-C24 straight-chain alkenyl.

[0152] In a specific embodiment, X and Y are each independently a C1-C3 straight-chain alkyl group, Z is a C2-C4 alkylene group, and X, Z together with the nitrogen to which they are attached form a ring; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene group; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C2-C24 straight-chain alkyl group, an optionally substituted C2-C24 straight-chain alkenyl group.

[0153] In a specific embodiment, X and Y are each independently an optionally substituted C1-C3 straight-chain alkyl group, Z is a C2-C4 alkylene group; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene group; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C2-C24 straight-chain alkyl group, an optionally substituted C2-C24 straight-chain alkenyl group.

[0154] In a specific embodiment, X and Y are each independently -G1L1G3L3G5, Z is a C2-C4 alkylene group; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene group; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C2-C24 straight-chain alkyl group, an optionally substituted C2-C24 straight-chain alkenyl group.

[0155] In a specific embodiment, X is an optionally substituted C1-C3 straight-chain alkyl group, Y is -G1L1G3L3G5, Z is a C2-C4 alkylene group; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene group; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C2-C24 straight-chain alkyl group, an optionally substituted C2-C24 straight-chain alkenyl group.

[0156] In a specific embodiment, X is -G1L1G3L3G5, Y is an optionally substituted C1-C3 straight-chain alkyl group, and Z is a C2-C4 alkylene group; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene group; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C2-C24 straight-chain alkyl group, an optionally substituted C2-C24 straight-chain alkenyl group.

[0157] In a specific embodiment, X and Y are each independently an optionally substituted C1-C3 straight-chain alkyl group, and Z is optionally substituted -R e G7R f -, R e and R f is an optionally substituted C2-C4 alkylene group, and G7 is -(3-7-membered heterocyclic alkylene)-; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene group; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C2-C24 straight-chain alkyl group, an optionally substituted C2-C24 straight-chain alkenyl group.

[0158] In a specific embodiment, X and Y are each independently -G1L1G3L3G5, and Z is optionally substituted -R e G7R f -, R e and R f is an optionally substituted C2-C4 alkylene group, and G7 is -(3-7-membered heterocyclic alkylene)-; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene group; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C2-C24 straight-chain alkyl group, an optionally substituted C2-C24 straight-chain alkenyl group.

[0159] In a specific embodiment, X is an optionally substituted C1-C3 straight-chain alkyl group, Y is -G1L1G3L3G5, and Z is optionally substituted -R e G7R f -, R e and R fis an optionally substituted C2-C4 alkylene group, G7 is -(3-7-membered heterocyclic alkylene)-; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene group; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C2-C24 straight-chain alkyl group, an optionally substituted C2-C24 straight-chain alkenyl group.

[0160] In a specific embodiment, X is -G1L1G3L3G5, Y is an optionally substituted C1-C3 straight-chain alkyl group, and Z is an optionally substituted -R e G7R f -, R e and R f is an optionally substituted C2-C4 alkylene group, G7 is -(3-7-membered heterocyclic alkylene)-; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene group; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C2-C24 straight-chain alkyl group, an optionally substituted C2-C24 straight-chain alkenyl group.

[0161] In a specific embodiment, X and Y are each independently a C1-C3 straight-chain alkyl group, Z is a C2-C4 alkylene group, and X, Z together with the nitrogen to which they are attached form a ring; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene group; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C2-C24 straight-chain alkyl group, an optionally substituted C2-C24 straight-chain alkenyl group.

[0162] In a specific embodiment, X and Y are each independently an optionally substituted C1-C3 straight-chain alkyl group, Z is a C2-C4 alkylene group; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene group; L3 and L4 are each independently -OC(=O)O-; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl group.

[0163] In a specific embodiment, X and Y are each independently -G1L1G3L3G5, and Z is a C2-C4 alkylene; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene; L3 and L4 are each independently -OC(=O)O-; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl.

[0164] In a specific embodiment, X is an optionally substituted C1-C3 straight-chain alkyl, Y is -G1L1G3L3G5, and Z is a C2-C4 alkylene; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene; L3 and L4 are each independently -OC(=O)O-; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl.

[0165] In a specific embodiment, X is -G1L1G3L3G5, Y is an optionally substituted C1-C3 straight-chain alkyl, and Z is a C2-C4 alkylene; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene; L3 and L4 are each independently -OC(=O)O-; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl.

[0166] In a specific embodiment, X and Y are each independently an optionally substituted C1-C3 straight-chain alkyl, and Z is an optionally substituted -R e G7R f -, R e and R f are each independently an optionally substituted C2-C4 alkylene, G7 is -(3-7 membered heterocyclic alkylene)-; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene; L3 and L4 are each independently -OC(=O)O-; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl.

[0167] In a specific embodiment, X and Y are each independently -G1L1G3L3G5, and Z is an optionally substituted -Re G7R f -, R e and R f is an optionally substituted C2-C4 alkylene group, G7 is -(3-7 membered heterocyclic alkylene)-; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene group; L3 and L4 are each independently -OC(=O)O-; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl group.

[0168] In a specific embodiment, X is an optionally substituted C1-C3 straight-chain alkyl group, Y is -G1L1G3L3G5, and Z is an optionally substituted -R e G7R f -, R e and R f is an optionally substituted C2-C4 alkylene group, G7 is -(3-7 membered heterocyclic alkylene)-; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene group; L3 and L4 are each independently -OC(=O)O-; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl group.

[0169] In a specific embodiment, X is -G1L1G3L3G5, Y is an optionally substituted C1-C3 straight-chain alkyl group, and Z is an optionally substituted -R e G7R f -, R e and R f is an optionally substituted C2-C4 alkylene group, G7 is -(3-7 membered heterocyclic alkylene)-; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene group; L3 and L4 are each independently -OC(=O)O-; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl group.

[0170] In a specific embodiment, X and Y are each independently a C1-C3 straight-chain alkyl group, Z is a C2-C4 alkylene group, and X, Z together with the nitrogen to which they are attached form a ring; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene group; L3 and L4 are each independently -OC(=O)O-; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl group.

[0171] In a specific embodiment, X and Y are each independently an optionally substituted C1-C3 straight-chain alkyl group, Z is a C2-C4 alkylene group; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene group; L3 and L4 are each independently -OC(=O)O-; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl group.

[0172] In a specific embodiment, X and Y are each independently -G1L1G3L3G5, Z is a C2-C4 alkylene group; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene group; L3 and L4 are each independently -OC(=O)O-; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl group.

[0173] In a specific embodiment, X is an optionally substituted C1-C3 straight-chain alkyl group, Y is -G1L1G3L3G5, Z is a C2-C4 alkylene group; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene group; L3 and L4 are each independently -OC(=O)O-; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl group.

[0174] In a specific embodiment, X is -G1L1G3L3G5, Y is an optionally substituted C1-C3 straight-chain alkyl group, and Z is a C2-C4 alkylene group; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene group; L3 and L4 are each independently -OC(=O)O-; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl group.

[0175] In a specific embodiment, X and Y are each independently an optionally substituted C1-C3 straight-chain alkyl group, and Z is an optionally substituted -R e G7R f -, R e and R f are an optionally substituted C2-C4 alkylene group, G7 is -(3-7-membered heterocyclic alkylene)-; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene group; L3 and L4 are each independently -OC(=O)O-; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl group.

[0176] In a specific embodiment, X and Y are each independently -G1L1G3L3G5, and Z is an optionally substituted -R e G7R f -, R e and R f are an optionally substituted C2-C4 alkylene group, G7 is -(3-7-membered heterocyclic alkylene)-; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene group; L3 and L4 are each independently -OC(=O)O-; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl group.

[0177] In a specific embodiment, X is an optionally substituted C1-C3 straight-chain alkyl group, Y is -G1L1G3L3G5, and Z is an optionally substituted -R e G7R f -, R e and R fis an optionally substituted C2-C4 alkylene, G7 is -(3-7-membered heterocyclic alkylene)-; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene; L3 and L4 are each independently -OC(=O)O-; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl.

[0178] In a specific embodiment, X is -G1L1G3L3G5, Y is an optionally substituted C1-C3 straight-chain alkyl, and Z is an optionally substituted -R e G7R f -, R e and R f is an optionally substituted C2-C4 alkylene, G7 is -(3-7-membered heterocyclic alkylene)-; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene; L3 and L4 are each independently -OC(=O)O-; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl.

[0179] In a specific embodiment, X and Y are each independently a C1-C3 straight-chain alkyl, Z is a C2-C4 alkylene, and X, Z together with the nitrogen to which they are attached form a ring; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene; L3 and L4 are each independently -OC(=O)O-; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl.

[0180] In a specific embodiment, X and Y are each independently an optionally substituted C1-C3 straight-chain alkyl, Z is a C2-C4 alkylene; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl.

[0181] In a specific embodiment, X and Y are each independently -G1L1G3L3G5, Z is a C2-C4 alkylene group; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene group; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl group.

[0182] In a specific embodiment, X is an optionally substituted C1-C3 straight-chain alkyl group, Y is -G1L1G3L3G5, Z is a C2-C4 alkylene group; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene group; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl group.

[0183] In a specific embodiment, X is -G1L1G3L3G5, Y is an optionally substituted C1-C3 straight-chain alkyl group, Z is a C2-C4 alkylene group; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene group; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl group.

[0184] In a specific embodiment, X and Y are each independently an optionally substituted C1-C3 straight-chain alkyl group, Z is an optionally substituted -R e G7R f -, R e and R f are each independently an optionally substituted C2-C4 alkylene group, G7 is -(3-7 membered heterocyclic alkylene)-; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene group; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl group.

[0185] In a specific embodiment, X and Y are each independently -G1L1G3L3G5, Z is an optionally substituted -R e G7R f -, Re and R f is an optionally substituted C2-C4 alkylene group, G7 is -(3-7 membered heterocyclic alkylene)-; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene group; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl group.

[0186] In a specific embodiment, X is an optionally substituted C1-C3 straight-chain alkyl group, Y is -G1L1G3L3G5, and Z is an optionally substituted -R e G7R f -, R e and R f is an optionally substituted C2-C4 alkylene group, G7 is -(3-7 membered heterocyclic alkylene)-; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene group; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl group.

[0187] In a specific embodiment, X is -G1L1G3L3G5, Y is an optionally substituted C1-C3 straight-chain alkyl group, and Z is an optionally substituted -R e G7R f -, R e and R f is an optionally substituted C2-C4 alkylene group, G7 is -(3-7 membered heterocyclic alkylene)-; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene group; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl group.

[0188] In a specific embodiment, X and Y are each independently a C1-C3 straight-chain alkyl group, Z is a C2-C4 alkylene group, and X, Z and the nitrogen atom to which they are attached form a ring; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene group; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl group.

[0189] In a specific embodiment, X and Y are each independently an optionally substituted C1-C3 straight-chain alkyl group, Z is a C2-C4 alkylene group; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene group; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl group.

[0190] In a specific embodiment, X and Y are each independently -G1L1G3L3G5, Z is a C2-C4 alkylene group; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene group; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl group.

[0191] In a specific embodiment, X is an optionally substituted C1-C3 straight-chain alkyl group, Y is -G1L1G3L3G5, Z is a C2-C4 alkylene group; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene group; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl group.

[0192] In a specific embodiment, X is -G1L1G3L3G5, Y is an optionally substituted C1-C3 straight-chain alkyl group, and Z is a C2-C4 alkylene group; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene group; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl group.

[0193] In a specific embodiment, X and Y are each independently an optionally substituted C1-C3 straight-chain alkyl group, and Z is an optionally substituted -R e G7R f -, R e and R f is an optionally substituted C2-C4 alkylene group, and G7 is -(3-7 membered heterocyclic alkylene)-; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene group; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl group.

[0194] In a specific embodiment, X and Y are each independently -G1L1G3L3G5, and Z is an optionally substituted -R e G7R f -, R e and R f is an optionally substituted C2-C4 alkylene group, and G7 is -(3-7 membered heterocyclic alkylene)-; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene group; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl group.

[0195] In a specific embodiment, X is an optionally substituted C1-C3 straight-chain alkyl group, Y is -G1L1G3L3G5, and Z is an optionally substituted -R e G7R f -, R e and R fis an optionally substituted C2-C4 alkylene group, G7 is -(3-7 membered heterocyclic alkylene)-; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene group; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl group.

[0196] In a specific embodiment, X is -G1L1G3L3G5, Y is an optionally substituted C1-C3 straight-chain alkyl group, and Z is an optionally substituted -R e G7R f -, R e and R f is an optionally substituted C2-C4 alkylene group, G7 is -(3-7 membered heterocyclic alkylene)-; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene group; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl group.

[0197] In a specific embodiment, X and Y are each independently a C1-C3 straight-chain alkyl group, Z is a C2-C4 alkylene group, and X, Z together with the nitrogen to which they are attached form a ring; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight-chain alkylene group; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl group.

[0198] In a specific embodiment, X and Y are each independently an optionally substituted C1-C3 straight-chain alkyl group, Z is a C2-C4 alkylene group; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are a bond or an unsubstituted C2-C4 alkylene group; L3 and L4 are each independently -OC(=O)O-; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl group.

[0199] In a specific embodiment, X and Y are each independently -G1L1G3L3G5, Z is a C2-C4 alkylene; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene; L1 and L2 are each independently -C(=O)O-; G3 and G4 are a bond or an unsubstituted C2-C4 alkylene; L3 and L4 are each independently -OC(=O)O-; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl.

[0200] In a specific embodiment, X is an optionally substituted C1-C3 straight-chain alkyl, Y is -G1L1G3L3G5, Z is a C2-C4 alkylene; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene; L1 and L2 are each independently -C(=O)O-; G3 and G4 are a bond or an unsubstituted C2-C4 alkylene; L3 and L4 are each independently -OC(=O)O-; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl.

[0201] In a specific embodiment, X is -G1L1G3L3G5, Y is an optionally substituted C1-C3 straight-chain alkyl, Z is a C2-C4 alkylene; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene; L1 and L2 are each independently -C(=O)O-; G3 and G4 are a bond or an unsubstituted C2-C4 alkylene; L3 and L4 are each independently -OC(=O)O-; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl.

[0202] In a specific embodiment, X and Y are each independently an optionally substituted C1-C3 straight-chain alkyl, Z is an optionally substituted -R e G7R f -, R e and R f are each independently an optionally substituted C2-C4 alkylene, G7 is -(3-7 membered heterocyclic alkylene)-; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene; L1 and L2 are each independently -C(=O)O-; G3 and G4 are a bond or an unsubstituted C2-C4 alkylene; L3 and L4 are each independently -OC(=O)O-; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl.

[0203] In a specific embodiment, X and Y are each independently -G1L1G3L3G5, Z is an optionally substituted -R e G7R f -, R eand R f is optionally substituted C2-C4 alkylene, G7 is -(3-7 membered heterocyclic alkylene)-; G1 and G2 are each independently optionally substituted C2-C24 straight-chain alkylene; L1 and L2 are each independently -C(=O)O-; G3 and G4 are a bond or unsubstituted C2-C4 alkylene; L3 and L4 are each independently -OC(=O)O-; G5 and G6 are each independently optionally substituted C4-C16 straight-chain alkenyl.

[0204] In a specific embodiment, X is optionally substituted C1-C3 straight-chain alkyl, Y is -G1L1G3L3G5, and Z is optionally substituted -R e G7R f -, R e and R f is optionally substituted C2-C4 alkylene, G7 is -(3-7 membered heterocyclic alkylene)-; G1 and G2 are each independently optionally substituted C2-C24 straight-chain alkylene; L1 and L2 are each independently -C(=O)O-; G3 and G4 are a bond or unsubstituted C2-C4 alkylene; L3 and L4 are each independently -OC(=O)O-; G5 and G6 are each independently optionally substituted C4-C16 straight-chain alkenyl.

[0205] In a specific embodiment, X is -G1L1G3L3G5, Y is optionally substituted C1-C3 straight-chain alkyl, and Z is optionally substituted -R e G7R f -, R e and R f is optionally substituted C2-C4 alkylene, G7 is -(3-7 membered heterocyclic alkylene)-; G1 and G2 are each independently optionally substituted C2-C24 straight-chain alkylene; L1 and L2 are each independently -C(=O)O-; G3 and G4 are a bond or unsubstituted C2-C4 alkylene; L3 and L4 are each independently -OC(=O)O-; G5 and G6 are each independently optionally substituted C4-C16 straight-chain alkenyl.

[0206] In a specific embodiment, X and Y are each independently C1-C3 straight-chain alkyl, Z is C2-C4 alkylene, and X, Z together with the nitrogen to which they are attached form a ring; G1 and G2 are each independently optionally substituted C2-C24 straight-chain alkylene; L1 and L2 are each independently -C(=O)O-; G3 and G4 are a bond or unsubstituted C2-C4 alkylene; L3 and L4 are each independently -OC(=O)O-; G5 and G6 are each independently optionally substituted C4-C16 straight-chain alkenyl.

[0207] In a specific embodiment, X and Y are each independently an optionally substituted C1-C3 straight-chain alkyl group, Z is a C2-C4 alkylene group; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are a bond or an unsubstituted C2-C4 alkylene group; L3 and L4 are each independently -OC(=O)O-; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl group.

[0208] In a specific embodiment, X and Y are each independently -G1L1G3L3G5, Z is a C2-C4 alkylene group; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are a bond or an unsubstituted C2-C4 alkylene group; L3 and L4 are each independently -OC(=O)O-; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl group.

[0209] In a specific embodiment, X is an optionally substituted C1-C3 straight-chain alkyl group, Y is -G1L1G3L3G5, Z is a C2-C4 alkylene group; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are a bond or an unsubstituted C2-C4 alkylene group; L3 and L4 are each independently -OC(=O)O-; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl group.

[0210] In a specific embodiment, X is -G1L1G3L3G5, Y is an optionally substituted C1-C3 straight-chain alkyl group, Z is a C2-C4 alkylene group; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are a bond or an unsubstituted C2-C4 alkylene group; L3 and L4 are each independently -OC(=O)O-; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl group.

[0211] In a specific embodiment, X and Y are each independently an optionally substituted C1-C3 straight-chain alkyl group, Z is an optionally substituted -R e G7R f -, R e and R fis an optionally substituted C2-C4 alkylene, G7 is -(3-7-membered heterocyclic alkylene)-; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene; L1 and L2 are each independently -C(=O)O-; G3 and G4 are a bond or an unsubstituted C2-C4 alkylene; L3 and L4 are each independently -OC(=O)O-; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl.

[0212] In a specific embodiment, X and Y are each independently -G1L1G3L3G5, and Z is an optionally substituted -R e G7R f -, R e and R f is an optionally substituted C2-C4 alkylene, G7 is -(3-7-membered heterocyclic alkylene)-; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene; L1 and L2 are each independently -C(=O)O-; G3 and G4 are a bond or an unsubstituted C2-C4 alkylene; L3 and L4 are each independently -OC(=O)O-; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl.

[0213] In a specific embodiment, X is an optionally substituted C1-C3 straight-chain alkyl, Y is -G1L1G3L3G5, and Z is an optionally substituted -R e G7R f -, R e and R f is an optionally substituted C2-C4 alkylene, G7 is -(3-7-membered heterocyclic alkylene)-; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene; L1 and L2 are each independently -C(=O)O-; G3 and G4 are a bond or an unsubstituted C2-C4 alkylene; L3 and L4 are each independently -OC(=O)O-; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl.

[0214] In a specific embodiment, X is -G1L1G3L3G5, Y is an optionally substituted C1-C3 straight-chain alkyl, and Z is an optionally substituted -R e G7R f -, R e and R fis an optionally substituted C2-C4 alkylene group, G7 is -(3-7-membered heterocyclic alkylene)-; said G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; said L1 and L2 are each independently -C(=O)O-; said G3 and G4 are a bond or an unsubstituted C2-C4 alkylene group; said L3 and L4 are each independently -OC(=O)O-; said G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl group.

[0215] In a specific embodiment, X and Y are each independently a C1-C3 straight-chain alkyl group, Z is a C2-C4 alkylene group, and X, Z together with the nitrogen to which they are attached form a ring; said G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; said L1 and L2 are each independently -C(=O)O-; said G3 and G4 are a bond or an unsubstituted C2-C4 alkylene group; said L3 and L4 are each independently -OC(=O)O-; said G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl group.

[0216] In a specific embodiment, X and Y are each independently an optionally substituted C1-C3 straight-chain alkyl group, Z is a C2-C4 alkylene group; said G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; said L1 and L2 are each independently -C(=O)O-; said G3 and G4 are a bond or an unsubstituted C2-C4 alkylene group; said L3 and L4 are each independently a bond; said G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl group.

[0217] In a specific embodiment, X and Y are each independently -G1L1G3L3G5, Z is a C2-C4 alkylene group; said G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; said L1 and L2 are each independently -C(=O)O-; said G3 and G4 are a bond or an unsubstituted C2-C4 alkylene group; said L3 and L4 are each independently a bond; said G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl group.

[0218] In a specific embodiment, X is an optionally substituted C1-C3 straight-chain alkyl group, Y is -G1L1G3L3G5, Z is a C2-C4 alkylene group; said G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; said L1 and L2 are each independently -C(=O)O-; said G3 and G4 are a bond or an unsubstituted C2-C4 alkylene group; said L3 and L4 are each independently a bond; said G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl group.

[0219] In a specific embodiment, X is -G1L1G3L3G5, Y is an optionally substituted C1-C3 straight-chain alkyl group, and Z is a C2-C4 alkylene group; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are a bond or an unsubstituted C2-C4 alkylene group; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl group.

[0220] In a specific embodiment, X and Y are each independently an optionally substituted C1-C3 straight-chain alkyl group, and Z is an optionally substituted -R e G7R f -, R e and R f is an optionally substituted C2-C4 alkylene group, and G7 is -(3-7-membered heterocycloalkylene)-; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are a bond or an unsubstituted C2-C4 alkylene group; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl group.

[0221] In a specific embodiment, X and Y are each independently -G1L1G3L3G5, and Z is an optionally substituted -R e G7R f -, R e and R f is an optionally substituted C2-C4 alkylene group, and G7 is -(3-7-membered heterocycloalkylene)-; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are a bond or an unsubstituted C2-C4 alkylene group; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl group.

[0222] In a specific embodiment, X is an optionally substituted C1-C3 straight-chain alkyl group, Y is -G1L1G3L3G5, and Z is an optionally substituted -R e G7R f -, R e and R fis an optionally substituted C2-C4 alkylene group, G7 is -(3-7 membered heterocyclic alkylene)-; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are a bond or an unsubstituted C2-C4 alkylene group; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl group.

[0223] In a specific embodiment, X is -G1L1G3L3G5, Y is an optionally substituted C1-C3 straight-chain alkyl group, and Z is an optionally substituted -R e G7R f -, R e and R f is an optionally substituted C2-C4 alkylene group, G7 is -(3-7 membered heterocyclic alkylene)-; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are a bond or an unsubstituted C2-C4 alkylene group; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl group.

[0224] In a specific embodiment, X and Y are each independently a C1-C3 straight-chain alkyl group, Z is a C2-C4 alkylene group, and X, Z together with the nitrogen to which they are attached form a ring; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are a bond or an unsubstituted C2-C4 alkylene group; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl group.

[0225] In a specific embodiment, X and Y are each independently an optionally substituted C1-C3 straight-chain alkyl group, Z is a C2-C4 alkylene group; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are a bond or an unsubstituted C2-C4 alkylene group; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl group.

[0226] In a specific embodiment, X and Y are each independently -G1L1G3L3G5, Z is a C2-C4 alkylene; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene; L1 and L2 are each independently -C(=O)O-; G3 and G4 are a bond or an unsubstituted C2-C4 alkylene; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl.

[0227] In a specific embodiment, X is an optionally substituted C1-C3 straight-chain alkyl, Y is -G1L1G3L3G5, Z is a C2-C4 alkylene; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene; L1 and L2 are each independently -C(=O)O-; G3 and G4 are a bond or an unsubstituted C2-C4 alkylene; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl.

[0228] In a specific embodiment, X is -G1L1G3L3G5, Y is an optionally substituted C1-C3 straight-chain alkyl, Z is a C2-C4 alkylene; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene; L1 and L2 are each independently -C(=O)O-; G3 and G4 are a bond or an unsubstituted C2-C4 alkylene; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl.

[0229] In a specific embodiment, X and Y are each independently an optionally substituted C1-C3 straight-chain alkyl, Z is an optionally substituted -R e G7R f -, R e and R f are each independently an optionally substituted C2-C4 alkylene, G7 is -(3-7-membered heterocyclic alkylene)-; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene; L1 and L2 are each independently -C(=O)O-; G3 and G4 are a bond or an unsubstituted C2-C4 alkylene; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl.

[0230] In a specific embodiment, X and Y are each independently -G1L1G3L3G5, Z is an optionally substituted -R e G7R f -, R e and R fis an optionally substituted C2-C4 alkylene group, G7 is -(3-7-membered heterocyclic alkylene)-; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are a bond or an unsubstituted C2-C4 alkylene group; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl group.

[0231] In a specific embodiment, X is an optionally substituted C1-C3 straight-chain alkyl group, Y is -G1L1G3L3G5, and Z is an optionally substituted -R e G7R f -, R e and R f is an optionally substituted C2-C4 alkylene group, G7 is -(3-7-membered heterocyclic alkylene)-; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are a bond or an unsubstituted C2-C4 alkylene group; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl group.

[0232] In a specific embodiment, X is -G1L1G3L3G5, Y is an optionally substituted C1-C3 straight-chain alkyl group, and Z is an optionally substituted -R e G7R f -, R e and R f is an optionally substituted C2-C4 alkylene group, G7 is -(3-7-membered heterocyclic alkylene)-; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are a bond or an unsubstituted C2-C4 alkylene group; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl group.

[0233] In a specific embodiment, X and Y are each independently a C1-C3 straight-chain alkyl group, Z is a C2-C4 alkylene group, and X, Z together with the nitrogen to which they are attached form a ring; G1 and G2 are each independently an optionally substituted C2-C24 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are a bond or an unsubstituted C2-C4 alkylene group; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl group.

[0234] In a specific embodiment, X and Y are each independently an optionally substituted C1-C3 linear alkyl group, Z is a C2-C4 alkylene group; G1 and G2 are each independently an unsubstituted C2-C4 linear alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are a bond or an unsubstituted C2-C4 alkylene group; L3 and L4 are each independently -OC(=O)O-; G5 and G6 are each independently an optionally substituted C4-C16 linear alkenyl group.

[0235] In a specific embodiment, X and Y are each independently -G1L1G3L3G5, Z is a C2-C4 alkylene group; G1 and G2 are each independently an unsubstituted C2-C4 linear alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are a bond or an unsubstituted C2-C4 alkylene group; L3 and L4 are each independently -OC(=O)O-; G5 and G6 are each independently an optionally substituted C4-C16 linear alkenyl group.

[0236] In a specific embodiment, X is an optionally substituted C1-C3 linear alkyl group, Y is -G1L1G3L3G5, Z is a C2-C4 alkylene group; G1 and G2 are each independently an unsubstituted C2-C4 linear alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are a bond or an unsubstituted C2-C4 alkylene group; L3 and L4 are each independently -OC(=O)O-; G5 and G6 are each independently an optionally substituted C4-C16 linear alkenyl group.

[0237] In a specific embodiment, X is -G1L1G3L3G5, Y is an optionally substituted C1-C3 linear alkyl group, Z is a C2-C4 alkylene group; G1 and G2 are each independently an unsubstituted C2-C4 linear alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are a bond or an unsubstituted C2-C4 alkylene group; L3 and L4 are each independently -OC(=O)O-; G5 and G6 are each independently an optionally substituted C4-C16 linear alkenyl group.

[0238] In a specific embodiment, X and Y are each independently an optionally substituted C1-C3 linear alkyl group, Z is an optionally substituted -R e G7R f -, R e and R fis an optionally substituted C2-C4 alkylene group, G7 is -(3-7 membered heterocyclic alkylene)-; G1 and G2 are each independently an unsubstituted C2-C4 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are a bond or an unsubstituted C2-C4 alkylene group; L3 and L4 are each independently -OC(=O)O-; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl group.

[0239] In a specific embodiment, X and Y are each independently -G1L1G3L3G5, and Z is an optionally substituted -R e G7R f -, R e and R f is an optionally substituted C2-C4 alkylene group, G7 is -(3-7 membered heterocyclic alkylene)-; G1 and G2 are each independently an unsubstituted C2-C4 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are a bond or an unsubstituted C2-C4 alkylene group; L3 and L4 are each independently -OC(=O)O-; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl group.

[0240] In a specific embodiment, X is an optionally substituted C1-C3 straight-chain alkyl group, Y is -G1L1G3L3G5, and Z is an optionally substituted -R e G7R f -, R e and R f is an optionally substituted C2-C4 alkylene group, G7 is -(3-7 membered heterocyclic alkylene)-; G1 and G2 are each independently an unsubstituted C2-C4 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are a bond or an unsubstituted C2-C4 alkylene group; L3 and L4 are each independently -OC(=O)O-; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl group.

[0241] In a specific embodiment, X is -G1L1G3L3G5, Y is an optionally substituted C1-C3 straight-chain alkyl group, and Z is an optionally substituted -R e G7R f -, R e and R fis an optionally substituted C2-C4 alkylene group, G7 is -(3-7 membered heterocyclic alkylene)-; said G1 and G2 are each independently an unsubstituted C2-C4 straight-chain alkylene group; said L1 and L2 are each independently -C(=O)O-; said G3 and G4 are a bond or an unsubstituted C2-C4 alkylene group; said L3 and L4 are each independently -OC(=O)O-; said G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl group.

[0242] In a specific embodiment, X and Y are each independently a C1-C3 straight-chain alkyl group, Z is a C2-C4 alkylene group, and X, Z together with the nitrogen to which they are attached form a ring; said G1 and G2 are each independently an unsubstituted C2-C4 straight-chain alkylene group; said L1 and L2 are each independently -C(=O)O-; said G3 and G4 are a bond or an unsubstituted C2-C4 alkylene group; said L3 and L4 are each independently -OC(=O)O-; said G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl group.

[0243] In a specific embodiment, X and Y are each independently an optionally substituted C1-C3 straight-chain alkyl group, Z is a C2-C4 alkylene group; said G1 and G2 are each independently an unsubstituted C2-C4 straight-chain alkylene group; said L1 and L2 are each independently -C(=O)O-; said G3 and G4 are a bond or an unsubstituted C2-C4 alkylene group; said L3 and L4 are each independently -OC(=O)O-; said G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl group.

[0244] In a specific embodiment, X and Y are each independently -G1L1G3L3G5, Z is a C2-C4 alkylene group; said G1 and G2 are each independently an unsubstituted C2-C4 straight-chain alkylene group; said L1 and L2 are each independently -C(=O)O-; said G3 and G4 are a bond or an unsubstituted C2-C4 alkylene group; said L3 and L4 are each independently -OC(=O)O-; said G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl group.

[0245] In a specific embodiment, X is an optionally substituted C1-C3 straight-chain alkyl group, Y is -G1L1G3L3G5, Z is a C2-C4 alkylene group; said G1 and G2 are each independently an unsubstituted C2-C4 straight-chain alkylene group; said L1 and L2 are each independently -C(=O)O-; said G3 and G4 are a bond or an unsubstituted C2-C4 alkylene group; said L3 and L4 are each independently -OC(=O)O-; said G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl group.

[0246] In a specific embodiment, X is -G1L1G3L3G5, Y is an optionally substituted C1-C3 straight-chain alkyl group, and Z is a C2-C4 alkylene group; G1 and G2 are each independently an unsubstituted C2-C4 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are a bond or an unsubstituted C2-C4 alkylene group; L3 and L4 are each independently -OC(=O)O-; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl group.

[0247] In a specific embodiment, X and Y are each independently an optionally substituted C1-C3 straight-chain alkyl group, and Z is an optionally substituted -R e G7R f -, R e and R f is an optionally substituted C2-C4 alkylene group, and G7 is -(3-7-membered heterocyclic alkylene)-; G1 and G2 are each independently an unsubstituted C2-C4 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are a bond or an unsubstituted C2-C4 alkylene group; L3 and L4 are each independently -OC(=O)O-; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl group.

[0248] In a specific embodiment, X and Y are each independently -G1L1G3L3G5, and Z is an optionally substituted -R e G7R f -, R e and R f is an optionally substituted C2-C4 alkylene group, and G7 is -(3-7-membered heterocyclic alkylene)-; G1 and G2 are each independently an unsubstituted C2-C4 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are a bond or an unsubstituted C2-C4 alkylene group; L3 and L4 are each independently -OC(=O)O-; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl group.

[0249] In a specific embodiment, X is an optionally substituted C1-C3 straight-chain alkyl group, Y is -G1L1G3L3G5, and Z is an optionally substituted -R e G7R f -, R e and R fis an optionally substituted C2-C4 alkylene, G7 is -(3-7 member heterocyclic alkylene)-; G1 and G2 are each independently an unsubstituted C2-C4 straight-chain alkylene; L1 and L2 are each independently -C(=O)O-; G3 and G4 are a bond or an unsubstituted C2-C4 alkylene; L3 and L4 are each independently -OC(=O)O-; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl.

[0250] In a specific embodiment, X is -G1L1G3L3G5, Y is an optionally substituted C1-C3 straight-chain alkyl, and Z is an optionally substituted -R e G7R f -, R e and R f is an optionally substituted C2-C4 alkylene, G7 is -(3-7 member heterocyclic alkylene)-; G1 and G2 are each independently an unsubstituted C2-C4 straight-chain alkylene; L1 and L2 are each independently -C(=O)O-; G3 and G4 are a bond or an unsubstituted C2-C4 alkylene; L3 and L4 are each independently -OC(=O)O-; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl.

[0251] In a specific embodiment, X and Y are each independently a C1-C3 straight-chain alkyl, Z is a C2-C4 alkylene, and X, Z together with the nitrogen to which they are attached form a ring; G1 and G2 are each independently an unsubstituted C2-C4 straight-chain alkylene; L1 and L2 are each independently -C(=O)O-; G3 and G4 are a bond or an unsubstituted C2-C4 alkylene; L3 and L4 are each independently -OC(=O)O-; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl.

[0252] In a specific embodiment, X and Y are each independently an optionally substituted C1-C3 straight-chain alkyl, Z is a C2-C4 alkylene; G1 and G2 are each independently an unsubstituted C2-C4 straight-chain alkylene; L1 and L2 are each independently -C(=O)O-; G3 and G4 are a bond or an unsubstituted C2-C4 alkylene; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl.

[0253] In a specific embodiment, X and Y are each independently -G1L1G3L3G5, Z is a C2-C4 alkylene; G1 and G2 are each independently an unsubstituted C2-C4 straight-chain alkylene; L1 and L2 are each independently -C(=O)O-; G3 and G4 are a bond or an unsubstituted C2-C4 alkylene; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl.

[0254] In a specific embodiment, X is an optionally substituted C1-C3 straight-chain alkyl, Y is -G1L1G3L3G5, Z is a C2-C4 alkylene; G1 and G2 are each independently an unsubstituted C2-C4 straight-chain alkylene; L1 and L2 are each independently -C(=O)O-; G3 and G4 are a bond or an unsubstituted C2-C4 alkylene; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl.

[0255] In a specific embodiment, X is -G1L1G3L3G5, Y is an optionally substituted C1-C3 straight-chain alkyl, Z is a C2-C4 alkylene; G1 and G2 are each independently an unsubstituted C2-C4 straight-chain alkylene; L1 and L2 are each independently -C(=O)O-; G3 and G4 are a bond or an unsubstituted C2-C4 alkylene; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl.

[0256] In a specific embodiment, X and Y are each independently an optionally substituted C1-C3 straight-chain alkyl, Z is an optionally substituted -R e G7R f -, R e and R f are an optionally substituted C2-C4 alkylene, G7 is -(3-7-membered heterocycloalkylene)-; G1 and G2 are each independently an unsubstituted C2-C4 straight-chain alkylene; L1 and L2 are each independently -C(=O)O-; G3 and G4 are a bond or an unsubstituted C2-C4 alkylene; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl.

[0257] In a specific embodiment, X and Y are each independently -G1L1G3L3G5, Z is an optionally substituted -R e G7R f -, R e and R fis an optionally substituted C2-C4 alkylene group, G7 is -(3-7-membered heterocyclic alkylene)-; G1 and G2 are each independently an unsubstituted C2-C4 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are a bond or an unsubstituted C2-C4 alkylene group; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl group.

[0258] In a specific embodiment, X is an optionally substituted C1-C3 straight-chain alkyl group, Y is -G1L1G3L3G5, and Z is an optionally substituted -R e G7R f -, R e and R f is an optionally substituted C2-C4 alkylene group, G7 is -(3-7-membered heterocyclic alkylene)-; G1 and G2 are each independently an unsubstituted C2-C4 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are a bond or an unsubstituted C2-C4 alkylene group; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl group.

[0259] In a specific embodiment, X is -G1L1G3L3G5, Y is an optionally substituted C1-C3 straight-chain alkyl group, and Z is an optionally substituted -R e G7R f -, R e and R f is an optionally substituted C2-C4 alkylene group, G7 is -(3-7-membered heterocyclic alkylene)-; G1 and G2 are each independently an unsubstituted C2-C4 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are a bond or an unsubstituted C2-C4 alkylene group; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl group.

[0260] In a specific embodiment, X and Y are each independently a C1-C3 straight-chain alkyl group, Z is a C2-C4 alkylene group, and X, Z together with the nitrogen to which they are attached form a ring; G1 and G2 are each independently an unsubstituted C2-C4 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are a bond or an unsubstituted C2-C4 alkylene group; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl group.

[0261] In a specific embodiment, X and Y are each independently an optionally substituted C1-C3 straight-chain alkyl group, Z is a C2-C4 alkylene group; G1 and G2 are each independently an unsubstituted C2-C4 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are a bond or an unsubstituted C2-C4 alkylene group; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl group.

[0262] In a specific embodiment, X and Y are each independently -G1L1G3L3G5, Z is a C2-C4 alkylene group; G1 and G2 are each independently an unsubstituted C2-C4 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are a bond or an unsubstituted C2-C4 alkylene group; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl group.

[0263] In a specific embodiment, X is an optionally substituted C1-C3 straight-chain alkyl group, Y is -G1L1G3L3G5, Z is a C2-C4 alkylene group; G1 and G2 are each independently an unsubstituted C2-C4 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are a bond or an unsubstituted C2-C4 alkylene group; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl group.

[0264] In a specific embodiment, X is -G1L1G3L3G5, Y is an optionally substituted C1-C3 straight-chain alkyl group, Z is a C2-C4 alkylene group; G1 and G2 are each independently an unsubstituted C2-C4 straight-chain alkylene group; L1 and L2 are each independently -C(=O)O-; G3 and G4 are a bond or an unsubstituted C2-C4 alkylene group; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl group.

[0265] In a specific embodiment, X and Y are each independently an optionally substituted C1-C3 straight-chain alkyl group, Z is an optionally substituted -R e G7R f -, R e and R fis an optionally substituted C2-C4 alkylene, G7 is -(3-7-membered heterocyclic alkylene)-; G1 and G2 are each independently an unsubstituted C2-C4 straight-chain alkylene; L1 and L2 are each independently -C(=O)O-; G3 and G4 are a bond or an unsubstituted C2-C4 alkylene; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl.

[0266] In a specific embodiment, X and Y are each independently -G1L1G3L3G5, and Z is an optionally substituted -R e G7R f -, R e and R f is an optionally substituted C2-C4 alkylene, G7 is -(3-7-membered heterocyclic alkylene)-; G1 and G2 are each independently an unsubstituted C2-C4 straight-chain alkylene; L1 and L2 are each independently -C(=O)O-; G3 and G4 are a bond or an unsubstituted C2-C4 alkylene; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl.

[0267] In a specific embodiment, X is an optionally substituted C1-C3 straight-chain alkyl, Y is -G1L1G3L3G5, and Z is an optionally substituted -R e G7R f -, R e and R f is an optionally substituted C2-C4 alkylene, G7 is -(3-7-membered heterocyclic alkylene)-; G1 and G2 are each independently an unsubstituted C2-C4 straight-chain alkylene; L1 and L2 are each independently -C(=O)O-; G3 and G4 are a bond or an unsubstituted C2-C4 alkylene; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl.

[0268] In a specific embodiment, X is -G1L1G3L3G5, Y is an optionally substituted C1-C3 straight-chain alkyl, and Z is an optionally substituted -R e G7R f -, R e and R fis an optionally substituted C2-C4 alkylene, G7 is -(3-7 membered heterocyclic alkylene)-; G1 and G2 are each independently an unsubstituted C2-C4 straight-chain alkylene; L1 and L2 are each independently -C(=O)O-; G3 and G4 are a bond or an unsubstituted C2-C4 alkylene; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl.

[0269] In a specific embodiment, X and Y are each independently a C1-C3 straight-chain alkyl, Z is a C2-C4 alkylene, and X, Z together with the nitrogen to which they are attached form a ring; G1 and G2 are each independently an unsubstituted C2-C4 straight-chain alkylene; L1 and L2 are each independently -C(=O)O-; G3 and G4 are a bond or an unsubstituted C2-C4 alkylene; L3 and L4 are each independently a bond; G5 and G6 are each independently an optionally substituted C4-C16 straight-chain alkenyl.

[0270] More preferably, the compound has the structure shown in formula (I-A-1):

[0271]

[0272] wherein, m is 1 or 3, n is 0 or 1, G5 and G6 are optionally substituted C4-C16 straight-chain alkenyls, G8 is as defined in formula (I-A), G9 and G 10 is an optionally substituted C1-C5 straight-chain alkane.

[0273] Or more preferably, the compound has the structure shown in formula (I-A-2):

[0274]

[0275] wherein, m is 1 or 3, n is 0 or 1, G5 and G6 are optionally substituted C4-C16 straight-chain alkenyls.

[0276] Or more preferably, the compound has the structure shown in formula (I-A-3):

[0277]

[0278] wherein, m is 1 or 3, n is 0 or 1, G5 and G6 are optionally substituted C4-C16 straight-chain alkenyls.

[0279] Or more preferably, the compound has the structure shown in formula (I-B-1):

[0280]

[0281] Wherein, m is 1 or 3, n is 0 or 1, and G5 and G6 are optionally substituted C4-C16 linear alkenyl groups.

[0282] Alternatively, more preferably, the compound has the structure shown in formula (I-B-2):

[0283]

[0284] Wherein, m is 1 or 3, n is 0 or 1, and G5 and G6 are optionally substituted C4-C16 linear alkenyl groups.

[0285] Alternatively, more preferably, the compound has the structure shown in formula (I-B-3):

[0286]

[0287] Wherein, m is 1 or 3, n is 0 or 1, and G5 and G6 are optionally substituted C4-C16 linear alkenyl groups.

[0288] More preferably, G8 is an optionally substituted C2-C4 alkylene group;

[0289] More preferably, G9 or G 10 or both have one of the following structures: methyl, ethyl, 2-hydroxyethyl;

[0290] More preferably, G5 or G6 or both have one of the following structures:

[0291]

[0292] This application provides the compounds in Table 1 below or their pharmaceutically available salts, prodrugs or stereoisomers:

[0293] Table 1 Representative Compounds

[0294]

[0295]

[0296]

[0297]

[0298]

[0299]

[0300]

[0301]

[0302] The present application further provides a composition comprising a therapeutic agent or a prophylactic agent; and a carrier for delivering the therapeutic agent or the prophylactic agent, wherein the carrier comprises a cationic lipid, and the cationic lipid comprises one or more of the cationic lipid compounds provided in any of the above applications, or their pharmaceutically acceptable salts.

[0303] In the composition of the present application, the therapeutic agent or preventive agent can be a nucleic acid molecule, a small molecule compound, a polypeptide or a protein, or a mixture of two or more thereof.

[0304] In a specific embodiment, the nucleic acid molecule is selected from single-stranded DNA, double-stranded DNA, short isomers, agomir, antagomir, antisense molecules, small interfering RNA (siRNA), asymmetric interfering RNA (aiRNA), microRNA (miRNA), Dicersubstrate RNA (dsRNA), small hairpin RNA (shRNA), transfer RNA (tRNA), messenger RNA (mRNA) and other forms of RNA molecules known in the art, or nucleic acid mimics such as locked nucleic acid (LNA), peptide nucleic acid (PNA) and morpholino oligonucleotides.

[0305] In a specific embodiment, the therapeutic agent or preventive agent comprises at least one mRNA encoding an antigen or a fragment or epitope thereof. Preferably, the mRNA is a monocistronic mRNA or a polycistronic mRNA.

[0306] In a specific embodiment, the antigen is a pathogenic antigen.

[0307] In a specific embodiment, the mRNA contains one or more functional nucleotide analogs. Preferably, the functional nucleotide analogs are selected from one or more of pseudouridine, 1-methyl-pseudouridine or 5-methylcytosine.

[0308] In a specific embodiment, the small molecule compound is selected from one or more of antitumor drugs, anti-infective drugs, local anesthetics, antidepressants, anticonvulsants, antibiotics / antibacterial agents, antifungals, antiparasitic drugs, hormones, hormone antagonists, immunomodulators, neurotransmitter antagonists, anti-glaucoma agents, anesthetics or imaging agents.

[0309] In the composition provided by the present application as described above, the present application does not limit the amounts of the carrier and the therapeutic or prophylactic agent. In a specific embodiment, the mass ratio of the carrier to the therapeutic or prophylactic agent is 5:1 to 50:1. For example, it can be 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, 15:1, 16:1, 17:1, 18:1, 19:1, 20:1, 25:1, 30:1, 35:1, 40:1, 41:1, 42:1, 43:1, 44:1, 45:1, 46:1, 47:1, 48:1, 49:1.

[0310] In a specific embodiment, the composition of the present application is a nanoparticle preparation, and the average size of the nanoparticle preparation is 10 - 500 nm. For example, it can be 20 nm, 30 nm, 40 nm, 50 nm, 60 nm, 70 nm, 80 nm, 90 nm, 100 nm, 150 nm, 200 nm, 250 nm, 300 nm, 350 nm, 400 nm, 450 nm.

[0311] In a specific embodiment, the pKa of the nanoparticle preparation of the present application is 4.5 - 8.5. For example, it can be 4.6, 4.7, 4.8, 4.9, 5, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6, 6.5, 7, 7.5, 8, 8.1, 8.2, 8.3, 8.4.

[0312] In the composition provided by the present application as described above, the carrier further comprises one or more neutral lipids. Preferably, the neutral lipid is selected from one or more of phosphatidylcholine, phosphatidylethanolamine, sphingomyelin, ceramide, sterol and its derivatives.

[0313] In a specific embodiment, the molar ratio of the cationic lipid to the neutral lipid is in the range of about 100:1 to about 5:1. For example, it can be 90:1, 85:1, 80:1, 75:1, 70:1, 65:1, 60:1, 55:1, 50:1, 45:1, 40:1, 35:1, 30:1, 25:1, 20:1, 15:1, 10:1.

[0314] In a specific embodiment, the steroid is selected from one or more of cholesterol, non-sterol, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, tomatine, tomatidine, ursolic acid, α-tocopherol, corticosteroid.

[0315] In a specific embodiment, the molar ratio of the cationic lipid to the steroid ranges from about 2:1 to about 4:1, and for example, it can be 2.1:1, 2.2:1, 2.3:1, 2.4:1, 2.5:1, 2.6:1, 2.7:1, 2.8:1, 2.9:1, 3:1, 3.1:1, 3.2:1, 3.3:1, 3.4:1, 3.5:1, 3.6:1, 3.7:1, 3.8:1, 3.9:1.

[0316] As described above, the composition provided by the present application, wherein the composition carrier further comprises one or more lipids capable of binding to the polymer. Preferably, the lipid capable of binding to the polymer is one or more selected from PEG-modified phosphatidylethanolamine, PEG-modified phosphatidic acid, PEG-modified ceramide, PEG-modified dialkylamine, PEG-modified diacylglycerol, and PEG-modified dialkylglycerol.

[0317] In a specific embodiment, the molar ratio of the cationic lipid to the lipid capable of binding to the polymer ranges from about 100:1 to about 20:1, and for example, it can be 95:1, 90:1, 85:1, 80:1, 75:1, 70:1, 65:1, 60:1, 55:1, 50:1, 45:1, 40:1, 35:1, 30:1, 25:1.

[0318] In a specific embodiment, in the composition of the present application, the carrier further comprises neutral lipid, structural lipid, and polymer-conjugated lipid, and the molar ratio of the cationic lipid, the neutral lipid, the steroid lipid, and the polymer-conjugated lipid is (15-70):(1-15):(15-35):(0-3).

[0319] In a specific embodiment, in the composition of the present application, the carrier further comprises neutral lipid and structural lipid, and the molar ratio of the cationic lipid, the neutral lipid, and the steroid lipid is (15-70):(1-15):(15-35).

[0320] In a specific embodiment, the composition further comprises a pharmaceutically acceptable excipient.

[0321] In a specific embodiment, the excipient comprises a pharmaceutically acceptable diluent.

[0322] The present application further provides the use of the compound shown in formula (I) provided by any one of the above, or its pharmaceutically acceptable salt, prodrug or stereoisomer in the preparation of a drug.

[0323] The present application further provides the use of the composition provided by any one of the above in the preparation of a drug.

[0324] In a specific embodiment, the drug is any one selected from gene drugs, nucleic acid vaccines, small molecule drugs, polypeptides or protein drugs. Specific embodiments

[0326] The present application will be further illustrated below in conjunction with specific embodiments. However, these examples are only used to illustrate the present application and not to limit the scope of the present application. The implementation conditions used in the examples can be further adjusted according to different requirements of specific use. The implementation conditions not specified are the conventional conditions in the industry. The technical features involved in each embodiment of the present application can be combined with each other as long as they do not conflict with each other.

[0327] In the specific examples of the present application, the raw materials used can all be obtained commercially.

[0328] Example 1 Synthesis of Compound 1

[0329] Synthesis route

[0330] Step 1: Synthesis of Intermediate 1-2

[0331] To a solution of geraniol (5 g, 16.86 mmol, 1 eq) and triethylamine (2.33 mL, 16.86 mmol, 1 eq) in dichloromethane (100 mL), p-nitrophenyl chloroformate (4.07 g, 20.03 mmol, 1.2 eq) dissolved in dichloromethane was slowly added dropwise. The reaction mixture was stirred at room temperature for 3 h and then the reaction was stopped. The mixture was extracted with water, and the combined organic layers were dried over MgSO4 and the solvent was removed under vacuum to obtain the crude product 1-1. In a 250 mL round-bottom flask containing the crude product 1-1, hydroxyethyl acrylate (2.11 g, 20.03 mmol, 1.2 eq), potassium carbonate (2.76 g, 20.03 mmol, 1.2 eq) and N,N-dimethylformamide solvent (200 mL) were added, and the mixture was stirred at 80 °C for 3 h. TLC showed that compound 1-1 had completely disappeared. After removing DMF under vacuum, the mixture was washed with brine, and the combined organic layers were dried over MgSO4 and the solvent was removed under vacuum to obtain the crude product. The crude product was purified by column chromatography (eluent: PE / EA = 10 / 1), and the pure product fraction was evaporated to obtain a slightly yellow oily compound 1-2 (10.06 g, 69%). 11H NMR (400 MHz, CDCl3) δ 6.44 (dt, J = 17.4, 1.2 Hz, 1H), 6.14 (ddd, J = 17.3, 10.4, 1.0 Hz, 1H), 5.86 (dt, J = 10.5, 1.2 Hz, 1H), 5.45–5.33 (m, 1H), 5.07 (dt, J = 6.8, 3.4 Hz, 1H), 4.68 (d, J = 7.2 Hz, 2H), 4.39 (d, J = 1.0 Hz, 4H), 2.13–2.04 (m, 4H), 1.72 (s, 3H), 1.68 (s, 3H), 1.60 (s, 3H).

[0332] Step 2: Synthesis of Compound 1

[0333] At 70 °C, N,N-dimethylethylenediamine (30 μL, 0.33 mmol, 1 eq) and Compound 1-2 (300 μL, 1.01 mmol, 3 eq) were mixed and stirred for 48 h. The mixture was purified by column chromatography (silica gel column, eluent: dichloromethane solution containing 0 - 10% methanol (volume percentage)) to obtain Compound 1 (370 mg, 54%), which was a slightly yellow oil. 1 1H NMR (400 MHz, CDCl3) δ 5.38 (t, J = 6.6 Hz, 2H), 5.08 (s, 2H), 4.67 (d, J = 7.2 Hz, 4H), 4.38–4.25 (m, 8H), 2.79 (t, J = 7.0 Hz, 4H), 2.63 (s, 2H), 2.49 (t, J = 6.9 Hz, 6H), 2.35 (s, 6H), 2.12–2.02 (m, 8H), 1.70 (d, J = 15.9 Hz, 12H), 1.58 (d, J = 11.9 Hz, 6H).

[0334] Example 2 Synthesis of Compound 2

[0335] Compound 2 was prepared by the method in Example 1. 1 1H NMR (400 MHz, CDCl3) δ 5.43–5.27 (m, 2H), 5.08 (s, 2H), 4.67 (d, J = 7.2 Hz, 2H), 4.60 (dd, J = 13.8, 7.0 Hz, 2H), 4.28 (dt, J = 36.3, 19.1 Hz, 6H), 2.74 (dd, J = 21.3, 14.6 Hz, 5H), 2.62 (s, 6H), 2.44 (ddd, J = 32.9, 16.7, 9.9 Hz, 6H), 2.13–2.02 (m, 8H), 1.88 (s, 2H), 1.73–1.67 (m, 12H), 1.60 (s, 6H), 1.27 (d, J = 12.3 Hz, 3H).

[0336] Synthesis of Compound 3 in Example 3

[0337] Compound 3 was prepared by the method in Example 1. 1 H NMR(400MHz,CDCl3)δ5.37(t,J=7.1Hz,4H),5.06(d,J=6.6Hz,4H),4.66(d,J=7.2Hz,8H),4.33–4.28(m,16H),2.78(t,J=7.0Hz,9H),2.49(dd,J=22.3,15.4Hz,16H),2.23(s,2H),2.06(dd,J=11.6,6.0Hz,16H),1.69(d,J=16.1Hz,24H),1.59(s,12H).

[0338] Synthesis of Compound 4 in Example 4

[0339] Compound 4 was prepared by the method in Example 1. 1 H NMR(400MHz,CDCl3)δ5.31(t,J=7.0Hz,4H),5.00(d,J=6.5Hz,4H),4.60(d,J=7.2Hz,8H),4.24(dd,J=13.2,5.0Hz,18H),2.68(t,J=6.6Hz,8H),2.39(t,J=6.7Hz,17H),2.09–1.86(m,20H),1.63(d,J=16.2Hz,24H),1.53(s,12H).

[0340] Synthesis of Compound 5 in Example 5

[0341] Compound 5 was prepared by the method in Example 1. 1 H NMR(400MHz,CDCl3)δ5.37(t,J=7.0Hz,3H),5.07(d,J=6.6Hz,3H),4.67(d,J=7.2Hz,6H),4.31(dd,J=13.5,5.6Hz,12H),2.75(t,J=7.1Hz,6H),2.66(s,3H),2.56–2.33(m,19H),2.15–1.99(m,14H),1.73–1.67(m,18H),1.60(s,9H).

[0342] Synthesis of Compound 6 in Example 6

[0343] Compound 6 was prepared by the method in Example 1. 11H NMR (400 MHz, CDCl3) δ 5.37 (t, J = 7.2 Hz, 2H), 5.08 (t, J = 6.2 Hz, 2H), 4.66 (t, J = 8.5 Hz, 4H), 4.41–4.24 (m, 8H), 2.87–2.52 (m, 14H), 2.43 (t, J = 6.9 Hz, 7H), 2.12–2.02 (m, 8H), 1.73–1.67 (m, 12H), 1.60 (s, 6H), 1.08 (dt, J = 36.4, 6.0 Hz, 4H), 0.93 (d, J = 6.5 Hz, 3H).

[0344] Synthesis of Compound H77 in Example 7

[0345] Compound 7 was prepared by the method in Example 1. 1 1H NMR (400 MHz, CDCl3) δ 5.38 (t, J = 7.2 Hz, 4H), 5.08 (t, J = 6.3 Hz, 4H), 4.67 (d, J = 7.2 Hz, 8H), 4.34–4.27 (m, 16H), 2.75 (t, J = 7.0 Hz, 8H), 2.46 (t, J = 7.0 Hz, 16H), 2.31 (s, 6H), 2.16–2.00 (m, 18H), 1.70 (d, J = 16.4 Hz, 28H), 1.60 (s, 12H).

[0346] Synthesis of Compound 8 in Example 8

[0347] Compound 8 was prepared by the method in Example 1. 1 1H NMR (400 MHz, CDCl3) δ 5.38 (t, J = 7.2 Hz, 2H), 5.07 (d, J = 6.8 Hz, 2H), 4.67 (d, J = 7.2 Hz, 4H), 4.31 (ddd, J = 8.2, 5.1, 2.1 Hz, 8H), 2.75 (ddd, J = 48.6, 13.4, 6.5 Hz, 4H), 2.49–2.41 (m, 8H), 2.30 (s, 2H), 2.07 (dd, J = 11.8, 6.5 Hz, 8H), 1.95 (s, 2H), 1.72–1.67 (m, 12H), 1.60 (s, 6H), 1.52 (s, 3H), 1.27 (d, J = 12.2 Hz, 3H).

[0348] Synthesis of Compound 9 in Example 9

[0349] Compound 9 was prepared by the method in Example 1. 11H NMR (400 MHz, CDCl3) δ 5.38 (t, J = 6.9 Hz, 2H), 5.08 (t, J = 6.6 Hz, 2H), 4.65 (d, J = 7.2 Hz, 4H), 4.13 (dt, J = 26.9, 5.9 Hz, 8H), 2.79 (t, J = 7.1 Hz, 4H), 2.62 (d, J = 6.6 Hz, 2H), 2.45 (t, J = 7.1 Hz, 6H), 2.34 (s, 6H), 2.12–2.02 (m, 8H), 1.80–1.72 (m, 8H), 1.70 (d, J = 15.4 Hz, 12H), 1.60 (s, 6H).

[0350] Synthesis of Compound 10 in Example 10

[0351] Compound 10 was prepared by the method in Example 1. 1 1H NMR (400 MHz, CDCl3) δ 5.37 (dd, J = 7.8, 6.6 Hz, 2H), 5.08 (t, J = 6.7 Hz, 2H), 4.65 (d, J = 7.2 Hz, 4H), 4.12 (dt, J = 27.8, 6.0 Hz, 8H), 2.75 (t, J = 7.1 Hz, 4H), 2.42 (dq, J = 14.0, 7.3 Hz, 8H), 2.31 (s, 6H), 2.14–2.03 (m, 8H), 1.78–1.72 (m, 8H), 1.72 (s, 6H), 1.68 (s, 6H), 1.67–1.62 (m, 2H), 1.60 (s, 6H).

[0352] Synthesis of Compound 11 in Example 11

[0353] Compound 11 was prepared by the method in Example 1. 1 1H NMR (400 MHz, CDCl3) δ 5.37 (t, J = 7.2 Hz, 4H), 5.08 (dd, J = 6.7, 5.6 Hz, 4H), 4.65 (d, J = 7.2 Hz, 8H), 4.17–4.06 (m, 16H), 2.78 (t, J = 7.1 Hz, 8H), 2.72–2.48 (m, 8H), 2.44 (t, J = 7.1 Hz, 8H), 2.26 (d, J = 9.3 Hz, 3H), 2.12–2.02 (m, 16H), 1.74 (s, 10H), 1.72 (d, J = 4.3 Hz, 18H), 1.68 (s, 12H), 1.60 (s, 12H).

[0354] Synthesis of Compound 12 in Example 12

[0355] Compound 12 was prepared by the method in Example 1.1 1H NMR (400 MHz, CDCl3) δ 5.37 (dd, J = 7.2, 6.1 Hz, 4H), 5.08 (t, J = 6.7 Hz, 4H), 4.65 (d, J = 7.2 Hz, 8H), 4.12 (dt, J = 28.4, 5.9 Hz, 17H), 2.74 (d, J = 6.5 Hz, 9H), 2.42 (t, J = 7.0 Hz, 12H), 2.16–2.00 (m, 18H), 1.73 (dd, J = 6.5, 3.4 Hz, 30H), 1.68 (s, 14H), 1.60 (s, 15H).

[0356] Synthesis of Compound 13 in Example 13

[0357] Compound 13 was prepared by the method in Example 1. 1 1H NMR (400 MHz, CDCl3) δ 5.37 (t, J = 7.2 Hz, 3H), 5.08 (t, J = 6.5 Hz, 3H), 4.65 (d, J = 7.2 Hz, 6H), 4.17–4.07 (m, 12H), 2.75 (t, J = 7.2 Hz, 6H), 2.53–2.29 (m, 20H), 2.12–2.02 (m, 12H), 1.78–1.73 (m, 11H), 1.72 (s, 12H), 1.68 (s, 10H), 1.60 (s, 8H), 1.57–1.52 (m, 2H).

[0358] Synthesis of Compound 14 in Example 14

[0359] Compound 14 was prepared by the method in Example 1. 1 1H NMR (400 MHz, CDCl3) δ 5.38 (t, J = 7.2 Hz, 3H), 5.09 (s, 6H), 4.67 (d, J = 7.2 Hz, 4H), 4.31 (dd, J = 13.6, 5.1 Hz, 12H), 2.74 (t, J = 6.7 Hz, 6H), 2.44 (dd, J = 24.0, 17.5 Hz, 20H), 2.12–1.87 (m, 26H), 1.77–1.63 (m, 22H), 1.60 (s, 18H).

[0360] Synthesis of Compound 15 in Example 15

[0361] Compound 15 was prepared by the method in Example 1. 11H NMR (400 MHz, CDCl3) δ 5.38 (t, J = 7.1 Hz, 4H), 5.08 (t, J = 6.3 Hz, 4H), 4.65 (d, J = 7.2 Hz, 8H), 4.12 (dt, J = 28.2, 5.6 Hz, 18H), 2.75 (t, J = 7.1 Hz, 8H), 2.42 (t, J = 7.2 Hz, 16H), 2.13–1.99 (m, 18H), 1.73 (dd, J = 6.2, 3.2 Hz, 30H), 1.68 (s, 15H), 1.60 (s, 15H).

[0362] Synthesis of Compound 16 in Example 16

[0363] Compound 16 was prepared by the method in Example 1. 1 1H NMR (400 MHz, CDCl3) δ 5.37 (t, J = 7.2 Hz, 2H), 5.08 (t, J = 6.6 Hz, 2H), 4.65 (d, J = 7.2 Hz, 4H), 4.12 (dt, J = 27.1, 5.9 Hz, 8H), 2.87–2.67 (m, 4H), 2.49–2.34 (m, 9H), 2.14–2.00 (m, 9H), 1.92 (dd, J = 19.8, 12.4 Hz, 3H), 1.79–1.69 (m, 16H), 1.68 (s, 6H), 1.60 (s, 6H), 1.46 (d, J = 17.4 Hz, 3H).

[0364] Synthesis of Compound 17 in Example 17

[0365] Compound 17 was prepared by the method in Example 1. 1 1H NMR (400 MHz, CDCl3) δ 5.13–5.03 (m, 2H), 4.31 (dd, J = 11.0, 5.0 Hz, 8H), 4.24–4.15 (m, 4H), 2.80 (t, J = 7.1 Hz, 4H), 2.64–2.58 (m, 2H), 2.56–2.37 (m, 8H), 2.31 (s, 6H), 1.97 (ddd, J = 22.2, 14.8, 7.3 Hz, 4H), 1.74 (dd, J = 12.7, 7.0 Hz, 2H), 1.68 (s, 6H), 1.60 (s, 6H), 1.53–1.45 (m, 2H), 1.36–1.15 (m, 4H), 0.92 (d, J = 6.4 Hz, 6H).

[0366] Synthesis of Compound 18 in Example 18

[0367] Compound 18 was prepared by the method in Example 1. 11H NMR (400 MHz, CDCl3) δ 5.08 (t, J = 7.1 Hz, 2H), 4.34–4.27 (m, 8H), 4.20 (ddd, J = 14.1, 8.4, 4.3 Hz, 4H), 2.76 (t, J = 7.0 Hz, 4H), 2.47 (t, J = 6.8 Hz, 6H), 2.33 (d, J = 7.3 Hz, 2H), 2.29 (s, 6H), 2.02–1.92 (m, 4H), 1.73–1.67 (m, 8H), 1.63–1.57 (m, 8H), 1.50 (dd, J = 13.3, 7.2 Hz, 2H), 1.39–1.12 (m, 6H), 0.92 (d, J = 6.5 Hz, 6H).

[0368] Synthesis of Compound 19 in Example 19

[0369] Compound 19 was prepared by the method in Example 1. 1 1H NMR (400 MHz, CDCl3) δ 5.08 (dd, J = 7.7, 6.5 Hz, 4H), 4.31 (dd, J = 11.7, 5.6 Hz, 18H), 4.19 (dd, J = 13.5, 6.5 Hz, 8H), 2.79 (t, J = 7.1 Hz, 8H), 2.55–2.40 (m, 16H), 1.98 (dt, J = 14.8, 7.2 Hz, 8H), 1.75–1.69 (m, 4H), 1.68 (s, 12H), 1.60–1.52 (m, 17H), 1.51–1.43 (m, 4H), 1.34 (dt, J = 11.7, 7.1 Hz, 4H), 1.20 (ddd, J = 13.7, 8.0, 5.4 Hz, 4H), 0.92 (d, J = 6.5 Hz, 12H).

[0370] Synthesis of Compound 20 in Example 20

[0371] Compound 20 was prepared by the method in Example 1. 1 1H NMR (400 MHz, CDCl3) δ 5.08 (td, J = 7.1, 1.2 Hz, 4H), 4.31 (dd, J = 11.9, 5.1 Hz, 16H), 4.19 (dd, J = 13.7, 6.2 Hz, 8H), 2.75 (t, J = 6.9 Hz, 8H), 2.46 (d, J = 7.0 Hz, 12H), 2.23 (d, J = 42.7 Hz, 4H), 1.98 (dt, J = 21.3, 7.3 Hz, 8H), 1.74–1.64 (m, 20H), 1.61–1.49 (m, 23H), 1.37–1.10 (m, 8H), 0.92 (d, J = 6.5 Hz, 12H).

[0372] Synthesis of Compound 21 in Example 21

[0373] Compound 21 was prepared by the method in Example 1. 1 H NMR(400MHz,CDCl3)δ5.08(td,J=7.1,1.2Hz,3H),4.34–4.29(m,12H),4.21–4.16(m,6H),2.74(d,J=7.0Hz,6H),2.49–2.25(m,24H),1.98(dt,J=21.2,7.3Hz,6H),1.75–1.67(m,14H),1.60–1.54(m,13H),1.41–1.11(m,6H),0.92(d,J=6.1Hz,9H).

[0374] Synthesis of Compound 22 in Example 22

[0375] Compound 22 was prepared by the method in Example 1. 1 H NMR(400MHz,CDCl3)δ5.08(t,J=7.1Hz,2H),4.34–4.14(m,12H),2.77(ddd,J=20.0,13.3,7.0Hz,3H),2.71–2.53(m,9H),2.53–2.37(m,6H),2.04–1.92(m,4H),1.77–1.70(m,2H),1.68(s,6H),1.60(s,6H),1.58–1.47(m,4H),1.41–1.33(m,3H),1.26–1.14(m,4H),1.06(dt,J=28.0,7.1Hz,4H),0.92(dd,J=6.5,2.6Hz,9H).

[0376] Synthesis of Compound 23 in Example 23

[0377] Compound 23 was prepared by the method in Example 1. 11H NMR (400 MHz, CDCl3) δ 5.08 (t, J = 7.0 Hz, 4H), 4.31 (dd, J = 12.8, 5.8 Hz, 16H), 4.22–4.15 (m, 8H), 2.75 (t, J = 6.9 Hz, 8H), 2.54–2.21 (m, 21H), 1.98 (td, J = 14.4, 7.3 Hz, 8H), 1.79–1.69 (m, 5H), 1.68 (s, 12H), 1.60 (s, 14H), 1.57–1.44 (m, 8H), 1.28 (dddd, J = 30.2, 23.0, 11.5, 6.7 Hz, 12H), 0.92 (d, J = 6.5 Hz, 12H).

[0378] Synthesis of Compound 24 in Example 24

[0379] Compound 24 was prepared by the method in Example 1. 1 1H NMR (400 MHz, CDCl3) δ 5.08 (t, J = 7.1 Hz, 2H), 4.35–4.30 (m, 6H), 4.22–4.14 (m, 4H), 2.83–2.67 (m, 4H), 2.54–2.30 (m, 10H), 2.20 (s, 2H), 2.06–1.80 (m, 8H), 1.73 (td, J = 7.6, 2.2 Hz, 3H), 1.68 (s, 6H), 1.60 (s, 7H), 1.49 (tdd, J = 32.3, 19.6, 12.6 Hz, 6H), 1.35–1.14 (m, 4H), 0.92 (d, J = 6.5 Hz, 6H).

[0380] Synthesis of Compound 25 in Example 25

[0381] Compound 25 was prepared by the method in Example 1. 1 1H NMR (400 MHz, CDCl3) δ 5.38 (t, J = 7.2 Hz, 2H), 5.09 (s, 4H), 4.67 (d, J = 7.2 Hz, 4H), 4.3 (dd, J = 12.9, 5.7 Hz, 8H), 2.79 (t, J = 7.0 Hz, 4H), 2.64 (s, 2H), 2.49 (t, J = 7.0 Hz, 6H), 2.35 (s, 6H), 2.08 (dt, J = 16.2, 6.9 Hz, 12H), 1.99–1.94 (m, 4H), 1.72 (s, 6H), 1.68 (s, 6H), 1.60 (s, 12H).

[0382] Synthesis of Compound 26 in Example 26

[0383] Compound 26 was prepared by the method in Example 1. 1 H NMR(400MHz,CDCl3)δ5.42–5.28(m,2H),5.08(s,4H),4.74–4.51(m,4H),4.30(dd,J=15.2,5.7Hz,6H),2.71(d,J=6.5Hz,4H),2.65–2.37(m,12H),2.31(s,4H),2.12–2.01(m,12H),1.99–1.90(m,4H),1.73–1.65(m,12H),1.59(s,12H),1.28(m,2H).

[0384] Synthesis of Compound 27 in Example 27

[0385] Compound 27 was prepared by the method in Example 1. 1 H NMR(400MHz,CDCl3)δ5.38(t,J=7.2Hz,4H),5.08(s,8H),4.66(d,J=7.2Hz,8H),4.30(dd,J=13.3,5.7Hz,16H),2.78(t,J=7.1Hz,8H),2.62–2.33(m,16H),2.22(s,3H),2.07(dt,J=22.4,7.8Hz,24H),1.99–1.90(m,8H),1.72(s,12H),1.67(s,12H),1.59(s,24H).

[0386] Synthesis of Compound 28 in Example 28

[0387] Compound 28 was prepared by the method in Example 1. 1 H NMR(400MHz,CDCl3)δ5.38(t,J=7.0Hz,4H),5.09(s,8H),4.67(d,J=7.2Hz,8H),4.31(dd,J=13.8,5.6Hz,16H),2.76(s,8H),2.46(t,J=7.0Hz,11H),2.27(s,3H),2.19–1.87(m,37H),1.78–1.66(m,24H),1.65–1.50(m,28H).

[0388] Synthesis of Compound 29 in Example 29

[0389] Compound 29 was prepared by the method in Example 1.

[0390] Synthesis of Compound 30 in Example 30

[0391] Compound 30 was prepared by the method in Example 1. 1 H NMR(400MHz,CDCl3)δ5.38(s,2H),5.09(s,4H),4.66(d,J=7.0Hz,4H),4.30(d,J=11.8Hz,8H),2.72(dd,J=41.3,32.6Hz,12H),2.43(d,J=6.6Hz,4H),2.19–1.97(m,18H),1.70(d,J=17.8Hz,12H),1.59(s,12H),1.43–0.89(m,10H).

[0392] Synthesis of Compound 31 in Example 31

[0393] Compound 31 was prepared by the method in Example 1. 1 H NMR(400MHz,CDCl3)δ5.38(t,J=6.8Hz,4H),5.09(s,8H),4.67(d,J=7.2Hz,8H),4.34–4.26(m,16H),2.75(t,J=7.0Hz,8H),2.46(t,J=7.0Hz,16H),2.31(s,4H),2.15–2.01(m,26H),1.99–1.90(m,8H),1.70(d,J=18.5Hz,27H),1.58(d,J=11.1Hz,27H).

[0394] Synthesis of Compound 32 in Example 32

[0395] Compound 32 was prepared by the method in Example 1. 1 H NMR(400MHz,CDCl3)δ5.38(dd,J=7.2,6.1Hz,2H),5.10(dd,J=7.2,2.5Hz,4H),4.67(d,J=7.2Hz,4H),4.36–4.27(m,8H),2.89–2.60(m,4H),2.49–2.40(m,8H),2.32–1.79(m,24H),1.73–1.67(m,12H),1.61–1.47(m,14H).

[0396] Synthesis of Compound 33 in Example 33

[0397] The synthesis route is as follows:

[0398]

[0399] 33.1 Preparation of Intermediate 33-1

[0400] The starting material, farnesol (10 g, 45.25 mmol, 1 eq), was dissolved in 50 mL of dichloromethane. Acryloyl chloride (54.30 mmol, 1.2 eq) and triethylamine (67.88 mmol, 1.5 eq) were added dropwise, and the reaction was carried out overnight. The mixture was purified by column chromatography (PE / EA = 10:1) to obtain intermediate 33-1. 1 H NMR (400 MHz, CDCl3) δ 6.46–6.34 (m, 1H), 6.12 (dd, J = 17.3, 10.4 Hz, 1H), 5.86–5.76 (m, 1H), 5.40 (t, J = 7.0 Hz, 1H), 5.17–5.03 (m, 2H), 4.66 (d, J = 7.3 Hz, 2H), 2.16–2.03 (m, 6H), 2.00–1.95 (m, 2H), 1.78 (s, 3H), 1.68 (s, 3H), 1.60 (s, 6H).

[0401] Preparation of Compound 33.2

[0402] At 70 °C, N,N-dimethylethylenediamine (32 μL, 0.36 mmol, 1 eq) and compound 33-1 (300 μL, 1.09 mmol, 3 eq) were mixed and stirred for 48 h. The mixture was purified by column chromatography (silica gel column, eluent: dichloromethane solution containing 0 - 10% methanol (volume percentage)) to obtain compound 33 (380 mg, 60%), which was a slightly yellow oil. 1 H NMR (400 MHz, CDCl3) δ 5.34 (t, J = 7.2 Hz, 2H), 5.14–5.04 (m, 4H), 4.56 (d, J = 7.2 Hz, 4H), 2.79 (t, J = 7.2 Hz, 4H), 2.60 (t, J = 7.1 Hz, 2H), 2.45 (t, J = 7.2 Hz, 6H), 2.30 (s, 6H), 2.13–2.04 (m, 12H), 1.99–1.95 (m, 4H), 1.76 (s, 6H), 1.68 (s, 6H), 1.60 (s, 12H).

[0403] Synthesis of Compound 34 in Example 34

[0404] Compound 34 was prepared by the method in Example 33. 11H NMR (400 MHz, CDCl3) δ 5.34 (t, J = 7.2 Hz, 2H), 5.15–5.04 (m, 4H), 4.56 (d, J = 7.2 Hz, 4H), 2.75 (t, J = 7.2 Hz, 4H), 2.48–2.35 (m, 8H), 2.31 (s, 6H), 2.17–2.04 (m, 12H), 2.00–1.95 (m, 4H), 1.76 (s, 6H), 1.70–1.64 (m, 8H), 1.60 (s, 12H).

[0405] Synthesis of Compound 35 in Example 35

[0406] Compound 35 was prepared by the method in Example 33. 1 1H NMR (400 MHz, CDCl3) δ 5.33 (t, J = 6.9 Hz, 4H), 5.09 (q, J = 6.6 Hz, 8H), 4.56 (d, J = 7.2 Hz, 8H), 2.78 (t, J = 7.2 Hz, 8H), 2.44 (t, J = 7.2 Hz, 15H), 2.28–1.91 (m, 36H), 1.76 (s, 12H), 1.68 (s, 12H), 1.58 (d, J = 12.7 Hz, 24H).

[0407] Synthesis of Compound 36 in Example 36

[0408] Compound 36 was prepared by the method in Example 33. 1 1H NMR (400 MHz, CDCl3) δ 5.34 (t, J = 7.1 Hz, 4H), 5.16–5.04 (m, 8H), 4.56 (d, J = 7.2 Hz, 8H), 2.75 (t, J = 7.2 Hz, 8H), 2.42 (t, J = 7.2 Hz, 12H), 2.33–1.93 (m, 39H), 1.76 (s, 12H), 1.69 (d, J = 9.1 Hz, 12H), 1.58 (d, J = 12.6 Hz, 28H).

[0409] Synthesis of Compound 37 in Example 37

[0410] Compound 37 was prepared by the method in Example 33. 11H NMR (400 MHz, CDCl3) δ 5.34 (t, J = 7.2 Hz, 3H), 5.15–5.03 (m, 6H), 4.56 (d, J = 7.2 Hz, 6H), 2.75 (t, J = 7.4 Hz, 6H), 2.45–2.32 (m, 14H), 2.28 (s, 6H), 2.08 (dt, J = 15.6, 5.8 Hz, 18H), 2.01–1.95 (m, 6H), 1.76 (s, 9H), 1.70–1.64 (m, 11H), 1.63–1.52 (m, 20H).

[0411] Synthesis of Compound 38 in Example 38

[0412] Compound 38 was prepared by the method in Example 33. 1 1H NMR (400 MHz, CDCl3) δ 5.34 (t, J = 7.1 Hz, 2H), 5.15–5.04 (m, 4H), 4.56 (d, J = 7.2 Hz, 4H), 2.84–2.50 (m, 10H), 2.50–2.15 (m, 6H), 2.13–1.92 (m, 17H), 1.76 (s, 6H), 1.69 (d, J = 9.3 Hz, 7H), 1.58 (d, J = 12.8 Hz, 14H), 1.43 (d, J = 7.6 Hz, 2H), 1.13 (dd, J = 40.4, 33.4 Hz, 4H), 0.92 (d, J = 6.5 Hz, 2H).

[0413] Synthesis of Compound 39 in Example 39

[0414] Compound 39 was prepared by the method in Example 33. 1 1H NMR (400 MHz, CDCl3) δ 5.34 (t, J = 7.2 Hz, 4H), 5.16–5.03 (m, 8H), 4.56 (d, J = 7.3 Hz, 8H), 2.75 (t, J = 7.2 Hz, 8H), 2.40 (dd, J = 30.4, 23.2 Hz, 20H), 2.14–1.91 (m, 34H), 1.77 (s, 12H), 1.69 (d, J = 9.1 Hz, 14H), 1.64–1.54 (m, 28H).

[0415] Synthesis of Compound 40 in Example 40

[0416] Compound 40 was prepared by the method in Example 33. 11H NMR (400 MHz, CDCl3) δ 5.34 (t, J = 7.0 Hz, 2H), 5.15 - 5.04 (m, 4H), 4.56 (d, J = 7.3 Hz, 4H), 2.76 (ddd, J = 20.3, 13.2, 6.3 Hz, 4H), 2.44 (d, J = 7.4 Hz, 8H), 2.26 (d, J = 8.9 Hz, 3H), 2.15 - 1.86 (m, 20H), 1.77 (s, 6H), 1.69 (d, J = 9.2 Hz, 7H), 1.60 (s, 12H), 1.48 (dd, J = 54.9, 23.8 Hz, 2H).

[0417] Synthesis of Compound 41 in Example 41

[0418] Compound 41 was prepared by the method in Example 33. 1 1H NMR (400 MHz, CDCl3) δ 5.33 (t, J = 7.1 Hz, 2H), 4.59 (d, J = 7.1 Hz, 4H), 2.80 (t, J = 7.2 Hz, 4H), 2.61 (t, J = 7.0 Hz, 2H), 2.46 (t, J = 7.2 Hz, 6H), 2.31 (s, 6H), 2.00 (t, J = 6.5 Hz, 4H), 1.69 (s, 6H), 1.52 (dd, J = 13.3, 6.6 Hz, 2H), 1.42 - 1.32 (m, 8H), 1.31 - 1.03 (m, 28H), 0.93 - 0.77 (m, 24H).

[0419] Synthesis of Compound 42 in Example 42

[0420] Compound 42 was prepared by the method in Example 33. 1 1H NMR (400 MHz, CDCl3) δ 5.32 (d, J = 7.1 Hz, 2H), 4.59 (d, J = 7.1 Hz, 4H), 2.76 (t, J = 7.0 Hz, 4H), 2.48 - 2.33 (m, 8H), 2.30 (s, 6H), 2.00 (s, 4H), 1.67 (d, J = 14.0 Hz, 8H), 1.52 (dd, J = 13.2, 6.6 Hz, 2H), 1.22 (ddd, J = 34.9, 33.1, 22.4 Hz, 36H), 0.86 (t, J = 6.4 Hz, 24H).

[0421] Synthesis of Compound 43 in Example 43

[0422] Compound 43 was prepared by the method in Example 33. 11H NMR (400 MHz, CDCl3) δ 5.32 (t, J = 7.2 Hz, 4H), 4.60 (dd, J = 11.5, 7.1 Hz, 8H), 2.79 (t, J = 7.1 Hz, 8H), 2.48 (dd, J = 34.0, 27.0 Hz, 16H), 2.28 (s, 3H), 1.99 (d, J = 6.5 Hz, 8H), 1.69 (s, 12H), 1.52 (dt, J = 13.2, 6.6 Hz, 4H), 1.41–1.03 (m, 72H), 0.97–0.79 (m, 48H).

[0423] Example 44 Synthesis of Compound 44

[0424] Compound 44 was prepared by the method in Example 33. 1 1H NMR (400 MHz, CDCl3) δ 5.33 (t, J = 7.1 Hz, 4H), 4.58 (d, J = 7.1 Hz, 8H), 2.75 (d, J = 6.8 Hz, 8H), 2.43 (t, J = 7.0 Hz, 12H), 1.99 (d, J = 6.1 Hz, 10H), 1.69 (s, 14H), 1.53 (dt, J = 13.2, 6.6 Hz, 6H), 1.43–0.96 (m, 77H), 0.92–0.81 (m, 48H).

[0425] Example 45 Synthesis of Compound 45

[0426] Compound 45 was prepared by the method in Example 33. 1 1H NMR (400 MHz, CDCl3) δ 5.32 (t, J = 7.0 Hz, 3H), 4.58 (d, J = 7.1 Hz, 6H), 2.76 (t, J = 7.3 Hz, 6H), 2.40 (dd, J = 16.7, 7.5 Hz, 12H), 2.30 (s, 6H), 2.00 (t, J = 6.3 Hz, 6H), 1.69 (s, 9H), 1.59–0.99 (m, 63H), 0.99–0.75 (m, 36H),

[0427] Example 46 Synthesis of Compound 46

[0428] Compound 46 was prepared by the method in Example 33. 11H NMR (400 MHz, CDCl3) δ 5.32 (t, J = 7.0 Hz, 2H), 4.57 (d, J = 7.1 Hz, 4H), 4.21–4.15 (m, 6H), 3.62 (t, J = 5.2 Hz, 2H), 2.84–2.78 (m, 2H), 2.72–2.58 (m, 8H), 2.44–2.39 (m, 6H), 2.21 (td, J = 5.2, 2.5 Hz, 2H), 2.00–1.94 (m, 6H), 1.74 (dd, J = 7.6, 4.5 Hz, 6H), 1.68 (s, 6H), 1.54–1.49 (m, 2H), 1.41–1.35 (m, 6H), 1.24 (dd, J = 8.3, 4.5 Hz, 8H), 1.15–1.00 (m, 16H), 0.87–0.80 (m, 24H).

[0429] Example 47 Synthesis of Compound 47

[0430] Compound 47 was prepared by the method in Example 33. 1 1H NMR (400 MHz, CDCl3) δ 5.32 (t, J = 6.7 Hz, 4H), 4.58 (d, J = 7.1 Hz, 8H), 2.75 (t, J = 7.2 Hz, 8H), 2.43 (t, J = 7.1 Hz, 20H), 2.00 (t, J = 6.2 Hz, 8H), 1.69 (s, 12H), 1.63–0.98 (m, 84H), 0.92–0.79 (m, 48H).

[0431] Example 48 Synthesis of Compound 48

[0432] Compound 48 was prepared by the method in Example 33. 1 1H NMR (400 MHz, CDCl3) δ 5.32 (t, J = 7.0 Hz, 2H), 4.58 (d, J = 7.1 Hz, 4H), 2.82 (dd, J = 13.9, 6.7 Hz, 2H), 2.75–2.62 (m, 2H), 2.49–2.29 (m, 10H), 2.00 (t, J = 6.5 Hz, 8H), 1.69 (s, 6H), 1.56–0.99 (m, 42H), 0.93–0.76 (m, 24H).

[0433] Example 49 Synthesis of Compound 49

[0434] Compound 49 was prepared by the method in Example 1. 11H NMR (400 MHz, CDCl3) δ 5.37 (s, 2H), 4.67 (d, J = 6.8 Hz, 4H), 4.31 (d, J = 10.0 Hz, 8H), 2.78 (d, J = 6.5 Hz, 4H), 2.72 (s, 2H), 2.49 (d, J = 6.0 Hz, 8H), 1.95 (d, J = 45.4 Hz, 6H), 1.71 (s, 6H), 1.52 (dd, J = 12.4, 5.9 Hz, 2H), 1.37 (s, 10H), 1.27 (d, J = 11.5 Hz, 16H), 1.16–1.03 (m, 12H), 0.86 (t, J = 7.1 Hz, 24H).

[0435] Synthesis of Compound 50 in Example 50

[0436] Compound H2T750 was prepared by the method in Example 1. 1 1H NMR (400 MHz, CDCl3) δ 5.37 (t, J = 7.0 Hz, 2H), 4.67 (d, J = 7.2 Hz, 4H), 4.31 (qd, J = 6.3, 2.6 Hz, 8H), 2.74 (t, J = 6.8 Hz, 4H), 2.49–2.35 (m, 12H), 2.00 (t, J = 6.6 Hz, 6H), 1.71 (s, 6H), 1.53 (dd, J = 13.3, 6.7 Hz, 2H), 1.35 (dd, J = 14.5, 6.1 Hz, 8H), 1.31–1.19 (m, 16H), 1.09 (dddd, J = 14.8, 12.4, 10.5, 7.1 Hz, 14H), 0.85 (dd, J = 8.7, 6.7 Hz, 24H).

[0437] Synthesis of Compound 51 in Example 51

[0438] Compound 51 was prepared by the method in Example 1. 1 1H NMR (400 MHz, CDCl3) δ 5.37 (t, J = 7.2 Hz, 4H), 4.67 (d, J = 7.2 Hz, 8H), 4.31 (dd, J = 13.2, 5.7 Hz, 16H), 2.79 (t, J = 6.9 Hz, 8H), 2.48 (s, 17H), 2.00 (t, J = 6.2 Hz, 8H), 1.71 (s, 12H), 1.52 (dt, J = 13.2, 6.6 Hz, 4H), 1.46–1.32 (m, 18H), 1.32–1.18 (m, 32H), 1.09 (dddd, J = 14.6, 12.1, 10.3, 7.1 Hz, 26H), 0.90–0.81 (m, 48H).

[0439] Synthesis of Compound 52 in Example 52

[0440] Compound 52 was prepared by the method in Example 1. 1 H NMR(400MHz,CDCl3)δ5.37(t,J=7.2Hz,4H),4.67(d,J=7.2Hz,8H),4.31(dd,J=13.9,5.6Hz,16H),2.74(s,8H),2.46(t,J=6.7Hz,12H),2.00(d,J=6.4Hz,10H),1.71(s,12H),1.65(s,6H),1.52(dd,J=13.2,6.7Hz,4H),1.38(dd,J=18.1,13.7Hz,18H),1.32–1.20(m,32H),1.14(dd,J=11.4,4.5Hz,9H),1.11–1.01(m,16H),0.86(dd,J=8.3,6.8Hz,48H).

[0441] Synthesis of Compound 53 in Example 53

[0442] Compound 53 was prepared by the method in Example 1. 1 H NMR(400MHz,CDCl3)δ5.36(d,J=7.4Hz,3H),4.67(d,J=7.2Hz,3H),4.29(dd,J=15.6,6.4Hz,9H),2.74(d,J=3.4Hz,6H),2.60(s,6H),2.52–2.35(m,12H),2.00(d,J=6.0Hz,6H),1.70(d,J=9.2Hz,10H),1.51(dt,J=19.8,6.6Hz,6H),1.37(ddd,J=15.7,11.6,4.4Hz,16H),1.30–1.20(m,26H),1.18–1.11(m,8H),1.07(ddd,J=14.9,11.5,5.9Hz,12H),0.86(t,J=7.6Hz,36H).

[0443] Synthesis of Compound 54 in Example 54

[0444] Compound 54 was prepared by the method in Example 1. 11H NMR (400 MHz, CDCl3) δ 5.36 (s, 2H), 4.81 (d, J = 7.4 Hz, 2H), 4.66 (t, J = 6.1 Hz, 4H), 4.35–4.24 (m, 6H), 2.77 (dd, J = 13.7, 7.4 Hz, 3H), 2.72–2.51 (m, 3H), 2.43 (t, J = 6.7 Hz, 3H), 2.14–1.96 (m, 10H), 1.77 (s, 3H), 1.70 (d, J = 7.4 Hz, 12H), 1.64–1.57 (m, 6H), 1.57–1.46 (m, 4H), 1.45–1.32 (m, 8H), 1.31–1.17 (m, 18H), 1.13 (dd, J = 11.6, 4.5 Hz, 4H), 1.09–1.00 (m, 6H), 0.92 (d, J = 6.4 Hz, 2H), 0.85 (dd, J = 8.5, 6.6 Hz, 18H).

[0445] Example 55 Synthesis of Compound 55

[0446] Compound 55 was prepared by the method in Example 1. 1 1H NMR (400 MHz, CDCl3) δ 5.37 (t, J = 7.1 Hz, 4H), 4.67 (d, J = 7.2 Hz, 8H), 4.31 (dd, J = 13.5, 5.1 Hz, 16H), 2.75 (t, J = 6.9 Hz, 8H), 2.59–2.21 (m, 22H), 2.00 (t, J = 6.5 Hz, 8H), 1.71 (s, 16H), 1.63–1.48 (m, 8H), 1.22 (dddd, J = 38.6, 30.2, 19.0, 12.2 Hz, 80H), 0.90–0.82 (m, 48H).

[0447] Example 56 Synthesis of Compound 56

[0448] Compound 56 was prepared by the method in Example 1. 1 1H NMR (400 MHz, CDCl3) δ 5.36 (t, J = 6.8 Hz, 2H), 4.67 (d, J = 7.2 Hz, 3H), 4.34–4.27 (m, 6H), 2.83 (dd, J = 13.6, 6.9 Hz, 2H), 2.63 (dd, J = 13.8, 7.4 Hz, 6H), 2.52–2.41 (m, 6H), 2.22–1.78 (m, 9H), 1.70 (d, J = 8.4 Hz, 8H), 1.60–0.97 (m, 42H), 0.85 (dd, J = 8.5, 6.7 Hz, 24H).

[0449] Example 57

[0450] Preparation of nanoparticle composition

[0451] Fifty-six cationic lipid compounds prepared in Examples 1-56 were respectively dissolved in absolute ethanol with cholesterol (AVT (Shanghai) Pharmaceutical Technology Co., Ltd.), DSPC alcohol (AVT (Shanghai) Pharmaceutical Technology Co., Ltd.) and DMG-PEG2000 (AVT (Shanghai) Pharmaceutical Technology Co., Ltd.) at a molar ratio of 66.67:25.67:6.67:1.00. Lipid nanoparticles (LNPs) were prepared at a weight ratio of approximately 10:1 of cationic lipid to firefly luciferase (Fluc) mRNA. Briefly, the mRNA was diluted in 25 mM sodium acetate solution (pH 5.2), and the ethanol solution of lipids was mixed with the aqueous solution of mRNA at a ratio of approximately 1:3 (volume / volume) using a syringe pump, with a total flow rate of 12 mL / min. The ethanol was removed by dialysis to displace the LNPs into dd H2O. Finally, the lipid nanoparticles were filtered through a sterile filter with a 0.2 μm pore size to obtain an LNP preparation (LNP-mFluc) encapsulating firefly luciferase mRNA.

[0452] Example 58

[0453] In vivo evaluation of luciferase mRNA using the lipid nanoparticle composition

[0454] The luciferase mRNA was evaluated in vivo using the lipid nanoparticle composition (LNP-mFluc) prepared in Example 57. The FLuc mRNA from Shanghai Hexincheng Biotechnology will express luciferase protein, which was originally isolated from fireflies. Fluc is commonly used in mammalian cell cultures to measure gene expression and cell viability. It emits bioluminescence in the presence of the substrate luciferin. The study was conducted on 5-6-week-old female Balb / c mice (Shanghai Slake Experimental Animal Co., Ltd.) according to the guidelines established by the Animal Care Committee (ACC) and the Canadian Council on Animal Care (CCAC). After intravenous injection of 5 μg luciferase mRNA and 50 μg cationic lipid nanoparticles via the tail vein, 100 μL of 30 mg / mL potassium D-luciferin (Adamas Reagent Co., Ltd.) was injected intraperitoneally into the mice 6 h after administration. The mice were imaged using a live imaging system (PerkinElmer) 10 minutes later. Among them, the compounds with strong fluorescence intensity in the liver and their specific fluorescence values are shown in Table 2. Compounds 9, 32, 21, 8, 10, 33, 16, 30, 15, 2, 51, 56, 26, 25, 29, 5, 42, 53, 52, 13, and 50 had strong fluorescence signals in the spleen, with fluorescence intensities generally above about 1.17E+07. In particular, the fluorescence intensity of Compound 50 reached up to 1.03E+08. The fluorescence signal intensity of Compound 17, which had a strong signal in the lungs, was approximately 6.95E+05.

[0455] Table 2 Fluorescence Intensity in the Liver

[0456]

Claims

1. A compound of formula (I): or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof, wherein: The G1 and G2 are each independently an optionally substituted C2-C24 straight chain alkylene group; The L1 and L2 are each independently -OC(=O)-, -C(=O)O-, -OC(=O)O-, -C(=O)-, -O-, -S(O) x -, -SS-, -C(=O)S-, -SC(=O)-, -NR a C(=O)-, -C(=O)NR b -、-NR a C(=O)NR b -、-OC(=O)NR b -、-NR a C(=O)O-, -SC(=S)-, -C(=S)S-, -C(=S)-, -CH(OH)-, -P(=O)(OR b )O-, -(C6-C10 arylene)-, or -(6- to 10-membered heteroarylene)-; R a and R b are each independently H, optionally substituted C1-C12 alkyl, or optionally substituted C1-C12 alkenyl; x is 0, 1, or 2; G3 and G4 are each independently a bond, an optionally substituted C2-C24 straight chain alkylene group; The L3 and L4 are each independently a bond, -OC(=O)-, -C(=O)O-, -OC(=O)O-, -C(=O)-, -O-, -S(O) i -, -SS-, -C(=O)S-, -SC(=O)-, -NR c C(=O)-, -C(=O)NR c -、-NR c C(=O)NR d -、-OC(=O)NR c -、-NR c C(=O)O-, -SC(=S)-, -C(=S)S-, -C(=S)-, -CH(OH)-, -P(=O)(OR c )O-, -(C6-C10 arylene)-, or -(6- to 10-membered heteroarylene)-; R c and R d are each independently H, optionally substituted C1-C12 alkyl, or optionally substituted C1-C12 alkenyl; i is 0, 1, or 2; G5 and G6 are each independently an optionally substituted C2-C24 straight chain alkyl group or an optionally substituted C2-C24 straight chain alkenyl group; The Z is an optionally substituted C1-C12 alkylene, an optionally substituted -R e G7R f -; Among them, R e and R f is an optionally substituted C1-C12 alkylene group; G7-NR g -, -(3-7 membered saturated cycloalkane)-, -(3-7 membered heterocycloalkane)-, -(3-7 membered cyclic arylene)-, or -(3-7 membered cyclic heteroarylene)-; R g is an optionally substituted C1-C12 alkylene group; Said X and Y are each independently an optionally substituted C1-C12 straight chain alkyl, -G1L1G3L3G5, or X and Z together with the nitrogen to which they are attached form a ring.

2. The compound according to claim 1, or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof, characterized in that The compound has the structure shown in formula (IA): wherein G1, G2, G3, G4, G5, G6, L1, L2, L3, L4, X and Y are as defined in claim 1; G8 is an optionally substituted C1-C12 alkylene group.

3. The compound according to claim 1, or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof, characterized in that The compound has the structure shown in formula (IB): Among them, G1, G2, G3, G4, G5, G6, G7, L1, L2, L3, L4, R e 、R f , X and Y are as defined in claim 1.

4. The compound according to any one of claims 1 to 3, or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof, characterized in that wherein G1 and G2 are unsubstituted C2-C4 alkylene.

5. The compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof, characterized in that wherein L1 and L2 are -C(=O)O-.

6. The compound according to any one of claims 1 to 5, or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof, characterized in that Among them, G3 and G4 are bonds.

7. The compound according to any one of claims 1 to 5, or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof, characterized in that wherein G3 and G4 are unsubstituted C2-C4 alkylene groups.

8. The compound according to any one of claims 1 to 6, or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof, characterized in that Wherein L3 and L4 are bonds.

9. The compound according to any one of claims 1 to 5 and 7, or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof, characterized in that: wherein L3 and L4 are -OC(=O)O-.

10. The compound according to any one of claims 1 to 9, or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof, characterized in that G5 and G6 are optionally substituted C4-C16 straight-chain alkenyl groups.

11. The compound according to any one of claims 2, 4-10, or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof, characterized in that: The compound has a structure shown in formula (IA-1): Wherein, m is 1 or 3, n is 0 or 1, G5 and G6 are defined as defined in claim 10, G8 is defined in claim 2, G9 and G 10 is an optionally substituted C1-C5 straight-chain alkane.

12. The compound according to any one of claims 2, 4-10, or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof, characterized in that: The compound has a structure shown in formula (IA-2): wherein m is 1 or 3, n is 0 or 1, and G5 and G6 are as defined in claim 10.

13. The compound according to any one of claims 2, 4-10, or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof, characterized in that: The compound has a structure shown in formula (IA-3): wherein m is 1 or 3, n is 0 or 1, and G5 and G6 are as defined in claim 10.

14. The compound according to any one of claims 3 to 10, or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof, characterized in that: The compound has a structure shown in formula (IB-1): wherein m is 1 or 3, n is 0 or 1, and G5 and G6 are as defined in claim 10.

15. The compound according to any one of claims 3 to 10, or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof, characterized in that: The compound has a structure shown in formula (IB-2): wherein m is 1 or 3, n is 0 or 1, and G5 and G6 are as defined in claim 10.

16. The compound according to any one of claims 3 to 10, or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof, characterized in that: The compound has a structure shown in formula (IB-3): wherein m is 1 or 3, n is 0 or 1, and G5 and G6 are as defined in claim 10.

17. The compound according to any one of claims 2, 4-11, or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof, characterized in that: wherein G8 is an optionally substituted C2-C4 alkylene group.

18. The compound according to any one of claims 2, 4-11, or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof, characterized in that: Among them G9 or G 10 Or both have one of the following structures: methyl, ethyl, 2-hydroxyethyl.

19. A compound according to any one of claims 1 to 18, wherein G5 or G6 or both have one of the following structures:

20. The compound according to any one of claims 1 to 19, or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof, which is:

21. A composition comprising: a therapeutic agent or a prophylactic agent; and a carrier for delivering the therapeutic agent or the prophylactic agent, wherein: The carrier comprises a cationic lipid, and the cationic lipid comprises one or more of the compound represented by formula (I) according to any one of claims 1 to 20, or a pharmaceutically acceptable salt thereof.

22. The composition of claim 21, wherein the therapeutic agent or preventive agent is selected from one or more of a nucleic acid molecule, a small molecule compound, a polypeptide or a protein, preferably, wherein the nucleic acid molecule is selected from one or more of single-stranded DNA, double-stranded DNA, a short isomer, agomir, antagomir, antisense molecule, small interfering RNA (siRNA), asymmetric interfering RNA (aiRNA), microRNA (miRNA), Dicersubstrate RNA (dsRNA), small hairpin RNA (shRNA), transfer RNA (tRNA), messenger RNA (mRNA), locked nucleic acid (LNA), peptide nucleic acid (PNA) or morpholino oligonucleotide.

23. The composition of claim 22, wherein the therapeutic or prophylactic agent comprises at least one mRNA encoding an antigen or a fragment or epitope thereof. Preferably, the mRNA is a monocistronic mRNA or a polycistronic mRNA.

24. The composition according to claim 23, wherein the antigen is a pathogenic antigen.

25. The composition of claim 22, wherein the mRNA comprises one or more functional nucleotide analogs selected from one or more of pseudouridine, 1-methyl-pseudouridine, or 5-methylcytosine.

26. According to claim 21, the small molecule compound is selected from one or more of antitumor drugs, anti-infective drugs, local anesthetics, antidepressants, anticonvulsants, antibiotics / antibacterial agents, antifungals, antiparasitic drugs, hormones, hormone antagonists, immunomodulators, neurotransmitter antagonists, anti-glaucoma agents, anesthetics or imaging agents. The composition according to claim 21 , wherein the mass ratio of the carrier to the therapeutic or preventive agent is 5:1 to 50:

1.

28. The composition according to claim 21, wherein the composition is a nanoparticle preparation, the average size of the nanoparticle preparation is 10 to 500 nm; or the pKa of the nanoparticles is 4.5 to 8.

5.

29. The composition according to any one of claims 21 to 28, wherein The carrier further comprises one or more neutral lipids.

30. The composition according to claim 29, wherein the neutral lipid is one or more selected from phosphatidylcholine, phosphatidylethanolamine, sphingomyelin, ceramide, sterol and derivatives thereof.

31. The composition according to any one of claims 21 to 30, wherein the molar ratio of cationic lipid to neutral lipid is 100:1 to 5:

1.

32. according to the composition described in any one of claims 21 to 28, it further comprises steroid, preferably, described steroid is selected from cholesterol, non-sterol, sitosterol, ergosterol, campesterol, stigmasterol, brassicasterol, tomatine, tomatine, ursolic acid, alpha-tocopherol, one or more in corticosteroid.

33. The composition of any one of claims 21 to 32, wherein the molar ratio of cationic lipid to steroid is 2:1 to 4:

1.

34. The composition according to any one of claims 21 to 32, wherein the composition further comprises one or more lipids capable of binding to a polymer, preferably, the lipid capable of binding to a polymer is one or more selected from PEG-modified phosphatidylethanolamine, PEG-modified phosphatidic acid, PEG-modified ceramide, PEG-modified dialkylamine, PEG-modified diacylglycerol or PEG-modified dialkylglycerol, further preferably, the molar ratio of the cationic lipid to the lipid capable of binding to a polymer is 100:1 to 20:

1.

35. The composition according to any one of claims 21 to 32, wherein the carrier further comprises a neutral lipid, a structural lipid, and a polymer-conjugated lipid, and the molar ratio of the cationic lipid, the neutral lipid, the steroid lipid, and the polymer-conjugated lipid is (15-70): (1-15): (15～55):(0～3)。 36. The composition according to claim 21, characterized in that The composition further comprises a pharmaceutically acceptable excipient. Preferably, the excipient comprises a pharmaceutically acceptable diluent.

37. Use of a compound of formula (I) as described in any one of claims 1 to 20, or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof, or a composition as described in any one of claims 21 to 36 in the preparation of a drug, wherein the drug is preferably any one selected from a gene drug, a nucleic acid vaccine, a small molecule drug, a polypeptide or a protein drug.

Images